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General introduction and 
outline of the thesis
1
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1.1 Epidemiology and treatment 
Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer-
related death worldwide (1). In the Netherlands, over 13.000 people were diagnosed with 
lung cancer in 2017, representing 12% of the national cancer diagnoses (2). Based on 
pathology, lung cancer can be divided in two groups: small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC), where the latter accounts for 80 – 85% of all lung cancers 
diagnoses. Five years after the diagnosis of NSCLC only 25% of the patients is still alive (3). 
Based on the size of the primary tumor and whether the disease has spread to lymph nodes 
or distant organs, NSCLC can be divided in different stages according to the 
TNM classification for lung cancer (Appendix 1A – B). When using this classification, every 
stage reflects an overall survival prognosis (4, 5) (Figure 1). 
Figure 1 – Overall survival by clinical stage according to the TNM classification* 
* eight edition (ref: Goldstraw 2015)
The different stages are explained in Appendix 1A – B.
Early stage NSCLC are tumors which in principle can be treated locally with surgery or 
radiotherapy, with surgery as the preferred treatment according to the EMSO and the Dutch 
national guidelines (5, 6). If a patient is unfit for surgery due to comorbidities, or is unfit for 
lobectomy and a segment resection or wedge resection are the alternatives, stereotactic 
radiotherapy can be considered as the non-surgical treatment (6).  
1.2 Stereotactic radiotherapy for lung tumors 
For nearly 20 years, stereotactic body radiation therapy (SBRT) has been the radiation 
treatment modality for early stage NSCLC. The first prospective cohorts described patients 
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treated with 60 Gy in 10 fractions and with 48 Gy in 4 fractions. The results were promising 
having a low local recurrence rate and a 3 years overall survival of 56 – 83%, without any 
grade 3 toxicity or higher reported (7, 8). In the following years, multiple studies analyzed 
SBRT in early stage NSCLC and all found comparable outcomes. Higher local control and 
overall survival were demonstrated when prescribing a biologically equivalent dose (BED10, 
using an α/β ratio of 10 Gy) of 100 Gy and higher (9).  
Nowadays, SBRT is widely accepted as standard treatment for inoperable early stage 
NSCLC patients and for those refusing surgery (10-12). However, there is a subgroup of 
patients that carries unique and significant toxicity risks and therefore requires more 
specific attention, i.e. the centrally located tumors (10, 11). 
1.3 Central lung tumors 
A publication of a prospective trial did result in the distinction between peripherally and 
centrally located lung tumors treated with SBRT (13). This phase II trial, published in 2006, 
treated patients with medically inoperable early-stage NSCLC with SBRT in 3 fractions of 20 
– 22 Gy without having an enrollment restriction based on tumor localization. Although the
survival and disease outcomes were promising, an 11-fold higher risk of high-grade toxicity
for patients having a tumor located within 2 cm of the proximal bronchial tree was reported 
(13).
Since this publication, risk-adapted fractionation schedules associated with lower BED10 
are used for patients having a centrally located tumor. When using these adapted 
schedules, overall survival rates are comparable to peripherally located tumors, but the 
local control rates are slightly lower (14) highlighting the need of a dose of ≥ 100 Gy BED10 
(15). Additionally, dose-constraints are used for the organs at risk (OAR) to prevent high-
grade toxicity and nowadays, people are aware of excluding the OAR from the high-dose 
region to decrease toxicity risks (9). 
Stereotactic body radiation therapy for central lung tumors is currently practiced by 
multiple institutions, however without proper evidence-based guidelines. In the last years 
the first results of prospective multicenter studies are gradually published (16, 17), but most 
of the treatment consensus is based on retrospective experience of institutes shared in 
literature. Some studies have suggested to not treat tumors within 1 cm of the bronchial 
tree because of high toxicity probabilities, while other studies have reported high local 
control with acceptable toxicity rates (16-18).  
Despite all publications, the use of OAR dose-constraints and the first reports of 
prospective trials, high-grade toxicity after SBRT is still reported. This is keeping the 
discussion about the treatment of central lung tumors ongoing and is highlighting the need 
for more evidence-based guidelines. 
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If SBRT for a central lung tumor is declined, alternatives are a lower stereotactic dose, 
conventional radiotherapy, chemotherapy or no treatment. For a well-balanced treatment 
decision individualized toxicity risks and treatment outcomes, such as overall survival and 
disease control, should be taken into to account. The aim of this thesis is to improve decision 
making in SBRT of centrally located lung tumors by modelling the outcome in terms of 
overall survival, local control and toxicity probabilities of the esophagus and bronchial 
structures. 
1.4 This thesis 
A well-balanced treatment decision should start with the patient’s life expectancy. When 
patients are older or the performance status is lower, survival probabilities decline. If the 
survival probability of a patient is low, should any risk on life threatening toxicity be taken? 
Chapter 2 will discuss the overall survival probabilities for patients with centrally located 
NSCLC considered for SBRT using a nomogram, which is a feasible tool to describe the 
individual prognosis of a clinical event. This survival nomogram offers individualized 
predictions using multiple prognostic characteristics. Each of these characteristics can be 
scored for an individual patient such that the total sum of points will be linked to the 6 
months, 1, 2 and 3 years overall survival probability. 
When the survival probability of the patient is promising, the chances on local disease 
control have to be estimated. Next to the known cut-off of 100 Gy BED10, studies have 
searched for predictive dosimetric and clinical factors to minimize the local recurrence 
probability (19, 20). In case of a central tumor, fulfilling the dose-constraints of the OAR 
can result in less coverage of the planning target volume (PTV) with the prescribed dose. 
Whether a compromised dose on the PTV has consequences in terms of disease control 
is unknown. The impact of the underdosage of the PTV is discussed in Chapter 3 as 
well as other possible clinical and treatment characteristics predictive for disease control 
in central lung tumors treated with SBRT. 
The expected toxicity after treatment of a central lung tumor is depending on the organs 
close to the tumor. When the tumor is close to the bronchial structures, it is inevitable to 
prescribe some dose to the bronchi. Dose to the bronchi can result in stenosis, occlusion or 
fistula formation, and in some cases even death. Chapter 4 is describing the radiological 
changes of the bronchi after SBRT and its relation to the prescribed dose. Whether these 
radiographic changes will result in clinical toxicity is discussed in Chapter 5. Within this 
chapter, clinical pulmonary and radiographic bronchial toxicity is evaluated and 
after identifying the predictors for clinical toxicity, normal tissue complication probability 
(NTCP) models were derived.  
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Another important organ to consider within the treatment of central lung tumors is the 
esophagus. Toxicity of the esophagus can be seen as radiation esophagitis. Chapter 6 is 
describing the incidence of low-grade radiation esophagitis and its relation to the prescribed 
dose. Late effects in the esophagus can consist of strictures, perforation and fistulation, 
which can be life-threatening for patients. To evaluate late toxicity of the esophagus, 
another cohort of patients was analyzed in which late high-grade esophageal toxicity was 
found. Chapter 7 is describing these cases and their relation with SBRT. In both chapters, 
NTCP models were derived and evaluated against currently used esophagus dose-
constraints in order to improve decision making in the treatment of central lung tumors 
with SBRT. 
The previous chapters and further perspectives are discussed in Chapter 8.
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Stereotactic body radiation therapy (SBRT) results in high local control (LC) rates in patients 
with non-small cell lung cancer (NSCLC). For central lung tumors, risk-adapted fractionation 
schedules are used and underdosage to the planning target volume (PTV) is often accepted 
to respect the dose constraints of the organs at risk in order to avoid high rates of toxicity. 
The purpose of this study was to analyze the effect of PTV underdosage and other possible 
prognostic factors on local- and disease control after SBRT in patients with central lung 
tumors.  
 
Material and Methods 
Patients with centrally located NSCLC treated with SBRT were included. The doses were 
converted into biologically equivalent dose using α/β-value of 10 Gy (BED10). Underdosage 
to the PTV was defined as the (percentage of) PTV receiving less than 100 Gy BED10; (%)PTV 
< 100 BED10. Potential prognostic factors for LC and Disease Free Survival (DFS) were 
evaluated using Cox regression analysis.  
 
Results 
Two hundred and twenty patients received ≤ 12 fractions of SBRT. LC-rates were 88% at 2 
years and 81% at 3 years. Twenty-seven patients developed a local recurrence. Both the 
PTV < 100 BED10 and %PTV < 100 BED10 were not prognostic for LC. Tumor size and forced 
expiratory volume in 1 second (FEV1) were independently prognostic for LC. Disease 
progression was reported in 75 patients with DFS-rates of 66% at 2 years and 56% at 3 years. 
Disease recurrence was independent significantly associated with larger tumor diameter, 
lower lobe tumor location and decreased FEV1. Grade 4-5 toxicity was reported in 10 
patients (8 with ultra-central tumors) and was fatal in at least 3 patients. 
 
Conclusion 
Decrease in tumor coverage was not correlated with the local recurrence probability. The 
LC and DFS were promising after SBRT of centrally located NSCLC with tumor size, FEV1 and 
tumor location (for DFS only) as prognostic factors. 
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3.1 Introduction 
Stereotactic body radiation therapy (SBRT) is the golden standard in patients having early 
stage non-small cell lung cancer (NSCLC) not suitable for surgery (10, 11). Over more than 
15 years ago, reports of high-grade toxicity after stereotactic radiotherapy resulted in the 
definition of a ‘central lung tumor’ together with the proposal of risk-adapted fractionation 
schedules (13, 45) and accompanying dose constraints for organs at risk (OAR) (46). Despite 
these risk-adapted schedules and dose constraints, high-grade toxicity has been reported 
in recent prospective studies (16, 17, 39). This resulted in a higher awareness for toxicity in 
the treatment of central tumors, wherein prioritizing dose constraints of the OAR over 
tumor coverage is recommended.  
Additionally, a clear fractionation consensus for centrally located lung tumors is missing. 
As such, risk-adapted schedules vary between institutes. These different risk-adapted 
schedules are not all resulting in the same biologically equivalent dose (using an α/β-ratio 
of 10 Gy; BED10). Multiple studies report high local control (LC) rates when prescribing a 
minimum of 100 Gy BED10 (35, 47-49). However, a fractionation schedule with a minimum 
dose of 100 Gy BED10 covering more than 95% of the planning target volume (PTV), can still 
result in a wide variety of dose distributions to the PTV. This variety of dose in combination 
with the heterogeneity of stereotactic treatment plans, asks for additional PTV parameters 
to define the optimal treatment plan that gives adequate local tumor control (50). 
Therefore, additional PTV parameters, such as Dmean (19, 50) and D95% (19), have been 
proposed by various studies in the stereotactic treatment of NSCLC. Additionally, the ICRU 
91 suggests the use of the median dose to the PTV (D50%) as a representative absorbed-dose 
value for the PTV (51). 
Taking the increased priority of the OAR dose constraints and the previous mentioned 
studies in mind, the question can be raised whether only a prescribed dose of more than 
100 Gy BED10 is enough for adequate tumor control. Moreover, prioritizing the OAR 
constraints can result in a reduced PTV coverage and the effect of this underdosage on the 
LC probability is unknown. The purpose of this research is to determine the effect of 
reduced tumor coverage and other possible prognostic factors on local and disease control 
in patients with centrally located NSCLC treated with SBRT. 
3.2 Material and Methods 
We identified patients having T1-4N0M0 NSCLC treated between 2006 and 2016 with risk-
adaptive stereotactic radiotherapy in 2 Dutch centers: Erasmus Medical Center (EMC) and 
Haaglanden Medical Center (HMC). Tumors were considered central when the tumor was 
located within 2 cm of the esophagus and/or the bronchial structures (trachea, main 
bronchus, bronchus intermedius or upper-, middle-, or lower- lobe bronchi). Patients were 
excluded if they had: a second lung nodule, previous radiation with overlapping fields, 






chemotherapy during SBRT and if they did not have any follow-up. Diagnostic work-up 
consisted of a PET scan. An MRI scan of the brain was not performed in these patients 
without nodal disease. 
Treatment planning and delivery of both centers have been previously described (29, 
52). Briefly, the treatment in the HMC was initially delivered with a stereotactic linear 
accelerator (Novalis, Brainlab AG, Munich Germany), that was replaced by a linear 
accelerator with cone-beam CT-guidance (Elekta AB, Stockholm, Sweden) in 2013. Patients 
were treated with 60 Gy in 8 fractions 3 times a week or, 60 Gy in 12 fractions 4 times a 
week if the PTV overlapped with or was too close to the OAR. The PTV consisted of an 
internal target volume (ITV) that was expanded with 5 mm (6 mm in craniocaudal direction) 
for the Novalis linear accelerator and 6 mm in all directions for the Elekta linear accelerator. 
Until 2014, the ITV was created by expanding the gross tumor volume (GTV) based on 6 
scans taken randomly during the breathing cycle. Thereafter, the ITV was created by 
contouring the tumor in 10 respiratory phases of the 4D CT scan. The treatment dose was 
prescribed to the 100% isodose line and the maximum dose was not allowed to exceed 
140%. At least 95% of the PTV had to receive 100% of the prescribed dose and 99% of the 
PTV had to receive 90% of the prescribed dose. In EMC, patients were treated with the 
Cyberknife Robotic Radiosurgery System (Accuray Inc, Sunnyvale, AC) with 5 fractions of 9 
– 12 Gy or, when the tumor was close to the esophagus, 6 – 7 fractions of 7 – 8 Gy, except 
in 2 patients who received 3 fractions of 20 Gy. The PTV consisted of the GTV plus 5 mm. 
The dose to the PTV was prescribed to the 70 – 90% isodose line covering at least 95% of 
the PTV. At both institutions, underdosage was allowed in order to meet the dose 
constraints of the OAR (Appendix 3A) or an acceptable dose to the OAR at the discretion of 
the treating physician.  
Follow-up was generally performed 3 weeks, 3, 6, 12, 18 and 24 months following SBRT 
and annually thereafter. Patient records from hospitals and general practitioners were 
screened for disease control, survival status and toxicity. A local recurrence was defined as 
a recurrence within or adjacent to the PTV. Disease progression was defined as a tumor 
recurrence in any part of the body. In the absence of a biopsy, (local) tumor recurrence was 
defined as a 20% increase in tumor size on the CT scan compared with the previous CT scan 
according to the Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0). In 
addition, a corresponding avid lesion on the PET scan was required. In order to visualize the 
location of all the local recurrences, we contoured the center of the treated tumor as a small 
3D circle (diameter 7 mm) on one CT scan. Local control was calculated from the start of 
SBRT until the moment of diagnosis of the local recurrence. For patients without an event, 
the last date of a follow-up visit in the hospital was used. Overall survival and disease free 
survival (DFS) were calculated using the first date of SBRT and the date of death or disease 
progression, respectively. For patients without an event, the last date of follow-up visit or 
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the last date of contact was used. As the last date of follow-up contact was used, death was 
not a competing risk for disease recurrence. Underdosage of the tumor is described as 
absolute and relative volume of the PTV receiving less than 100 Gy BED10. All cases with 
grade 3 or higher toxicity according to the definition of the Common Terminology Criteria 
for Adverse Events (version 4.03) were scored. Toxicity was considered acute if it occurred 
within 3 months from the start of the SBRT and late if it occurred thereafter.  
Because of variations in the treatment schedules, all doses were converted into a BED10 
using the following formula: 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 = 𝐵𝐵𝐵𝐵 ×  (1 +  𝑑𝑑𝑑𝑑
𝛼𝛼𝛼𝛼/𝛽𝛽𝛽𝛽
) with D = total dose, d = dose per 
fractions and α/β-value is 10 Gy. Dosimetric PTV parameters were derived from the dose 
volume histogram (DVH) of each patient: maximum and minimum point dose (Dmax, Dmin), 
mean dose (Dmean), dose to 2 / 50 / 98 percent of the PTV (D2% / D50% / D98%) and volume of 
the PTV receiving less than 100 Gy BED10 (PTV < 100 BED10).  
Cox regression was used to determine LC and DFS and to test possible prognostic factors 
for (local) disease control. The following factors were entered into the univariate analyses: 
age, gender, previous (lung)malignancies, WHO status (0 versus ≥ 1), charlson comorbidity 
score (CCS; 0 – 2 versus ≥ 3), chronic obstructive pulmonary disease (COPD; GOLD 0 – 1 
versus 2 – 4), forced expiratory volume in 1 second (FEV1), endobronchial tumor location, 
availability of pathology, localization of the tumor in the upper/middle lobe or mediastinum 
versus the lower lobe, disease stage (TNM 8th; IA – IIA versus IIB – IIIA), tumor size, PTV 
volume, prescribed dose (< 100 Gy BED10 versus ≥ 100 Gy BED10), Dmax BED10, Dmin BED10, 
Dmean BED10, D2% BED10, D50% BED10 (as a continuous variable and dichotomized to < 100 Gy 
BED10 versus ≥ 100 Gy BED10), D98% BED10, PTV < 100 BED10 and percentage of the PTV 
receiving less than 100 Gy BED10 (%PTV < 100 BED10). The univariate analyses was followed 
by a multivariate analyses (MVA) with backward selection for all factors having a p-value < 
0.20. When multiple correlating variables were significant in univariate analyses, only the 
factor with the highest clinical relevance was entered in the MVA. The proportional hazards 
assumption, assuming that the hazard between the groups is constant over time, was 
checked for each variable that was entered into the Cox regression. Kaplan-Meier estimates 
were calculated for all clinical outcomes and curves were compared using log-rank tests. 
Tumor size was not only analyzed as a continuous variable, but also dichotomized with a 
cutoff of 5 cm, such that we could examine the relevance of this cutoff criteria used by the 
RTOG 0813 study for inclusion (in which tumors had to be ≤ 5 cm) (16). In all analyses a p-
value ≤ 0.05 was considered statistically significant. Analyses were performed using IBM 
SPSS statistics version 25.0.0.1 software package (SPSS Inc., Chicago, IL). This retrospective 
study received approval from the medical ethical committees of both centers. 
 
  




For this analysis 220 patients were eligible. Patient- and treatment characteristics are 
shown in Table 1. The diagnosis was confirmed by pathology in 58% of patients. All but one 
patient had a diagnostic PET-CT scan. In this patient pathology was available. The majority 
of the patients was diagnosed with stage I (38%) or stage II lung cancer (52%). The most 
commonly used fractionation schedules were 5 fractions (37%), 8 fractions (31%) and 12 
fractions (15%).  
Local control rates were 92% at 1 year, 88% at 2 years and 81% at 3 years. Twenty-seven 
patients (12%) were diagnosed with a local recurrence. No clear pattern of local relapse 
could be visualized when delineating all recurrences on one CT scan (Figure 1). Relative and 
absolute PTV underdosage were both not prognostic for a local recurrence (PTV < 100 BED10 
p-value = 0.593 and %PTV < 100 BED10 p-value = 0.127). The median PTV receiving less than
100 Gy BED10 was 4.2 cc in patients with a recurrence compared to 1.2 cc in patients without 
a recurrence. The median percentage of the PTV receiving less than 100 Gy BED10 was the
same in patients with and without a local recurrence (both 2%, Table 2).
Figure 1 – Pattern of recurrence: a) anterior view and b) lateral view 
Small light blue circles 
represent the center of 
mass of each tumor 
reporting local
recurrence. 
Color legend organs at 
risk: orange = 
esophagus, dark blue = 
bronchial tree (trachea, 
main bronchus, 
bronchus intermedius 
or upper-, middle- or 
lower- lobe bronchi), 
light red = aorta, dark 
red = heart.  
Factors prognostic for the development of a local recurrence using univariate analysis were 
a larger tumor diameter (continuous variable), higher disease stage, a tumor localized in the 
lower lobe and a prescribed dose of < 100 Gy BED10 (Table 2). The 1 year LC rate was 
significantly higher for tumors < 5 cm compared to tumors ≥ 5 cm (96% versus 84%, p-value 
< 0.001, Figure 2a). When the prescribed dose was lower than 100 Gy BED10, patients were 
twice as likely to develop a local recurrence: Hazard Ratio (HR) 2.24, 95% Confidence 
Interval (CI) 1.02 – 4.95, p-value = 0.045. A PTV D50% of < 100 Gy BED10 was not prognostic 
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for local recurrence (LC at 1 year 85% for D50% of < 100 Gy BED10 versus 93% for D50% of ≥ 
100 Gy BED10, p-value = 0.139, Figure 2b).  
Table 1 – Patient- and tumor-characteristics (n = 220) 
n (%) / median (IQR, range) 
Age (years) 76 (68 – 82, 51 – 94) 
Gender 
Female 89 (40%) 
Male 131 (60%) 
COPD 
No COPD 39 (18%) 
GOLD I – II 113 (51%) 
GOLD III – IV 61 (28%) 
Unknown 7 (3%) 
Charlson Comorbidity Index 
0 – 2 128 (58%) 
3 – 5 83 (38%) 
6 – 9 9 (4%) 
WHO performance Scale 
0 74 (34%) 
1 117 (53%) 
2 14 (6%) 
3 – 4 6 (3%) 
Unknown 9 (4%) 
Tumor histology 
No pathology available 91 (42%) 
Squamous cell carcinoma 68 (31%) 
Adenocarcinoma 40 (18%) 
Large cell carcinoma 18 (8%) 
Different 3 (1%) 
Disease stage TNM 8th  
IA / IB 83 (38%) 
IIA / IIB 115 (52%) 
IIIA  22 (10%) 
Prescribed amount of fractions 
3 fractions of 20 Gy 2 (1%) 
5 fractions of 9/10/11/12 Gy 82 (37%) 
6 fractions of 7/8 Gy 17 (8%) 
7 fractions of 7 Gy 18 (8%) 
8 fractions of 7.5 Gy 69 (31%) 
12 fractions of 5 Gy 32 (15%) 
Tumor diameter (mm) 44 (33 – 58, 9 – 105) 
Abbreviations: COPD = chronic obstructive pulmonary disease, Gy = gray, IQR = interquartile range, PTV = planning 
target volume 
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Table 2 – Results of the Cox regression analyses focusing on patient- and dosimetric factors prognostic 




median (IQR) / n (%) 
Local progression 
median (IQR) / n (%) 
Hazard Ratio 
(95%CI) p-value 
Age 76 (68 – 81) 71 (62 – 77) 0.97 (0.93 – 1.01) 0.091 
FEV1 a 64 (50 – 80) 60 (48 – 72) 0.98 (0.96 – 1.01) 0.119 
Gender Male 117  (89%) 14  (11%) 1 
Female 76  (85%) 13  (15%) 1.18 (0.55 – 2.51) 0.672 
Localisation of  
tumor 
UMM 140  (90%) 16  (10%) 1 
Lower 53  (83%) 11  (17%) 2.26 (1.05 – 4.88) 0.038 
WHO status b 0 64  (86%) 10  (14%) 1 
1 – 4  120  (88%) 17  (12%) 1.12 (0.51 – 2.45) 0.775 
COPD c 0 – 1  63  (91%) 6 (9%) 1 
2 – 4  125  (87%) 19  (13%) 1.30 (0.52 – 3.25) 0.580 
Pathology available No 83 (91%) 8  (9%) 1 
Yes 110  (85%) 19 (15%) 1.97 (0.86 – 4.51) 0.107 
CCS 0 – 2 113  (88%) 15  (12%) 1 
≥ 3 80  (87%) 12  (13%) 1.14 (0.53 – 2.44) 0.741 
Previous  
malignancies d 
No 115  (86%) 18  (14%) 1 
Yes 78  (90%) 9  (10%) 0.84 (0.38 – 1.87) 0.666 
Previous lung 
carcinoma d 
No 175  (89%) 22  (11%) 1 
Yes 18  (78%) 5  (22%) 1.51 (0.57 – 4.02) 0.404 
Endobronchial  
tumor 
No 154  (87%) 23  (13%) 1 
Yes 39  (91%) 4  (9%) 1.05 (0.36 – 3.08) 0.923 
Disease stage IA – IIA 122  (93%) 9  (7%) 1 
IIB – IIIA 71  (80%) 18  (20%) 4.43 (1.97 – 9.94) < 0.001 
Tumordiameter (mm) 42  (32 – 54) 54  (38 – 62) 1.04 (1.02 – 1.06) 0.001 
PTV volume (cc) 75  (42 – 135) 118  (50 – 157) 1.00 (1.00 – 1.01) 0.054 
PTV < 100 BED10 (cc) 1.2 (0.2 – 27.4) 4.2 (0.4 – 75.4) 1.00 (1.00 – 1.00) 0.593 
%PTV < 100 BED10 2% (0% – 38%) 2% (1% – 55%) 2.26 (0.79 – 6.43) 0.127 
Prescribed dose BED10 < 100 56 (84%) 11 (16%) 1 
≥ 100 137 (90%) 16 (10%) 0.45 (0.20 – 0.98) 0.045 
PTV Dmax BED10 144 (127 – 175) 139 (122 – 157) 0.99 (0.98 – 1.01) 0.193 
PTV D2% BED10 139 (121 – 163) 134 (115 – 152) 0.99 (0.98 – 1.01) 0.203 
PTV Dmean BED10 122 (102 – 136) 115 (97 – 132) 0.99 (0.97 – 1.01) 0.278 
PTV D50% BED10 123 (103 – 137) 117 (98 – 132) 0.99 (0.97 – 1.01) 0.279 
PTV D98% BED10 100 (84 – 105) 92 (77 – 104) 0.99 (0.97 – 1.01) 0.383 
PTV Dmin BED10 75  (64 – 90) 72  (56 – 85) 0.99 (0.97 – 1.01) 0.186 
PTV D50% BED10 < 100 39 (85%) 7 (15%) 1 
≥ 100 154 (89%) 20 (11%) 0.49 (0.21 – 1.12) 0.092 
a 24 cases missing; b 9 cases missing; c 7 cases missing; d proportional hazard assumption is violated  
Abbreviations: BED10 = biologically effective dose using α/β-ratio of 10 Gy, CCS = charlson comorbidity score, COPD = 
chronic obstructive pulmonary disease, Dmax = maximum point dose, Dmean = mean dose, Dmin = minimum point dose, 
D..% = dose to .. percent of the PTV, FEV1 = forced expiratory volume in 1 second, NSCLC = non-small cell lung cancer, 
PTV = planning target volume, PTV < 100 Gy BED10 = volume of the PTV which is receiving less than 100 Gy BED10, SBRT 
= stereotactic body radiation therapy, UMM = upper/middle lobe or mediastinum, %PTV < 100 Gy BED10 = percentage 
of the volume of the PTV which is receiving less than 100 Gy BED10. 
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Table 3 – Results of the Cox regression analyses focusing on patient- and dosimetric factors prognostic 
for disease free survival for patients with T1-4N0M0 NSCLC treated with SBRT 
Univariate analysis 
Characteristic 
median (IQR) / n (%) 
Disease control  Disease progression Hazard Ratio 
(95%CI) 
p-value 
Age 77 (70 – 81) 72 (64 – 79) 0.98 (0.95 – 1.00) 0.066 
FEV1a 65 (50 – 84) 60 (49 – 72) 0.99 (0.97 – 1.00) 0.047 
Gender Male 83 (63%) 48 (37%) 1 
Female 62 (70%) 27 (30%) 0.77 (0.48 – 1.24) 0.281 
Localisation of  
tumor 
UMM 112 (72%) 44 (28%) 1 
Lower 33 (52%) 31 (48%) 2.36 (1.49 – 3.74) < 0.001 
WHO b 0 50 (68%) 24 (32%) 1 
1 – 4  91 (66%) 46 (34%) 1.26 (0.77 – 2.07) 0.354 
COPD c 0 – 1  52 (75%) 17 (25%) 1 
2 – 4  88 (61%) 56 (39%) 1.41 (0.82 – 2.42) 0.220 
PA available No 61 (67%) 30 (33%) 1 
Yes 84 (65%) 45 (35%) 1.22 (0.77 – 1.94) 0.393 
CCS 0 – 2 84 (66%) 44 (34%) 1 
≥ 3 61 (66%) 31 (34%) 0.96 (0.61 – 1.53) 0.877 
Previous  
malignancies 
No 85 (64%) 48 (36%) 1 
Yes 60 (69%) 27 (31%) 0.86 (0.54 – 1.38) 0.527 
Previous lung 
carcinoma d 
No 131 (66%) 66 (34%) 1 
Yes 14 (61%) 9 (39%) 0.92 (0.46 – 1.86) 0.821 
Endobronchial  
tumor 
No 114 (64%) 63 (36%) 1 
Yes 31 (72%) 12 (28%) 1.04 (0.56 – 1.94) 0.895 
Disease stage IA – IIA 101 (77%) 30 (23%) 1 
IIB – IIIA 44 (49%) 45 (51%) 3.23 (2.03 – 5.13) < 0.001 
Tumordiameter (mm) 38 (30 – 51) 51 (39 – 61) 1.03 (1.02 – 1.04) < 0.001 
PTV volume (cc) 64 (39 – 129) 102 (67 – 154) 1.00 (1.00 – 1.00) 0.003 
Prescribed dose BED10 < 100 41 (61%) 26 (39%) 1 
≥ 100 104 (68%) 49 (32%) 0.70 (0.43 – 1.13) 0.144 
PTV Dmax BED10 144 (130 – 173) 140 (122 – 176) 1.00 (0.99 – 1.00) 0.314 
PTV D2% BED10 140 (122 – 164) 136 (115 – 163) 1.00 (0.99 – 1.00) 0.258 
PTV Dmean BED10 122 (102 – 136) 120 (100 – 135) 0.99 (0.98 – 1.01) 0.253 
PTV D50% BED10 123 (103 – 136) 120 (101 – 136) 0.99 (0.98 – 1.01) 0.252 
PTV D98% BED10 # 101 (85 – 106) 92 (82 – 105) 0.99 (0.98 – 1.01) 0.244 
PTV Dmin BED10 77 (64 – 89) 73 (62 – 89) 0.99 (0.98 – 1.01) 0.307 
PTV D50% BED10 < 100 28 (19%) 18 (24%) 1 
≥ 100 117 (81%) 57 (76%) 0.60 (0.35 – 1.01) 0.056 
a 24 cases missing; b 9 cases missing; c 7 cases missing; d proportional hazard assumption is violated  
Abbreviations: BED10 = biologically effective dose, CCS = charlson comorbidity score, COPD = chronic obstructive 
pulmonary disease, Dmax = maximum point dose, Dmean = mean dose, Dmin = minimum point dose, D..p = dose to .. percent 
of the PTV, FEV1 = forced expiratory volume in 1 second, NSCLC = non-small cell lung cancer, PTV = planning target 
volume, SBRT = stereotactic body radiation therapy, UMM = upper/middle lobe or mediastinum. 






The MVA included age, localization of the tumor (upper/middle lobe or mediastinum versus 
lower lobe), FEV1, availability of pathology (no versus yes), tumor diameter, %PTV < 100 
BED10, PTV Dmin BED10, prescribed dose in BED10 (< 100 Gy versus ≥ 100 Gy) and PTV D50% 
BED10 (< 100 Gy versus ≥ 100 Gy). Factors independently prognostic for local tumor 
recurrence in MVA were larger tumor size and lower FEV1: HR tumor diameter 1.04, 95% CI 
1.02 – 1.06, p-value = 0.001 and HR FEV1 0.97, 95% CI 0.95 – 1.00, p-value = 0.031.  
Disease progression was reported in 75 patients (34%). The DFS was 73% at 1 year, 66% 
at 2 years and 56% at 3 years. Disease free survival was significantly better for patients with 
tumors smaller than 5 cm (p-value < 0.001, Figure 2c). There was a trend for increased DFS 
in patients who received PTV D50% of ≥ 100 Gy BED10 (p-value = 0.053, Figure 2d). Factors 
prognostic for progressive disease using univariate analyses were lower FEV1, larger tumor 
size (continuous), larger PTV volume, tumors located in the lower lobe and disease stage IIB 
– IIIA (Table 3). Factors prognostic for progressive disease using multivariate analyses were 
larger tumor diameter (HR 1.03, 95% CI 1.02 – 1.04, p-value < 0.001), lower FEV1 (HR 0.98, 
95% CI 0.97 – 0.99, p-value = 0.004) and localization of the tumor in the lower lobe (HR 1.87, 
95% CI 1.12 – 3.11, p-value = 0.017). 
Thirty-eight percent of the patients had a tumor overlapping or adjacent to the proximal 
bronchial tree (PBT) and/or the esophagus; 67 patients to the PBT, 8 to the esophagus and 
9 patients to both. The incidence of the local recurrences of these ultracentral tumors was 
only slightly higher compared to the central tumors: 14% versus 11%. The LC at 1 year was 
91% for ultracentral tumors and 92% for central tumors (p-value = 0.095). Although these 
comparable LC rates, almost all cases (8 of 10) of grade 4-5 toxicity occurred in the group of 
ultracentral tumors. These 8 patients all had an ultracentral tumor due to proximity to the 
PTB. Details of the grade 4-5 toxicity cases are outlined below. In the group of 10 patients 
reporting grade 4-5 toxicity greater concession was done to the %PTV < 100 BED10. The 
median %PTV < 100 BED10 was 26% in patients with grade 4-5 toxicity versus 2% in the rest 
of the patients. Three of the 10 patients received < 100 Gy BED10 in more than 90% of the 
volume of the PTV and in 3 patients less than 2.5% of the PTV received < 100 Gy BED10.  
One patient had grade 4 toxicity and 9 patients had grade 5 toxicity. Grade 4 was scored 
because of a necrotic post obstruction pneumonia. The PET scan showed a fibrotic mass 
most likely caused by the radiation. Of the 9 patients with grade 5 toxicity, 3 deaths were 
likely due to SBRT, while 6 deaths were possibly related to SBRT. The 3 patients with a death 
likely related to SBRT had hemoptoe 4.5, 9 and 22 months after treatment. The tumor was 
adjacent to the intermediate bronchus or main bronchus, and there was no evidence of 
disease recurrence in these patients. Three other patients, having their death possibly 
related to SBRT, died due to fatal hemoptoe in the presence of disease recurrence. In this 
group, 2 patients did not have an ultracentral tumor. In the last 3 patients, respiratory 
failure was the cause of death which was also possibly related to the SBRT. One patient died 
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due to a COPD exacerbation and 2 patients died of atelectasis in the lung in combination 
with disease progression. SBRT could not be excluded as a cause of death in these last 3 
patients. Grade 3 or higher toxicity was scored in 12% (n = 27) of the patients. The overall 
survival was 55% at 2 years, 42% at 3 years and 26% at 5 years. 
Figure 2 – Kaplan-Meier curves for local control (A, B) and disease free survival (C, D) 
3.4 Discussion 
Stereotactic treatment of central lung tumors frequently comes with underdosage of the 
PTV due to nearby OARs, however as far as we know the consequences of this underdosage 
were still unknown. Within our cohort, neither the absolute nor the relative amount of PTV 
underdosage was prognostic for a local recurrence. We did find the following factors to be 
independent significantly prognostic: larger tumor size and a lower FEV1 for local and 
disease recurrence and additionally a tumor location in the lower lobe for disease 
recurrence. 






Our reported LC rates were comparable to other studies (Table 4) (19, 27, 28, 35, 37, 39, 43, 
47, 53-56). The univariate analysis showed a significant correlation between a prescribed 
dose of ≥ 100 Gy BED10 and local tumor control. Previous studies confirmed the importance 
of a higher (prescribed) radiation dose on LC within the stereotactic treatment of centrally 
located NSCLC (19, 47). Tumor size has been frequently analyzed as a prognostic factor for 
local recurrence in patients with NSCLC treated with SBRT, but data is conflicting (20). 
Concerning studies only including central lung tumors, tumor size has been analyzed within 
one small study without finding a correlation (39). The authors stated that the study was 
underpowered due to the small number of events. For the same reason other central lung 
tumor studies were unable to define any prognostic factors (38, 57). However, within 
multiple combined (including both central and peripheral tumors) studies, larger tumor size 
was prognostic for local recurrence in SBRT treatment as in our analysis (19, 35, 43, 54, 56). 
Only 2 studies analyzed FEV1 as a prognostic factor, but without describing the same 
correlation we found (28, 43). However, a poor FEV1 is commonly caused by smoking and it 
is known that people who smoked had worse outcomes (58). Within our analysis, the 
incidence of local recurrences was almost similar between the ultracentral and central 
tumors and the LC rates were not significantly different. Other studies comparing LC for 
patients with an ultracentral versus a central lung tumor after SBRT confirmed these equal 
LC rates (59-61). 
Prognostic factors for DFS after SBRT in NSCLC have rarely been published. Several 
studies have only reported local-, regional- and distant control as separate analyses while 
others have reported only the DFS rates without possible prognostic factors. Three studies 
have confirmed our outcome that a larger tumor is correlated with disease recurrence, 2 
analyzing DFS (39, 56) and one analyzing distant control (43). FEV1 has been analyzed in one 
study focusing on DFS and one on distant control, but was not prognostic in either study 
(28, 43). Chang et al. investigated COPD for potential association with DFS, but did not find 
a relation (38). In our cohort, patients with tumors located in the lower lobe were at higher 
risk for disease recurrence, this was confirmed by another study (33). An explanation can 
be the more frequent upstaging due to unsuspected nodal involvement in lower lobe 
tumors that is seen after surgery. This can also be the case in tumors treated with SBRT (34). 
With regards to tumor location, other analyses have an inferior local and distant control for 
central tumors compared with peripheral tumors (55, 56). There was no significant 
correlation between dose and disease control in our study, which is comparable to other 
studies analyzing dosimetry as prognostic factor for DFS or distant control (28, 38, 41, 43).  
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Although some characteristics had missing values, we did enter all characteristics having a 
p-value of < 0.20 into the MVA. This resulted in an analysis based on 196 patients with an
adequate number of events (23 local failure events and 66 disease progression events) to
run a reliable MVA. However, next to the prognostic patient characteristics, we did not find
a relation between local recurrence and dose to the PTV or PTV underdosage. The number
of events may be too small for an elaborate MVA and it may not be able to identify a
potentially weaker association between dosimetric factors and disease control. In the MVA
for both LC and DFS, we only included tumor size and not PTV volume and disease stage as
these factors were highly correlated. Of the 3 factors tumor size was chosen as it is the most 
clinical relevant characteristic. A limitation of this study is its retrospective nature.
Additionally, as mentioned in the tables, some characteristics did not fulfill the proportional
hazard assumption in the Cox regression. Hence, the parameter being estimated by the Cox 
procedure may not be a meaningful measure of the between group difference and should
be further examined in future research.
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CHAPTER 4
Dose and volume of the 
irradiated main bronchi 
and related side effects 
in the treatment of 
central lung tumors with 
stereotactic radiotherapy
4







High radiation dose to the main bronchi can result in stenosis, occlusion or fistulation, and 
death. Only 8 articles have reported side effects to the main bronchi from stereotactic body 
radiation therapy (SBRT), mostly with only one symptomatic complication per article. 
Therefore, we calculated the dose to the bronchial structures, such as trachea; mainstem 
bronchi; intermediate bronchus; upper-, middle- and lower-lobe bronchus; and the 
segmental bronchi in 134 patients with central tumors and calculated the normal tissue 
complication probability (NTCP) for each of these structures, with toxicity determination 
based upon computed tomography imaging. No side effects were found in the trachea, and 
only stenosis occurred in the main bronchus and bronchus intermedius. Higher grades of 
side effects, such as occlusion and atelectasis, were only seen in the upper-, middle-, and 
lower bronchi and the segmental bronchi. When 0.5 cc of a segmental bronchi was 
irradiated to 50 Gy in five fractions, it was about 50% likely to be occluded radiographically. 
For grade 1 radiographically evident side effects, the 50% risk level for a 5-fraction Dmax was 
55 Gy for mid-bronchi and 65 Gy for mainstem bronchi. To assure the relationship between 
clinical toxicity and side effects to the bronchi, further investigation is needed.  
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4.1 Introduction 
For several years, stereotactic body radiotherapy (SBRT) has been used for the treatment 
of stage I inoperable non-small cell lung cancer (NSCLC) and solitary lung metastases. This 
resulted in promising results for the survival and local control (35, 47, 48). However, when 
treating central lung tumors (13, 46, 54), these results are sometimes combined with high 
toxicity. Central lung tumors are defined as those tumors being located less than 2 cm from 
the trachea, mainstem bronchus, main bronchi or esophagus; less than 6mm from the heart 
or tumors located in the mediastinum (Figure 1). High radiation dose to the main bronchi 
can result in stenosis, occlusion or fistula formation, and death (45, 54, 62). Not only SBRT 
causes radiation-induced side effects of the lung and bronchus, but also by other modalities. 
Gollins et al. (63) reported 38% and 58% bronchial stenosis after intraluminal brachytherapy 
(ILT) with a single dose of 15 and 20 Gy at 1 cm, respectively. Fibrotic reactions were seen 
10 – 13 months post ILT (64). 
Figure 1 – Bronchial structures 
Bronchial stenosis has also been reported after high-dose external beam radiotherapy. 
Miller et al. (65) used computed tomography (CT) scans to assess the incidence of bronchial 
stenosis after radiation treatment twice daily with high external beam radiotherapy. They 
reported a 1-year and 4-year actuarial rate of stenosis of 7% and 38%, respectively, with a 
median overall survival of 2.5 years. A suggestion for a dose-response effect was also found: 
4% and 25% at a dose of approximately 74 Gy and 86 Gy, respectively. Kelsey et al.(66) 
analyzed the bronchial stenosis of the mainstem bronchus in 18 patients with CT-scans and 






found in 17 of the 18 patients a decrease in the airway caliber ranging from 6% – 57%. The 
stenosis appeared to be dose dependent (p = 0.08), progressed with increasing time after 
radiotherapy (p = 0.04) and was worse in patients who also received chemotherapy (p = 
0.04). Although 17 of the 18 patients were diagnosed with stenosis, only 2 were known to 
have symptomatic bronchial stenosis.  
Despite those records, there is still no clear consensus about the dose-related side 
effects of the bronchial structures in SBRT. Therefore, the aim of this study was to calculate 
the dose to the bronchial structures, such as trachea; mainstem bronchi; intermediate 
bronchus; upper-, middle- and lower-lobe bronchus and the segmental bronchi, to 
determine the time for the onset of side effects and to calculate the normal tissue 





From July 2006 – December 2012, 134 patients with 143 central tumors were treated with 
SBRT on a robotic Cyberknife (Accuray Inc, Sunnyvale, CA) treatment unit (67). The planning 
target volume (PTV) was constructed by adding a 5 mm margin to the gross tumor volume 
(GTV). The PTV dose was prescribed at the 70% – 95% isodose line, which covered at least 
80% of the PTV. It was allowed to underdose the GTV or PTV or both to respect the 
constraints of the organs at risk (OAR). For the first 102 patients, dose calculations were 
performed using the ray-tracing algorithm implemented in the MultiPlan treatment 
planning system. For the other patients, a novel Monte Carlo (MC) dose-calculation 
algorithm was used in MultiPlan.  
According to the tumor location, various dose-prescription schedules were used. 
Tumors located near the esophagus (less than 2 cm) were in the first part of the study 
treated with 6 fractions of 8 Gy (n = 26), later with 7 fractions of 8 Gy (n = 8), and when the 
MC calculation algorithm was available with 7 fractions of 7 Gy (n = 9). All other central 
tumors (close to the mainstem bronchus, but not the esophagus) were initially treated with 
5 fractions of 9 Gy (n = 5). This dose was subsequently escalated to 5 fractions of 10 Gy (n = 
18) and later to 5 fractions of 12 Gy (n = 23). When the MC calculation algorithm was 
available, these tumors were treated with 5 fractions of 11 Gy (n = 19). A patient was treated 
with 3 fractions of 20 Gy. Over time, the constraints to the OAR changed, because no severe 
toxicity was seen and the prescription changed due to the use of the MC calculation 
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Table 1 – Currently used dose constraints 
 Dose Constraints for 
 55 Gy (5 fractions) 49 Gy (7 fractions) 
Organ Volume Total dose (Gy) Total dose (Gy) 
Spinal Cord Any point 27.5 32.9 
Esophagus Any point 35 42 
Trachea  Any point 45 49 
Main bronchus Any point 55 49 
Brachial plexus Any point 30 35 
Lung 30 % 16 18 
 
Dose (re)-calculation for the study 
For the purpose of the study, dose distributions for the first 102 patients, planned with the 
ray-tracing algorithm, were re-calculated with the more advanced MC dose-calculation 
algorithm. To compare doses in the OAR across the various fractionation schemes, all doses 
were converted into an equivalent dose of 2 Gy (EQD2) and a Biologically Equivalent Dose 
(BED). The BED and EQD2 were calculated using the following formulas: 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 = 𝐵𝐵𝐵𝐵 ∗  (1 +
(𝑑𝑑𝑑𝑑/(α/β)) and 𝐵𝐵𝐵𝐵𝐸𝐸𝐸𝐸𝐵𝐵𝐵𝐵2 = 𝐵𝐵𝐵𝐵 ∗  (𝑑𝑑𝑑𝑑 + α/β)/(2.0 +  α/β) where D = total dose and d = dose 
per fraction. For the tumors and normal tissues, we assumed α/β ratios of 10 and 3 (late 
side effects), respectively. The Dmax was the maximum dose of a structure in a point 
calculated by the planning system. Apart from Dmax, the volumes receiving an EQD2 of 65, 
80, 90, 100, and 130 Gy, and the volume receiving a BED of 100 Gy were calculated. Patients 
whose bronchial structures received an EQD2 lower than 65 Gy were excluded in the 
analyses.  
 
Assessment of side effects of the bronchi and survival 
In total, 690 bronchial structures were delineated in the planning CT-scan together with the 
PTV and GTV, and the structures 397 that had V65 Gy ≥ 0 cc were included in the analysis. 
The bronchial structures were divided into 4 groups based on diameter: (T) trachea; (MI) 
mainstem bronchus and intermediate bronchus; (UML) upper-, middle-, and lower lobe 
bronchi; and (SB) segmental bronchi (branches of the upper-, middle-, and lower bronchi). 
This difference was made because of the anatomical difference between those structures. 
To evaluate the late side effects in the bronchial structures, CT scans were compared with 
the planning CT scan and 3 side effects were scored: (1) stenosis, (2) occlusion without 
atelectasis in the same segment and (3) occlusion with atelectasis in the same segment. For 
each patient, all available CT scans after the SBRT were scored based on side effects of the 
irradiated bronchi. A bronchus was not scored if the bronchus was a branch of an already 
occluded bronchus with atelectasis. By scoring all the available CT scans, we wanted to 
measure the different time points of the development of the side effects. All available CT 






scans were independent scored by 2 researchers (M. Duijm and J. Nuyttens) and at different 
time periods. 
The first moment of the occurrence of a side effect for all structures was calculated using 
a Kaplan-Meier curve, with the follow-up until the moment of side effects, or when no side 
effects were reported until death or last follow-up CT scan. For the UML and SB, the 
moment of atelectasis was calculated in the same manner as described earlier, with the 
moment of atelectasis vs no side effect or, stenosis or occlusion. The log-rank test was used 
for the statistical significance of differences between the curves. 
Overall survival was calculated, using Kaplan-Meier curves, from the first day of 
treatment until the patient died. Patients lost in follow-up or patients who were still alive 
were censored on the last day of contact. The group was split into patients with and without 
measured side effects on the CT scan to determine the effect of side effects on the survival. 
We evaluated the cause of death of each patient, to ensure radiation was not (a part of) the 
cause of death. 
 
4.3 Results 
After (re-)calculation with the MC dose-calculation algorithm, 109 of the 134 patients had 
one or more bronchial structure(s) that received at least a total EQD2 of 65 Gy3. Of the 109 
patients, side effects of the bronchial structures could be evaluated in 104 patients with 109 
tumors. The CT scans of the remaining 5 patients were missing, because 2 patients died 
within 2 months after radiotherapy and no imaging was made. Only a chest X-ray was done 
in the other 3 patients, 2 of them died in less than 7 months after radiotherapy, and despite 
the 60-months survival of the last patient, no CT scan was done because of high 
comorbidity. 
The patient characteristics are shown in Table 2. The median Dmax in EQD2 of the 4 
groups, (T) trachea; (MI) mainstem bronchus and intermediate bronchus; (UML) upper-, 
middle-, and lower-lobe bronchi; and (SB) segmental bronchi, are 93 Gy3, 103 Gy3, 124 Gy3 
and 121 Gy3, respectively. The details of the Dmax and the median volume of the structures 
irradiated to the different EQD2 levels are shown in Table 3.  
In total 207 CT scans were scored, with a mean of 14.2 months after radiotherapy 
(minimum 0.77 months – maximum 68.1 months). Side effects were found in 59 patients 
(56.7%). No side effects were found in group T. In this group, the median V65 EQD2 was 0.365 
cm3 and the median V100 EQD2 was 0.077 cm3.  
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Table 2 – Patient and tumor characteristics 
Patient characteristics   
Median age, y (range) 73 (34 – 88) 
Male / female 59 / 45 
Charlson comorbidity score   
 > 4 14 (14%) 
 3 – 4 17 (16%) 
 1 – 2 51 (49%) 
 0 22 (21%) 
Cumulative illness score   
 > 6 14 (14%) 
 5 – 6 19 (18%) 
 0 – 4  71 (68%) 
Tumor characteristics   
Histology   
 Large-cell carcinoma 15 (13.5%) 
 Squamous-cell carcinoma 27 (25%) 
 Adenocarcinoma 15 (13.5%) 
 Undifferentiated carcinoma 3 (3%) 
 Others 3 (2%) 
 No biopsy or inconclusive biopsy 47 (43%) 
Primary / metastatic lung cancer 63 / 46 
Median gross tumor volume, cm3 (range) 31 (1 – 367) 
Median planned tumor volume, cm3 (range) 67 (5 – 523) 
Median tumor diameter, cm (range) 46 (10-105) 
 
Table 3 – Median observed Dmax and the dose and volume in cm3 per structure group 








 Dmax (EQD2) 93 103 124 121 
 range 66 – 137  65 – 173  67 – 233  39 – 245 
 Dmax (BED) 155 172 206 202 
 range 111 – 228  109 – 288  112 – 388  80 – 408  
 Median V65 0.365 0.820  0.633  0.307 
 range 0.003 – 4.602 0.002 – 8.457 0.001 – 5.791 0.001 – 1.890 
 number of structures V65 > 0 25 67 130 201 
 Median V80 0.236  0.615  0.502  0.294 
 range 0.001 – 2.253 0.001 – 7.775 0.001 – 5.131 0.001 – 1.890 
 number of structures V80 > 0 18 55 113 175 
 Median V90 0.063  0.408  0.518  0.294 
 range 0.004 – 1.213 0.004 – 6.122 0.001 – 4.607 0.002 – 1.890 
 number of structures V90 > 0 15 49 100 161 
 Median V100 0.077  0.280  0.453  0.274 
 range 0.002 – 0.731 0.003 – 3.626 0.002 – 4.145 0.001 – 1.890 
 number of structures V100 > 0 8 36 92 142 
 Median V130 0.010  0.041  0.075  0.186 
 range 0.010 – 0.010 0.003 – 1.743 0.001 – 2.878 0.001 – 1.184 
 number of structures V130 > 0 2 14 51 84 
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In all structures except group T some side effects were found, but only the group of UML 
and SB reported occlusion and atelectasis. Side effect were found after 1 year in 31% of the 
structures and after 2 years in 42.7% of the structures side effects were found. Figure 2 
shows the first moment of side effects for the different structure groups. After 1 year, side 
effects occurred for the MI, UML, and SB in 14.6%, 29.1% and 41.4% of the structures, 
respectively, and in 29.5%, 49.8%, and 47.5% of the structures after 2 years (p = 0.021). The 
median time for the first occurrence of a side effect was 26 and 25 months for the UML and 
SB, respectively. 
Figure 2 – a) First moment of side effects per structure group; b) Moment until the occurrence of 
atelectasis 
Abbreviations: MI = mainstem bronchus and intermediate bronchus; UML = upper, middle and lower lobe bronchi; 
SB = segmental bronchi 
The median volume for the MI was 0.820 cm3 at the V65 EQD2, 0.280 cm3 at the V100 EQD2 
and 0.041cm3 at the V130 EQD2. Stenosis was found in 13 of the 67 MI structures. Of the 130 
structures in the UML group, 22 showed stenosis, 6 showed occlusion, and 15 showed 
atelectasis at the end of the follow-up. The median volume was 0.633 cm3 at the V65 EQD2, 
0.453 cm3 at the V100 EQD2 and 0.057 cm3 at the V130 EQD2.  
The SB groups contained 200 structures, of which 10 showed stenosis at the end of the 
follow-up, 22 showed occlusion and 42 showed atelectasis. The median V65 EQD2 was 0.307 
cm3, the median V100 EQD2 was 0.274 cm3 and the median V130 EQD2 was 0.186 cm3.  
Figure 2 shows the time to atelectasis for the UML and SB. In the UML, atelectasis was 
found after 1 year in 11.6% of the structures and in 18.5% after 2 years. In the SB, atelectasis 
was found after 1 year in 24.3% of the structures and in 29.7% after 2 years. The 2 groups 
had a significant different incidence of side effects (p = 0.018). 
BA
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We compared the patients with side effects and without side effects and found several 
significant differences for different structures. The details are shown in Table 4. The Dmax 
and irradiated volumes at different dose levels were significantly different in the UML group 
and SB group when comparing structures with toxicity and without toxicity. A 25% 
probability of complication (stenosis) was found at a Dmax for the MI group of 136 Gy. For 
the UML group (mid-bronchi), a 25% probability of complication (any) was found at a Dmax 
of 110 Gy, and for the SB group, a 25% probability of complication (any) was found at a Dmax 
of 55 Gy. The details of the NTCPs are shown in Figures 3 – 5. 














Mean without side effects 93 155 1.063 0.545 0.166 1.422 
Mean with side effects n.a. n.a. n.a. n.a. n.a. n.a.
Percentage of structures with side effects 0 0 0 0 0 0 
Main bronchus or bronchus intermedius 
Mean without side effects 105 175 1.3 0.967 0.573 1.5 
Mean with side effects 116 194 2.1 1.315 1.247 2.3 
Percentage of structures with side effects 20 20 20 22 22 20 
p-value 0.100 0.100 0.130 0.170 0.100 0.120 
Upper-, middle-, and lower- bronchi 
Mean without side effects 113 189 0.7 0.649 0.5 0.766 
Mean with side effects 143 239 1.15 1.055 0.891 1.2 
Percentage of structures with side effects 33 33 33 36 40 33 
p-value > 0.0001 > 0.0001 0.007 0.015 0.014 0.010 
Segmental bronchi 
Mean without side effects 121 202 0.326 0.302 0.287 0.365 
Mean with side effects 135 225 0.438 0.442 0.409 0.456 
Percentage of structures with side effects 37 37 37 38 43 37 
p-value 0.011 0.011 0.008 0.002 0.011 0.036 
The overall survival for the 104 patients was 74% at 1 year and 51% at 2 years. Looking at 
the patients with measured occlusion or atelectasis or both on their upper-, middle-, lower 
bronchi or segmental bronchi compared with the other patients, there was no difference in 
overall survival (p = 0.964). Also, 74 of the 104 patients died – 36 of them as a consequence 
of malignancy, 15 died of progression of the primary tumor, 16 died of metastasis, and 5 
patients died due to a secondary malignancy. A total of 5 patients died due to a pneumonia 
and 1 patient died due to hemoptysis. A total of 32 patients died due to others causes 
(cardiac, stomach bleeding, sepsis, liver failure, etc.). The cause of death in 8 patients was 
unknown. 
145960 Duijm BNW-def.indd   53 13-11-2020   16:08
Chapter 4 
54 
Figure 3 – The NTCP of the main bronchi according to Dmax, V65, V80, V100 for the end point adverse 
event (AE) of radiographically evident stenosis. 
Figure 4 – The NTCP of the mid-bronchi according to the Dmax, V65, V80, V100 for the end point adverse 
event (AE) of radiographically event stenosis, occlusion and atelectasis
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Figure 4 – The NTCP of the mid-bronchi according to the Dmax, V65, V80, V100 for the end point adverse 
event (AE) of radiographically event stenosis, occlusion and atelectasis (continued) 
Figure 5 – The NTCP of the segmental bronchi according to the Dmax, V65, V80, V100 for the end point 
adverse event (AE) of radiographically event stenosis, occlusion and atelectasis. 




Multiple studies have described bronchial strictures after radiotherapy, but in most cases 
the fractionation scheme and Dmax were the only available parameters. In a study on 
conventional external beam radiotherapy, bronchial stenosis was found in 8 patients. In the 
group treated with 74 Gy, 3 patients (4%) were reported with bronchial stenosis, 1 patient 
(5%) in the group of 80 Gy and 4 patients (25%) in the group of 86 Gy (65). After stereotactic 
treatment, 3 studies reported the death of 3 patients due to a bronchial stricture. In those 
patients, the dose in EQD2 differed from 67 – 84 Gy3 (35, 64, 68). In another study, several 
cases of atelectasis were reported. The tumors of these patients were located next to the 
main bronchi and were treated with 50 – 100 Gy3 (68). An overview of the side effects to 
the main bronchi is described in Table 5. Looking at these different studies, no significant 
cut-off point in the Dmax can be found. 
Table 5 – An overview of the side effects to the main bronchi in SBRT for central lung tumors 
Reference Number of 
patients with 
side effects 
Description of the side effects Treatment 
schedule 
Dose in EQD2 
Joyner et al. (69) 1 Stenosis of right lower-lobe bronchus 3 x 12 Gy 108 Gy3 
Song et al. (45) 6 Died due to complete stricture (n = 1) 4 x 12 Gy 144 Gy3 
Complete (n = 2) and partial (n = 3) 
stricture 
3 x 20 Gy / 
4 x 10-12 Gy 
104 – 276 Gy3 
Bral et al. (54) 1 Died due to bronchial stenosis 4 x 15 Gy 216 Gy3 
Oshiro et al. (70) 1 Grade 3 stenosis 10 x 6 Gy 108 Gy3 
Unger et al. (62) 1 Fistula mainstem bronchus 4 x 12 Gy 144 Gy3 
Haasbeek et al. (71) 1 Bronchial stenosis with atelectasis 3 x 10-12 Gy 78-108 Gy3 
Lee et al. (41) 1 Died due to bronchus obstruction 5 x 10 Gy 130 Gy3 
5 Partial stenosis 5 x 10 Gy / 
7 x 8 Gy 
123-130 Gy3 
Baumann et al. (68) 10 Atelectasis Unknown 50-100 Gy3 
In this study, not only the Dmax was an important parameter, but also the volume of the 
bronchial structure. In the group of the mainstem bronchus and intermedius bronchus, no 
significantly different numbers were found when comparing the group with side effects and 
the group without side effects. In the UML and SB group, all the dose levels were 
significantly different. Figure 3 shows that for mainstem bronchus, the Dmax EQD2 = 208.2 
Gy corresponded to 50% risk of radiographically evident stenosis; this equates to 65 Gy in 5 
fractions. The UML mid-bronchi had lower tolerance to grade 1 side effects, as Figure 4 
shows that 50% risk occurs at a lower Dmax dose of EQD2 = 156.4 Gy, which would be 55 Gy 
in 5 fractions. Segmental bronchi were more susceptible to occlusion than the other 
segments of bronchus. The large percentage volume D50% had a steeper slope than Dmax, 
revealing volume dependence. When 0.5 cc of a segmental bronchi was irradiated to 50 Gy 
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in five fractions, it was 50% likely to become occluded radiographically, but because of the 
diversity of bronchi in the anatomy, the occlusion of a few segmental bronchi did not 
frequently lead to symptomatic side effects. In the segmental bronchi, occlusion with 
atelectasis was approximately twice as likely as occlusion without atelectasis. The volume-
response models were all steeper than the dose-response models, so the volume of bronchi 
irradiated has an important role for each segment of bronchi that was studied. For some of 
the side effects, 1 cc of a segment of bronchi irradiated to a particular dose had about 1.33 
times the risk as compared with 0.5 cc of the same segment irradiated to the same dose. In 
other words, doubling the irradiated volume could increase the risk by approximately 
33%. When sufficient data with grade 3 or higher complications becomes available, it will 
be very important to study the volume effects more in detail. Mid-bronchus had visible 
occlusion in 21 of the 130 contoured structures, and in this segment, occlusion was 2.5 
times more likely to occur with atelectasis than without. 
A patient died due to hemoptysis. This patient had tumor abutting the pulmonary vein 
over several centimeters and this patient died suddenly 3 months after the treatment. Fatal 
hemoptysis (FH) is often reported after ILT and ranges from 7% – 22% (72). After ILT, 
prognostic factors strongly correlated with FH and were the total BED (p = 0.001), the 
treatment intent (p < 0.001) and the number of fractions applied (p = 0.001). The median 
total BED value was 102 Gy in patients with FH whereas it was 66 Gy in patients with no FH 
(73). Whether our patient died due to a direct complication of the SBRT itself or due to 
tumor invasion in the blood vessel is a matter of debate, because either the high dose to 
the blood vessel or tumor invasion into the blood vessel could have been the cause of the 
death.  
A total of 5 patients died due to a pneumonia, an exacerbation of chronic obstructive 
pulmonary disease (COPD) or shortness of breath related to tumor progression. It is not 
clear whether late side effects of the radiation contributed to pneumonia and so to death. 
The stereotactic treatment with real-time tumor tracking uses small margins because of 
to the use of in-room interfraction and intrafraction tumor motion compensation by the 
respiratory tracking system. This system allows treatment with an accuracy of 2 mm or less 
while patients breath normally and therefore less healthy tissue is irradiated, and so the risk 
for side effects is lower.  
Speiser and Spratling (64) reported that the mean time for fibrotic reactions was 10 – 13 
months after ILT. The mean time to develop side effects was 14 months for the MI group, 
15 months for the UML group, and 11 months for the SB group. 
We did not correlate clinical lung toxicity such as dyspnea and cough as this was not the 
purpose of this research. Dyspnea and cough can be caused by other causes such as COPD, 
cardiac disease, and radiation pneumonitis. As at least 30% of our population had a high 
Charlson comorbidity score or cumulative illness score, the high comorbidity would 
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influence the toxicity such as dyspnea or cough. A patient with COPD Gold IV (the most 
advanced stage of COPD) will probably have more toxicity from an occlusion of an upper 
bronchus compared to a patient with the same side effect but without COPD. For this 
reason, we did not correlate the clinical toxicity with our results. 
4.5 Conclusion 
No side effects were found in the trachea and only stenosis in the main bronchus and 
bronchus intermedius, so the doses we prescribed are associated with low NTCP risks. 
Higher grades of side effects, such as occlusion and atelectasis, were only seen in the upper-
, middle-, and lower bronchi and the segmental bronchi. Most of the side effects occurred 
in the first 24 months after treatment with the largest amount in the first 12 months. When 
0.5 cc of a segmental bronchus was irradiated to 50 Gy in 5 fractions, it was about 50% likely 
to be occluded radiographically, but symptomatic toxicity could still be avoided as long as 
some segmental bronchi in each branch of lung were outside the high-dose region. For 
grade 1 radiographically evident side effects, the 50% risk level for a 5-fraction Dmax was 55 
Gy for mid bronchi and 65 Gy for mainstem bronchi. Our group of patients in this study is 
fragile, and their clinical toxicity depends on much more factors than only radiation-induced 
side effects of the bronchi. To assure the relation between clinical toxicity and side effects 
to the bronchi, further investigation is needed. 
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To evaluate clinical pulmonary and radiographic bronchial toxicity after stereotactic ablative 
radiation therapy and hypofractionated radiation therapy for central lung tumors, and 
perform normal tissue complication probability modeling and multivariable analyses to 
identify predictors for toxicity. 
 
Methods and materials 
A pooled analysis was performed of patients with a central lung tumor treated using ≤ 12 
fractions at 2 centers between 2006 and 2015. Airways were manually contoured on 
planning planning computed tomography scans and doses were recalculated to an 
equivalent dose of 2 Gy per fraction with an α/β ratio of 3. Grade ≥ 3 (≥ G3) clinical 
pulmonary toxicity was evaluated by 2 or more physicians. Radiographic toxicity was 
defined as a stenosis or an occlusion with or without atelectasis using follow-up computer 
tomography scans. Logistic regression analyses were used for statistical analyses. 
 
Results 
A total of 585 bronchial structures were studied in 195 patients who were mainly treated 
using 5 or 8 fractions (60%). Median patient survival was 27.9 months (95% confidence 
interval 22.3 – 33.6). Clinical ≥ G3 toxicity was observed in 24 patients (12%) and 
radiographic bronchial toxicity in 55 patients (28%), both mainly manifesting ≤ 12 months 
after treatment. All analyzed dosimetric parameters correlated with clinical and lobar 
bronchial radiographic toxicity, with V130Gy,EQD having the highest odds ratio. Normal tissue 
complication probability modelling showed a volume dependency for the development of 
both clinical and radiographic toxicity. On multivariate analyses, significant predictors for ≥ 
G3 toxicity were a planning target volume overlapping the trachea or main stem bronchus 
(p = 0.005), chronic obstructive pulmonary disease (p = 0.034), and the total V130Gy,EQD (p = 




We identified patient and dosimetric factors associated with clinical and radiographic 
toxicity after high-dose radiotherapy for central lung tumors. Additional data from 
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5.1 Introduction 
In contrast to the established role of stereotactic ablative radiotherapy (SABR) for 
peripheral non-small cell lung cancer (NSCLC), its role in centrally located tumors is less well 
defined (74). Data from prospective trials revealed severe toxicity to be uncommon for 
moderately central tumors when treated with 5-fraction SABR, and that high-grade toxicity 
was more frequently observed in tumors close to the main bronchi, than those close to the 
lobar bronchi (17, 75, 76). These findings are consistent with data from retrospective studies 
in patients with so-called “ultracentral” tumors, defined as target volumes overlapping the 
main stem bronchi or trachea (77, 78). 
Stereotactic ablative radiotherapy is increasingly used for moderately central tumors, 
and recent guidelines recommend the use of risk-adapted SABR regimens delivering 4 or 5 
fractions for central located lung tumors and more hypofractionated regimens in 6 – 15 
fractions for ultracentral tumors (10, 79). Compliance with normal organs constraints used 
in prospective trials (NCT01795521, NCT00750269) has been recommended, even though 
such constraints had not been validated in large populations. 
Patients with centrally located tumors have been treated since 2006 at VUmc and EMC, 
using both SABR and hypofractionated radiotherapy in ≤ 12 fractions. To identify patient 
and dosimetric predictors of clinical pulmonary and radiographic bronchial toxicity, we 
performed a pooled retrospective analysis using clinical records and follow-up computed 
tomography (CT) scans. 
5.2 Methods and Materials 
Patient selection and definitions 
This retrospective study was approved by the institutional medical ethics committees of 
VUmc and EMC. Institutional databases were queried to identify patients treated with ≤ 12 
fractions for primary NSCLC at VUmc and EMC and for lung metastasis at EMC. Patients 
were treated since 2006 (EMC) and 2008 (VUmc). Selected patients had a planning target 
volume (PTV) located ≤ 2 cm from the trachea, main stem-, intermediate-, upper-, middle- 
or lower lobe bronchus and at least 1 bronchial structure receiving ≥ 20.0 Gy (physical dose). 
Patients with thoracic irradiation before or after the index treatment were excluded.  
Risk-adapted fractionation based on tumor location and volume was used at both 
institutions (48, 80). At VUmc, patients with a PTV overlapping main bronchi or trachea were 
treated with 12 fractions of 5 Gy; other central tumors were treated using 8 fractions of 7.5 
Gy (Appendix 5A) (77, 81). At EMC, different fraction doses have been used and changed 
during the years with increasing experience and after introducing a Monte-Carlo based dose 
calculation algorithm. Briefly, 6 or 7 fractions were used for tumors close to the esophagus, 
and 5 fractions for other centrally located tumors (Appendix 5A). One patient was treated 
with 3 fractions.  
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Treatment planning and delivery 
Treatment planning and delivery were as previously described (67, 82, 83). At VUmc, a free-
breathing, 10-phase 4-dimensional CT scan was used to delineate the internal target 
volume, which was expanded with 5 mm to generate a PTV. Dose calculations were 
performed on the average intensity projection of the 4-dimensional CT scan, and treatment 
was delivered using volumetric modulated arc therapy (RapidArc, Varian Medical Systems, 
Palo Alto, CA) and online cone-beam CT. At least 95% and 99% of the PTV had to receive 
100% and 90% of prescribed dose, respectively. An inhomogeneous dose distribution was 
planned, with a maximum of 110% to 140% of the prescribed dose. Planning target volume 
underdosage was permitted only to avoid exceeding dose limits to the esophagus, spinal 
canal, and brachial plexus (Appendix 5B). No institutional dose limits were applied for the 
heart, trachea and main stem or lobar bronchi. However, individual physicians sometimes 
requested maximum point doses in these organs. Since 2009, contralateral lung doses were 
limited (84, 85).  
At EMC, gross tumor volumes (GTV) were delineated on a spiral CT scan, and PTV was 
generated by adding a 5 mm margin. Dose calculations were performed using MultiPlan 
(Accuray, Sunnyvale, CA). Patients were treated on a CyberKnife robotic radiosurgery 
system (Accuray) (67). Planning target volume dose was prescribed to the 70% to 90% 
isodose lines, which covered ≥ 95% of PTV. Gross tumor volume and PTV underdosage was 
allowed to meet dose limits of organs at risk summarized in Appendix 5B.  
Delineation 
For the purposes of this analysis, the following bronchial structures were manually 
delineated on planning CT scans: trachea, main stem and intermediate bronchi (MI), and 
upper-, middle -, and lower lobe bronchi (lobar bronchi). Both institutes randomly evaluated 
each other’s delineations.  
Dosimetric analysis 
All doses were converted into a biologically equivalent dose (BED) and an equivalent dose 
of 2 Gy per fraction (EQD2) and calculated using the following formulas: : 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 = 𝐵𝐵𝐵𝐵 ∗  (1 +
(𝑑𝑑𝑑𝑑/(α/β)) and 𝐵𝐵𝐵𝐵𝐸𝐸𝐸𝐸𝐵𝐵𝐵𝐵2 = 𝐵𝐵𝐵𝐵 ∗  (𝑑𝑑𝑑𝑑 + α/β)/(2.0 +  α/β), where D = total dose and d = dose 
per fraction. An α/β ratio of 10 was used for the tumor and a ratio of 3 for the bronchi (86). 
All EMC treatment plans which were originally calculated with Ray-Tracing were first 
recalculated using Monte Carlo algorithm (Appendix 5A). Ipsilateral bronchial structures 
receiving ≥ 20.0 Gy at both institutes were further analyzed. 
We report on maximum point doses (Dmax,EQD), and volumes receiving an EQD2 of 65 Gy 
(V65Gy,EQD), 80 Gy (V80Gy,EQD), 90 Gy (V90Gy,EQD), 100 Gy (V100Gy,EQD), and 130 Gy (V130Gy,EQD). For 
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analyses regarding clinical toxicity, the maximum point dose in all analyzed bronchial 
structures (“total Dmax,EQD”) and a total volume of all bronchial structures receiving the 
specified doses (“total V65Gy,EQD”, “total V80Gy,EQD” etc) were calculated for each patient. 
Radiographic toxicity was analyzed per bronchial structure, and dosimetric parameters of 
separate bronchial structures were therefore used. 
 
Evaluation of disease control and toxicity 
Clinical follow-up was generally performed at 3, 6, 12, 18, and 24 months after treatment 
and yearly thereafter. All available patient records, including information from general 
practitioners, were reviewed to determine disease control and high-grade pulmonary 
toxicity. All cases with potential grade 3 or higher toxicity (≥ G3) according to the Common 
Terminology Criteria for Adverse Events (version 4.03) were evaluated by at least 2 
physicians and were consensus based. Potential treatment-related deaths were sub-
classified into “possible’’ (when no other likely cause was identified and treatment 
contribution could not be excluded) or “likely” (when the cause was considered to be 
radiation-related) treatment-related.  
All available follow-up CT scans were used to evaluate radiographic bronchial toxicity. 
Posttreatment scans were compared with the planning CT, and the following features were 
reported if they were new or deteriorating with respect to the planning CT scan: stenosis, 
occlusion without atelectasis, or occlusion with atelectasis in the trachea, main stem, 
intermediate, or lobar bronchi. If there was also a local recurrence at the location of a 
stenosis/occlusion, this was not scored as toxicity, and that specific bronchial structure was 
excluded from analyses. High-grade toxicity was defined as an occlusion with or without 
atelectasis. All CT scans were evaluated by 2 physicians, and scans with relevant radiological 
changes were additionally evaluated by 2 senior radiation oncologists.  
 
Statistical analysis 
IBM SPSS (version 21.0; IBM, Armonk NY) and GraphPad Prism (version 7.0, Graphpad 
Software, Palo Alto, CA) were used for statistics. Kaplan-Meier estimates were generated 
for all clinical outcomes. Overall survival and disease-free survival were calculated using the 
first date of treatment and the date of death or disease recurrence, respectively. For 
patients without an event, the last date of follow-up visit or last date of contact with the 
patient, was used. Hence, in patients without disease recurrence, no competing event by 
means of death was present. Median follow-up times and 95% confidence intervals (95% 
CIs) were calculated using the reverse Kaplan-Meier method, and Kaplan-Meier curves were 
compared using the log-rank test (87). Normal tissue complication probability (NTCP) 
analysis was calculated to obtain probabilities for toxicity and was based on a logistic 
regression analysis. Dosimetric parameters with a p-value of < 0.05 were fitted into an NTCP 






model. The odds were obtained and introduced in the equation ln(odds) for calculation of 
log odds: ln � p
1−p
�∑ eβ0 +β ∗ Vx. The following equation was used to generate an NTCP: 
NTCP = 1
1+e−(_0+_∗Vx)
 (88, 89). 
A multivariable logistic regression analysis was performed to identify both clinical and 
dosimetric predictors for toxicity. Variables were first analyzed in univariable analyses and 
entered into a multivariable analysis if the p-value was ≤ 0.20. When more than 1 dosimetric 
parameter had a p-value of ≤ 0.20 in univariable analysis, the parameter with the highest 
odds ratio (OR) was included in multivariable analysis. A p-value < 0.05 was considered 
statistically significant. Two patients without data on clinical toxicity were excluded from all 
analyses regarding this endpoint. 
  
5.3 Results 
Patient and tumor characteristics 
A total of 195 patients with follow-up CT scans and treated between July 2006 and January 
2015 were eligible (Table 1). Ninety-one patients were treated at VUmc and 104 at EMC. 
Twelve patients from VUmc were treated for a primary NSCLC tumor accompanied by 1 or 
2 hilar or mediastinal lymph nodes. Three EMC patients were treated for 2 adjacent 
metastatic tumors (n = 2) and two mediastinal lymph nodes (n = 1). Treatment was 
performed for a primary or recurrent NSCLC in 154 patients (79%), most consisting of stage 
I disease (34%). Staging fluorodeoxyglucose positron emission tomography scans were 
performed in the majority of patients (92%), and pathological diagnosis was available in 49% 
of patients. Thirty-one patients (16%) had an endobronchial tumor location. Median PTV 
was 80.4 cm3 (range 5.2 – 522.6 cm3), and PTV overlap with trachea or main bronchi 
(ultracentral location) was present in 66 patients (33%). The majority of patients were 
treated with either 5 or 8 fractions (60%).  
 
Table 1 - Baseline patient and treatment characteristics 
Characteristics Total VUmc EMC 
No. of patients 195 91 104 
Male 123 (63%) 64 (70%) 59 (57%) 
Age (y) 74 (65 – 81) 76 (69 – 83) 73 (62 – 80) 
COPD in history 122 (63%) 58 (64%) 64 (62%) 
Gold I/II 18 (9%) / 54 (28%) 10 (11%) / 27 (30%) 8 (8%) / 27 (26%) 
Gold III/IV 36 (19%) / 9 (5%) 14 (15%) / 7 (8%) 22 (21%) / 2 (2%) 
Gold status unknown 5 (3%) - 5 (5%) 
18F-FDG PET/CT staging 180 (92%) 90 (99%) 90 (87%) 
Pathological diagnosis 95 (49%) 55 (28%) 40 (38%) 
Endobronchial tumor location 31 (16%) 24 (26%) 7 (7%) 
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Table 1 - Baseline patient and treatment characteristics (continued) 
Characteristics Total VUmc EMC 
Charlson comorbidity index  2 (1 – 4) 3 (2 – 4) 2 (1 – 3) 
0 – 2 101 (52%) 31 (34%) 70 (67%) 
3 – 5 78 (40%) 53 (58%) 25 (24%) 
6 – 9 16 (8%) 7 (7%) 9 (9%) 
Metastasis 41 (21%) - 41 (39%) 
Primary NSCLC 154 (79%) 91 (100%) 63 (61%) 
Tumor histology available*  85 (55%) 55 (60%) 30 (48%) 
Adenocarcinoma 43 (28%) 13 (14%) 30 (48%) 
Squamous cell carcinoma 29 (19%) 29 (32%) - 
NSCLC NOS 8 (5%) 8 (9%) - 
Large cell carcinoma 1 (1%) 1 (1%) - 
Undifferentiated carcinoma 1 (1%) 1 (1%) - 
Squamous dysplasia / CIS / 
adenosquamous carcinoma 
3 (2%) 3 (3%) - 
Disease stage TNM 7th * 
IA/IB 25 (16%) / 41 (27%) 19 (21%) / 22 (24%) 6 (7%) / 19 (21%) 
IIA/IIB 34 (22%) / 27 (18%) 11 (12%) / 15 (16%) 23 (25%) / 12 (13%) 
IIIA 18 (12%) 16 (18%) 2 (2%) 
IV 1 (1%) 1 (1%) - 
Recurrent NSCLC 7 (5%) 7 (8%) - 
Treatment characteristics # Total VUmc EMC 
Planning target volume (cm3) 80.4 (43.7 – 149.4) 88.7 (51.3 – 153.1) 67.6 (36.9 – 134.3) 
Ultracentral location 66 (33%) 43 (47%) 23 (22%) 
Prescribed treatment schedules 
3 fractions 1 (1%) - 1 (1%) 
5 fractions 65 (33%) - 65 (63%) 
6 fractions 22 (11%) - 22 (21%) 
7 fractions 16 (8%) - 16 (15%) 
8 fractions 52 (27%) 52 (57%) - 
12 fractions 39 (20%) 39 (43%) - 
Prescribed dose (BED10 in Gy) 100.8 (90 – 105) 105 (90 – 105) 100 (86.4 – 115.5) 
83.3 – 90.0 75 (38%) 39 (43%) 36 (35%) 
91.0 – 100.0 26 (13%) - 26 (25%) 
101.0 – 130.0 70 (36%) 52 (57%) 18 (17%) 
131.0 – 150.0 23 (12%) - 23 (22%) 
>150.0 1 (0.5%) - 1 (1%) 
PTV Dmax (BED10 in Gy) 150.7 (129.1 – 170.1) 160.0 (142.4 – 168.4) 134.8 (119.4 – 173.4) 
Abbreviations: BED10 = biologically equivalent dose with an α/β ratio of 10; CIS = carcinoma in situ; COPD = chronic 
obstructive pulmonary disease; CT = computed tomography; EMC = Erasmus Medical Center; FDG = 
fluorodeoxyglucose; IQR = interquartile range; NOS = not otherwise specified; NSCLC = non-small cell lung cancer; 
PET = positron emission tomography; PTV = planning target volume; VUmc = VU University Medical Center. 
Values are number (percentage) or median (interquartile range). 
*All percentages are calculated for the subgroup of patients with primary NSCLC. #All percentages are calculated 
for the total of analyzed PTVs (n = 195). 




Dosimetric details of 89 trachea, 121 main bronchi, 67 intermediate bronchi, and 308 lobar 
bronchi were analyzed (Figure 1). Median Dmax,EQD delivered to the trachea was 63 Gy (range 
21 – 146 Gy, interquartile range (IQR) 38 – 102 Gy), 103 Gy (range 23 – 334 Gy, IQR 56 – 131 
Gy) for the MI, and 119 Gy (range 23 – 416 Gy, IQR 69 – 142 Gy) for the lobar bronchi.  
Figure 1 – Volume parameters in equivalent dose of 2 Gy per fractions (EQD2) values (Gy) for the 
central airways. Circles and stars refer to outliers and extreme values, respectively 
Overall survival and disease control 
Median overall survival for all patients was 27.9 months (95% CI 22.3 – 33.6 months), and 
median follow-up of the surviving patients was 61.6 months (95% CI 50.9 – 72.4 months). 
Overall survival rates were 77.4% (95% CI 72.2 – 84.0%), 53.3% (95% CI 46.5 – 60.7%), and 
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similar between VUmc and EMC patients, with 29.8 months (95% CI 16.8 – 42.8 months) at 
VUmc and 24.7 months (95% CI 18.9 – 30.5 months) at EMC (p = 0.114). Median survival for 
patients with primary tumors was 26.6 months (95% CI 17.7 – 35.6 months) and 28.1 
months (95% CI 21.3 – 34.9 months) for patients with metastatic lesions (p = 0.748). Survival 
rates at 1, 2, and 3 years were 74.6% (95% CI 68.5 – 82.3%), 51.4% (95% CI 43.7 – 59.7 %), 
and 42.3% (95% CI 34.4 – 50.5%) for primary NSCLC, respectively. 
Median follow-up for disease control was 36.4 months (95% CI 30.7 – 42.1 months). Any 
disease failure was observed in 77 patients (39%), and median disease-free survival was 
27.0 months (95% CI 15.5 – 38.5 months). Local, regional, and distant failure manifested in 
13%, 10%, and 30% of patients, respectively. For patients with primary NSCLC, these rates 
were 10%, 8%, and 21%, respectively. 
 
Clinical pulmonary toxicity 
Details on clinical toxicity were available in 193 patients. Grade ≥ 3 pulmonary toxicity was 
observed in a total of 24 patients (12%) (Table 2), and the first toxicity event was observed 
within 12 months post-treatment in the majority of patients (67%). Radiation pneumonitis 
was the commonest G3 toxicity (n = 10), with 50% of the latter also having a radiographic 
bronchial toxicity, including 1 patient with an occlusion and 4 with an occlusion plus 
atelectasis. At the time of this analysis, 133 patients (68%) had died. No information was 
available on the cause of death in 22 patients (17%). A possible (n = 6) or likely (n = 9) 
treatment-related death was observed in 15 patients (8%). Fatal lung hemorrhage, the 
commonest treatment-related death, was considered either possible (n = 5) or likely (n = 6) 
treatment-related in 11 patients (6%). Two patients who died as a consequence of 
euthanasia were considered to have a likely treatment-related death, and the remaining 
two patients died due to a possible and likely treatment-related respiratory failure. (Table 
2). Four patients scored as having a likely fatal toxicity had also developed a previous G3 
toxicity. 
Grade ≥ 3 clinical symptoms of a bronchus obstruction was observed in 2 patients (1%), 
both of them having an ultracentral PTV location (Table 2). One patient developed G3 
symptoms from atelectasis of the left lung, after presenting with pretreatment occlusion of 
the main stem bronchus. The atelectasis was visible approximately 1 month before the 
clinical symptoms were recorded. Another patient with an endobronchial tumor developed 
G3 hemoptysis during treatment. Although the first follow-up scan at 4.7 months did not 
reveal any radiographic toxicities, clinical records stated that death at 11.3 months after 
treatment was a consequence of euthanasia, performed because of severe dyspnea arising 
from chronic obstructive pulmonary disease (COPD) and a bronchial obstruction. The 
bronchial occlusion was accompanied by atelectasis and edema of the main stem/lower 
lobe bronchus. However, only 1 follow-up CT scan was available for review.  
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Table 2 – High-grade clinical pulmonary and radiographic bronchial toxicity 





High-grade (grade ≥ 3) clinical pulmonary toxicity (n = 193) 
Grade 3 12 (6%) 0.2 – 14.1 
Radiation pneumonitis 10 (5%) 2.0 – 14.1 
Atelectasis due to main stem 
bronchus occlusion 1 (1%) 13.7 
Hemoptysis 1 (1%) 0.2 
Grade 4 Hemoptysis 1 (1%) 20.1 
Grade 5 15 (8%) 5.6 – 18.5 
Possible Fatal lung hemorrhage 5 (3%) 6.5 – 18.5 
Multifactorial respiratory failure 1 (1%) 5.6 
Likely Fatal lung hemorrhage 6 (3%) 5.2 – 18.2 Two patients also 
developed G3 RP 
Respiratory failure due to 
radiation pneumonitis / 
pneumonia with septicaemia 
1 (1%) 7.7 
Euthanasia performed due to 
disease progression and dyspnea. 
1 (1%) 13.1 Patient also 
developed G3 RP 
Euthanasia performed after 
severe dyspnea due to severe 
COPD, and atelectasis and edema, 
both arising from bronchial 
obstruction (main stem/lower 
lobe bronchus) 
1 (1%) 11.3 Patient also 
developed G3 
hemoptysis 
Total 24 (12%) 0.2 – 20.1 
High grade (occlusion with or without atelectasis) radiographic bronchial toxicity (n = 195) 
Main stem bronchus 1 (0.5%) 12.2 
Intermediate bronchus 2 (1%) 6.6 – 6.9 
Lobar bronchi 34 (17%) 2.3 – 38.4 
Total 36 (18%) 2.3 – 38.4 
Abbreviations: COPD = chronic obstructive pulmonary disease; G3 RP = grade 3 radiation pneumonitis. 
Grade ≥ 3 lung hemorrhage was observed in a total of 13 patients (7%) (Table 2). The 
Charlson comorbidity index was ≥ 3 in 9 of them. An endobronchial tumor was present in 
46% of this subgroup, and the PTV overlapped with the main bronchi or trachea in 70%. Of 
the 10 patients with a pathological diagnosis, 7 had squamous cell carcinoma / dysplasia. In 
11 patients who developed a fatal lung hemorrhage, a radiographic bronchial toxicity was 
identified in 2. One patient had a stenosis of the lower lobe bronchus, and the other a 
stenosis of the right intermediate bronchus with occlusion and atelectasis of both the 
middle and lower lobe bronchus.  
Radiographic bronchial toxicity 
A total of 585 bronchial structures were evaluated for radiographic toxicity. The main 
bronchus, upper lobe bronchus, and lower lobe bronchus could not be evaluated owing to 
an in-field recurrence in 3 patients. Follow-up CT scans were available for ≤ 12 months after 
treatment in 86 patients (44%), for 12 to 24 months in 55 patients (28%), for 24 to 36 
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months in 21 patients (11%), for 36 to 48 months in 14 patients (7%), and for > 48 months 
in 19 patients (10%). Any grade of radiographic toxicity was observed in 9 main stem 
bronchi, 8 intermediate bronchi, and 64 lobar bronchi at follow-up scans of 55 patients 
(28%) (Figure 2, Appendix 5E). No patients developed radiographic toxicity of the trachea. 
A single bronchus was affected in 36 patients, 2 bronchi in 12 patients, and 3 bronchi in 7 
patients. High-grade radiographic toxicity developed in 41 bronchial structures of 36 
patients (18%), and mostly in the lobar bronchi (17%) (Figure 2, Table 2). The first 
radiographic toxicity event occurred within 12 months after SABR in 39 of the 55 patients 
(71%) with any grade of radiographic toxicity (range 1.7 – 48.2 months), and in 25 of the 36 
patients (69%) with high-grade toxicity (range 2.3 – 38.4 months). 
Figure 2 – Radiographic toxicity in the central airways: main stem bronchi (n = 9), intermediate 
bronchus (n = 8), upper lobe bronchi (n = 25), middle lobe bronchus (n = 6), and lower lobe bronchi 
(n = 33)  
NTCP modelling for clinical and radiographic toxicity 
Univariate logistic regression analysis was performed to identify significant dosimetric 
parameters for the purposes of an NTCP model. All analyzed dosimetric parameters were 
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1.68; 95% CI 1.26 – 2.24; p < 0.001), which corresponds to ± 50 Gy in 5 fractions, ± 58 Gy in 
7 fractions, ± 61 Gy in 8 fractions, and ± 72 Gy in 12 fractions (Figure 3, Appendix 5C and 
Appendix 5F-G). A 25% probability of ≥ G3 toxicity was observed at a total V130Gy,EQD of 2.35 
cm3 and at a Dmax,EQD of 190 Gy (Figure 3). Grade 5 toxicity was associated with all analyzed 
parameters except for the total V130Gy,EQD, and a 5% probability was observed at a Dmax,EQD of 
84 Gy (Figure 3). Additional subgroup analysis for a likely or possible treatment-related 
death revealed that the total V65Gy,EQD, V80Gy,EQD, V90Gy,EQD, V100Gy,EQD were significantly 
associated with a likely treatment-related death, whereas none of the analyzed dosimetric 
parameters were correlated with possible fatal toxicity (Appendix 5C).  
Any grade of radiographic bronchial toxicity in the main stem/intermediate bronchus 
was only significantly associated with maximum point doses delivered to the MI, with a 25% 
probability at a Dmax,EQD of 193 Gy (Figure 3, Appendix 5C). This corresponds to ± 63 Gy in 5, 
± 72 Gy in 7, ± 77 Gy in 8, and ± 91 Gy in 12 fractions. An additional analysis for the 
development of a stenosis did not reveal any significantly associated parameters. All 
analyzed lobar bronchial dosimetric parameters were significantly associated with any 
grade and with high-grade toxicity in the lobar bronchi, and the lobar bronchial V130Gy,EQD 
had the highest OR for both (OR 2.47; 95% CI 1.52 – 4.00; p < 0.001, and, OR 2.29; CI 1.44 – 
3.65; p = 0.001, respectively) (Figure 3, Appendix 5C, Appendix 5H-I). A 25% probability of 
any grade and high-grade lobar bronchial toxicity was observed at a Dmax,EQD of 133 Gy and 
168 Gy, respectively.  
Normal tissue complication probability models of the volume parameters for both 
clinical and radiographic toxicity were all comparable with each other and steeper than the 
models of the Dmax,EQD. 
Univariate and multivariate regression analyses 
A univariate analysis was performed using clinical factors for the purposes of a multivariate 
analysis including both clinical and dosimetric predictors of toxicity (Appendix 5D). This 
revealed that radiographic bronchial toxicity was not significantly correlated with ≥ G3 
clinical toxicity (OR 1.22; 95% CI 0.49 – 3.05; p = 0.663). Planning target volume overlap with 
the main stem bronchi/trachea (OR 4.16; 95% CI 1.54 – 11.23; p = 0.005), COPD (OR 4.09; 
95% CI 1.11 – 15.05; p = 0.034), and the total V130Gy,EQD (OR 1.52; 95% CI 1.10 – 2.12; p = 
0.012) were significantly correlated with the development of ≥ G3 clinical toxicity on 
multivariate analysis. 
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Figure 3 – Normal tissue complication probability models for clinical and radiographic toxicity 
The x-axis shows the dose range and is divided into 5 equal parts (“bins”). Solid black squares represent the  
observed incidence of toxicity for each bin (%). Both the number of patients with toxicity and the numbers at risk 
in each bin are indicated. Bins not containing any patients had no square shown in the graph. For clinical normal 
tissue complication probability models, the maximum point dose in all analyzed structures, and a total volume of 
all structures receiving the specified doses, were calculated for each patient.  
Abbreviations: CI = confidence interval; EQD = equivalent dose of 2 Gy per fraction; VxxGy = volume receiving xx Gy 
in EQD values. 
For high-grade radiographic toxicity, univariate analysis revealed that age and PTV 
overlapping main stem bronchi/trachea were significant clinical predictors (Appendix 5D). 
Entering these variables into a multivariate analysis with the total V130Gy,EQD showed that 
only PTV overlapping the main stem bronchi/trachea remained as a significant predictor for 
high-grade radiographic toxicity (OR 2.87; 95% CI 1.16 – 7.06; p = 0.022). 
5.4 Discussion 
To the best of our knowledge, this study represents the largest to date on the treatment of 
centrally located lung tumors with either SABR or hypo-fractionated radiotherapy delivered 
in ≤ 12 fractions. Grade ≥ 3 clinical pulmonary toxicity and radiographic toxicity were 
observed in 12% and 28% of patients, respectively. The majority of both toxicities 
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cause of treatment-related death (6%), and most high-grade radiographic toxicities 
occurred in the lobar bronchi (17%). All analyzed dosimetric parameters were significantly 
correlated with clinical and radiographic lobar bronchial toxicity on univariate analysis, with 
V130Gy,EQD having the highest OR. Multivariate analysis revealed that PTV overlap with the 
trachea or main stem bronchus and COPD strongly correlated with ≥ G3 clinical toxicity, as 
did the total V130Gy, EQD. 
Rates of clinical toxicities observed in this study are consistent with ongoing prospective 
trials on central lung SABR, and with data from retrospective studies that have reported a 
15 to 24% incidence of pulmonary toxicity (17, 29, 75, 90, 91). Preliminary results of the 
Radiation Therapy Oncology Group protocol 0813 reported 15% high-grade toxicity, and all 
observed G5 toxicity was due to a fatal lung haemorrhage (4%) (75). This trial permitted a 
maximum point dose of 105% for the main bronchi, corresponding to a Dmax,EQD of ± 197 Gy 
for a regimen with 5 fractions of 12 Gy. In our NTCP model, a Dmax,EQD of 190 Gy resulted in 
a 25% probability for ≥ G3 clinical toxicity and in a probability of 15% for fatal toxicity. The 
prospective HILUS trial included 42 patients with tumors close to a main stem bronchus 
(group A) and 31 patients with tumors close to a lobar bronchus (group B) (17). All patients 
were treated with 8 fractions of 7 Gy. Dose limits were mandatory for trachea and 
contralateral main bronchus (Dmax,EQD = 89 Gy), and for the ipsilateral main stem bronchus 
only dose guidelines were recommended (Dmax,EQD = 112 Gy). Early toxicity analysis showed 
severe toxicity in 28% of patients, and G4/5 toxicity occurred more in group A (19%) than in 
group B (3%). Six of the 7 patients with a fatal toxicity died of a lung hemorrhage (14%). The 
current pooled analysis found PTV overlap with main stem bronchus or trachea to be 
significantly correlated with both ≥ G3 clinical toxicity and high-grade radiographic toxicity. 
A PTV overlap was present in 33% of all patients, and in 70% of patients who developed ≥ 
G3 lung bleeding. 
There are limited data available on radiographic bronchial toxicity after SABR. The HILUS 
trial reported a rate of 28% for G1/2 atelectasis and an 8% rate for G1/2 bronchus 
obstruction/stricture, which is in line with our rates of radiographic toxicity (28%) (17). 
Although the specific pathophysiological mechanism of radiation-induced bronchial 
damage is unclear, a correlation with airway diameter has been postulated (29). We 
observed no toxicities in the trachea, and the highest rate of radiographic toxicity was 
observed in the lobar bronchi. A 25% probability of any grade of toxicity in the lobar bronchi 
was observed at a Dmax,EQD of 133 Gy, whereas a higher point dose of 193 Gy was associated 
with toxicity to main stem and intermediate bronchi. However, radiographic bronchial 
toxicities were not significantly associated with clinical pulmonary toxicities in our series 
(Appendix 5D). A potential explanation could be the hypothesis that radiation damage to 
the lobar bronchi more often causes subclinical toxicity, as clinical relevant toxicity 
manifested in only two patients with radiological toxicity in the main stem bronchus. In 
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addition, factors besides radiographic bronchial damage, such as lung function and 
comorbidities, could play an important role in the development of clinical toxicity. We 
observed a volume dependency for the development of toxicity, consistent with previous 
work (62). The highest odd ratios for both clinical and radiographic toxicity were observed 
for the volumes receiving the highest doses, and the lowest OR was observed for the 
maximum point doses (Appendix 5D). Although the V130Gy had the highest OR for both ≥ G3 
clinical and radiographic toxicity, this parameter was not significantly associated with G5 
toxicity. When patients were stratified into groups based on a possible or likely treatment-
related death, dosimetric variables were found to be predictive only in patients scored to 
have a likely treatment-related death. This finding may reflect the inherent uncertainty 
when scoring G5 toxicity as “possibly treatment-related” if no other potential cause could 
be identified, leading to an over-reporting of G5 toxicity. However, our findings should be 
interpreted with caution given the small numbers of patients included in this subgroup 
analysis.  
A number of limitations of this study are acknowledged. Although all potential high-
grade toxicity was evaluated by at least 2 experienced radiation oncologists, the 
retrospective character of this pooled analysis and the variations in follow-up duration may 
have led to an under-reporting or less inaccurate scoring of toxicity. The difficulty of 
distinguishing between a recurrence and a bronchial injury in some cases may also have 
contributed to the latter. Observed dose-response relationships may have been 
confounded by differences in treatment techniques between the centers and possible 
discrepancies between planned versus delivered doses.  
In conclusion, the high-grade toxicity rates observed in this pooled analysis of central 
lung tumors treated with SABR or hypofractionated radiotherapy in ≤ 12 fractions seem to 
be consistent with emerging data from prospective trials of central lung SABR. No significant 
correlation was observed between radiographic bronchial damage and clinically relevant 
pulmonary toxicity, and NTCP modelling confirms the volume dependency of both clinical 
and radiographic toxicity. Because an ultracentral tumor location strongly correlates with 
both radiographic and clinical toxicity, SABR for such tumors should be pursued with caution 
until more data are forthcoming.
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To correlate esophagus toxicity and dose-volume histogram (DVH) parameters in order to 
assess risks, and derive a Normal Tissue Complication Probability (NTCP) model. 
 
Methods and Materials 
Patients with a central lung tumor from 2 centers, who underwent stereotactic or 
hypofractionated radiotherapy (≤ 12 fractions), were analyzed. Doses were recalculated to 
an equivalent dose of 2 Gy with an α/β ratio of 10 (EQD210). The esophagus was manually 
delineated and DVH-parameters (Dmax,EQD2, D1cc,EQD2, D2cc,EQD2, D5cc,EQD2) were analyzed and 
used for NTCP modelling based on logistic regression analysis. 
 
Results 
Two-hundred-and-thirty-one patients with 252 tumors were eligible. No acute or late grade 
3 – 5 esophageal toxicity was reported. Acute grade 1 – 2 esophagus toxicity was recorded 
in 38 patients (17%). All DVH-parameters were significantly higher in patients with toxicity. 
NTCP models showed a 50% probability of acute grade 1 – 2 toxicity at a Dmax of 67 Gy EQD210 
and D1cc of 42 Gy EQD210. No difference in overall survival was observed between patients 
with and without toxicity (p = 0.428). 
 
Conclusion 
As no grade 3 – 5 esophageal toxicity was observed in our cohort, a Dmax of 56 Gy EQD210 
and D5cc of 35.5 Gy EQD210 could be delivered without high risks of severe toxicity. The NTCP 
models of this study might be used as practical guidelines for the treatment of central lung 
tumors with stereotactic radiotherapy. 
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Stereotactic Body Radiation Therapy (SBRT), also referred as stereotactic ablative 
radiotherapy (SABR), has become the standard of care for patients with early stage Non-
Small Cell Lung Cancer (NSCLC) who are medically or surgically inoperable or refuse surgery 
(92). Patients with central lung tumors are at higher risk of toxicities when treated up to a 
dose of 60 – 66 Gy in 3 fractions (13). Although risk-adapted fractionation schedules with 
accompanying dose constraints are now implemented, both retrospective studies and 
prospective trials report radiation related complications following the treatment of central 
lung tumors (17, 21, 77, 78).  
 
While toxicity of the lung parenchyma, presenting as radiation pneumonitis, is not 
associated with tumor location (28, 93), central tumor position is an important factor in the 
development of toxicity of the bronchi. Bronchial stenosis, occlusion and atelectasis, have 
been associated with both the Dmax and the bronchial volume receiving more than 65 Gy 
EQD2 (α/β ratio of 3) (29). High grade esophagus toxicity has also been associated with high 
SBRT doses (38, 46, 94). Painful dysphagia followed by death due to an esophageal ulcer 5 
months after treatment has been associated with a Dmax of 50.5 Gy (94 Gy EQD2 using α/β 
ratio of 3) (46). Chang et al. suggested a limit of V30Gy ≤ 1 cm3 (in 4 fractions) after reporting 
grade 2 esophagitis in only 4% of the patients (38).  
 
Although many institutions have published their experiences with treating central lung 
tumors, there is currently no consensus on standard dose constraints for organs at risk (14). 
Commonly recommended constraints, derived from ongoing prospective trials, have not 
been validated in large populations (NCT01795521, NCT00750269). 
 
The goal of this study was to determine the incidence of esophageal toxicity in central lung 
tumors treated with SBRT and to identify dosimetric and clinical predictors for esophageal 
toxicity. Furthermore, the odds of toxicity were calculated and a Normal Tissue 
Complication Probability (NTCP) model was derived to predict the development of 
esophageal toxicity. 
 
6.2 Materials and methods 
We retrospectively analyzed patients from 2 centers, Erasmus Medical Center (EMC) and 
VU University Medical Center (VUmc), who were treated between 2006 and 2015 with SBRT 
or hypofractionated radiotherapy (≤ 12 fractions) for primary or metastatic central lung 
tumors. Central tumors were defined as tumors located within 2 cm of the trachea, 
mainstem-, intermediate-, upper-, middle- or lower- lobe bronchus or the esophagus.  
 






At both centers, patients were treated with risk-adaptive SBRT schedules based on tumor 
location and tumor volume (48, 80). At EMC, dose prescription varied over time due to 
changing dose constraints and the introduction of the Monte-Carlo based algorithm. 
Tumors close to the esophagus were treated with 6 – 7 fractions of 7 – 8 Gy, while other 
central tumors received 5 fractions of 9 – 12 Gy, except 2 tumors which received 3 fractions 
of 20 Gy. At VUmc, tumors with a planning target volume (PTV) overlapping the trachea or 
main stem bronchi were treated with 12 fractions of 5 Gy and all other central tumors 
received 8 fractions of 7.5 Gy (Appendix 6A). 
 
Treatment planning and delivery have been previously described (67, 82, 83). Briefly, at 
EMC the PTV consisted of the gross tumor volume plus 5 mm. The PTV dose was prescribed 
to the 70 – 90% isodose line covering at least 95% of the PTV. Organ at risk (OAR) dose 
constraints were given priority over PTV coverage (Appendix 6B). Dose calculations were 
performed using Multiplan® and patients were treated with a Cyberknife® Robotic 
Radiosurgery System (both Accuray Inc, Sunnyvale, CA). At VUmc, the PTV was generated 
using a 5mm expansion of the internal target volume. Dose calculations were performed on 
the average intensity projection (Ave-IP) of the 4D-CT scan. At least 95% and 99% of the PTV 
had to receive 100% and 90% of the prescribed dose, respectively. An inhomogeneous dose 
distribution was planned with a PTV maximum of 110 – 140% of the prescribed dose. A 
higher priority to the OAR was only given to avoid exceeding dose limits of the esophagus, 
spinal canal and brachial plexus (Appendix 6B). Treatment was delivered in free breathing 
using coplanar Volumetric Modulated Arc Therapy (VMAT) RapidArc™ (Varian Medical 
Systems, Palo Alto, USA) and online cone-beam CT based setup on the tumor. 
 
For all patients, the esophagus was manually delineated on the planning CT scan using 
mediastinal window levels. Due to variations in the fractionation schemes, all doses were 
converted into an equivalent dose of 2Gy per fraction (EQD2) using the following formula: 
𝐵𝐵𝐵𝐵𝐸𝐸𝐸𝐸𝐵𝐵𝐵𝐵2 = 𝐵𝐵𝐵𝐵 ∗  (𝑑𝑑𝑑𝑑 + α/β)/(2.0 +  α/β) ; with D = total dose, d = dose per fraction and α/β 
ratio of 10 Gy for tumor and esophagus (the abbreviation used for an EQD2 with α/β ratio 
of 10 Gy is EQD210). Doses delivered to specific volumes of the esophagus (Dmax,EQD2, D1cc,EQD2, 
D2cc,EQD2 and D5cc,EQD2) were derived from the dose volume histogram (DVH) of each patient.  
 
Follow-up was generally performed 3, 6, 12, 18 and 24 months following radiation and 
annually thereafter. All patient medical records from hospitals and general practitioners 
were screened for esophageal toxicity and disease control. Esophageal toxicity was 
retrospectively scored using the Common Terminology Criteria for Adverse Events v4.0. 
Toxicity was considered to be acute when it occurred within 3 months after the end of 
treatment and as late if it occurred thereafter.  
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Logistic regression analysis was performed to define clinical or dosimetric predictors of 
toxicity. Toxicity was dichotomized into the presence or absence of toxicity. Variables with 
a p-value of ≤ 0.20 in univariate analysis were entered into a multivariable analysis. When 
more than 1 dosimetric parameter had a p-value of < 0.05 in the univariate analyses, the 
parameter with the highest odds ratio was included in the multivariable analysis. The NTCP 
analysis was calculated based on a logistic model. The univariate logistic regression analysis 
was used for the correlation of toxicity with DVH parameters. Each significant dosimetric 
parameter (p < 0.05) was modelled into an individual NTCP curve. The odds were obtained 
and introduced in the equation ln(odds) for calculation of log odds: ln � p
1−p
�∑ eβ0 +β ∗ Vx. 
The following equation was used to build the NTCP models: NTCP = 100%
1+e−(β0+β∗Vx)
 (88, 89).  
 
Overall survival was defined as the first day of treatment until the date of death, and local 
control was defined as the first day of treatment until the date of local recurrence. If no 
event was observed, the patient was censored at the last date of contact that the patient 
was still alive. Survival and local control were calculated using Kaplan-Meier analysis and 
differences between groups were tested with log-rank tests. Non normally distributed 
variables were compared using the Mann-Whitney U Test. P-values of < 0.05 were 
considered statistically significant. All analyses were performed using IBM SPSS statistics 
version 21.0 (IBM, Armonk NY). This study was granted approval from the institutional 
medical ethics committees at both institutions. 
 
6.3 Results 
A total of 231 patients with 252 tumors were identified. There were 149 males (65%) 
included and the median age was 74 years. Twenty patients had multiple tumors treated in 
a single plan, according to the following scenarios: 2 adjacent metastatic tumors (n = 3), 2 
mediastinal lymph nodes (n = 1), a primary NSCLC tumor accompanied by a lymph node (n 
= 15) or a primary NSCLC accompanied by 2 lymph nodes (n = 1). One-hundred-and-eighty-
seven patients (81%) had primary lung cancer and 44 patients (19%) metastatic lung lesions. 
The median PTV volume was 80.1 cc with an inter quartile range (IQR) of 47.1 – 148.7 cc. 
The median follow up was 16.0 months (IQR 8.4 – 29.0). Additional patient characteristics 
are shown in Table 1.  
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Table 1 – Patient- and tumor characteristics 
Patient characteristics Total – n (%) or median (IQR) 
Age (years) 74 (67 – 80) 
Sex 
Female 82 (35%) 
Male 149 (65%) 
Disease 
Primary NSCLC 187 (81%) 
Lung metastasis 44  (19%) 
Charlson Comborbidity Index 
0 – 2 119 (52%) 
3 – 5 93  (40%) 
6 – 9 19  (8%) 
Prescribed dose* 
7 x 7 Gy 69.4 Gy EQD210 10 (4%) 
5 x 9 Gy 71.3 Gy EQD210 5 (2%) 
6 x 8 Gy 72.0 Gy EQD210 27 (12%) 
12 x 5 Gy 75.0 Gy EQD210 45 (19%) 
5 x 10 Gy 83.3 Gy EQD210 19 (8%) 
7 x 8 Gy 84.0 Gy EQD210 9 (4%) 
8 x 7.5 Gy 87.5 Gy EQD210 65 (28%) 
5 x 11 Gy 96.3 Gy EQD210 23 (10%) 
5 x 12 Gy 110 Gy EQD210 26 (11%) 
3 x 20 Gy 150 Gy EQD210 2 (1%) 
PTV size (cc) 80.1 (47.1 – 148.7) 
Follow-up (months) 16.0 (8.4 – 29.0) 
Abbreviations: EQD210 = equivalent dose of 2 Gy per fraction with α/β ratio of 10; IQR = inter quartile range; PTV = 
planning target volume; NSCLC = non-small cell lung cancer 
* For detailed information about the institutional fractionation schedules, see Appendix 6A
Acute or late grade 3 – 5 esophageal toxicity was not reported. Thirty-eight patients (16.5%) 
developed acute grade 1 or 2 esophageal toxicity. Grade 1 toxicity was seen in 31 patients 
(13.5%) and grade 2 toxicity in 7 patients (3.0%). The number of patients that have 
experienced grade 1 – 2 toxicity for each fractionation schedule were 0 out of 2 patients, 
9/73 patients, 9/27 patients, 8/19 patients, 5/65 patients and 7/45 patients for 3, 5, 6, 7, 8 
and 12 fractions, respectively. 
For all patients, the median esophagus Dmax was 29.8 Gy EQD210 (IQR 18.1 – 44.7). The 
median D1cc, D2cc and D5cc were 20.4 Gy EQD210, 17.7 Gy EQD210 and 13.2 Gy EQD210, 
respectively. Patients who developed acute esophageal toxicity received a significantly 
higher Dmax than those who did not develop toxicity (median 46.9 Gy EQD210 (IQR 39.7 – 
55.3) versus 26.7 Gy EQD210 (IQR 16.5 – 40.9), respectively; p < 0.001). The remaining 
dosimetric values, D1cc,EQD2, D2cc,EQD2 and D5cc,EQD2, were also significantly higher in patients 
who experienced toxicity (Table 2).  
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Table 2 – Dosimetric parameters in EQD210 for the esophagus 
Dmax (EQD210) D1cc (EQD210) D2cc (EQD210) D5cc (EQD210)
All patients 





18.1 – 44.7 
1.8 – 82.2 
20.4 
13.0 – 29.5 
0.9 – 55.7 
17.7 
11.8 – 25.5 
0.8 – 53.5 
13.2 
8.3 – 18.7 
0.4 – 49.2 
Patients with toxicity 





39.7 – 55.3 
23.4 – 62.4 
32.7 
23.5 – 43.3 
15.9 – 53.8 
28.8 
20.3 – 39.4 
12.7 – 52.1 
21.3 
14.5 – 31.5 
7.6 – 43.0 
Patients without toxicity  





16.5 – 40.9 
1.8 – 82.2 
18.3 
11.9 – 26.6 
0.9 – 55.7 
16.1 
10.5 – 22.9 
0.8 – 53.5 
11.8 
7.8 – 17.1 
0.4 – 49.2 
p – value * < 0.001 < 0.001 < 0.001 < 0.001 
Abbreviations: IQR = inter quartile range; EQD210 = equivalent dose of 2 Gy per fraction with α/β ratio of 10 
* The groups with and without toxicity are compared using the Mann-Whitney U Test 
The univariate logistic regression analysis showed significant correlations between grade 1 
– 2 acute toxicity and all analyzed dosimetric parameters (Table 3). Therefore, each
parameter was entered into a separate NTCP model, which resulted in four NTCP-curves
(Figures 1 and 2). The NTCP model for the maximum point dose showed a 50% probability
of acute grade 1 – 2 esophageal toxicity at a Dmax of 67Gy EQD210 (equal to ± 43 Gy in 5
fractions, ± 48 Gy in 7 fractions, ± 51 Gy in 8 fractions and ± 55 Gy in 12 fractions). The same
probability (50%) applied for a D1cc of 42 Gy EQD210 (equal to ± 31 Gy, ± 34 Gy, ± 35 Gy and
± 38 Gy in 5, 7, 8 and 12 fractions, respectively).
Table 3 – Results of logistic regression; acute grade 1-2 toxicity for each DVH parameter 
Dmax (EQD210) D1cc (EQD210) D2cc (EQD210) D5cc (EQD210)
Odds Ratio 1.058 1.107 1.119 1.135 
95% CI 1.034 – 1.082 1.069 – 1.147 1.077 – 1.162 1.086 – 1.187 
p – value < 0.001 < 0.001 < 0.001 < 0.001 
Abbreviations: DVH = dose-volume histogram; EQD210 = equivalent dose of 2 Gy per fraction with α/β ratio of 
10; 95% CI = 95% confidence interval; OR = odds ratio 
A univariate logistic regression was performed for the following clinical factors: age, gender, 
charlson comorbidity score, PTV (cc), number of given fractions and dose per fraction. None 
of these factors were significantly associated with toxicity, and only PTV (OR 1.00; 95% CI 
1.00 – 1.01; p = 0.051) and female gender (OR 1.81; 95% CI 0.90 – 3.67; p = 0.097) had a p-
value of < 0.20. A multivariable analysis including the latter two variables and the dosimetric 
parameter D5cc,EQD2 showed that only the D5cc,EQD2 (OR 1.16; 95% CI 1.10 – 1.22; p < 0.001) 
and female gender (OR 3.02; 95% CI 1.30 – 6.99; p = 0.010) were significantly correlated 
with low grade esophageal toxicity (Appendix 6C).  
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Figure 1 – Normal tissue complication probability (NTCP) models for grade 1 – 2 acute toxicity in the 
esophagus 
Abbreviations: EQD210 = equivalent dose of 2 Gy per fraction with α/β ratio of 10 
The x-axis shows the dose range, and is divided into 5 equal parts (“bin”). For each bin, the square represents the 
mean incidence of toxicity (%). Both the number of patients with toxicity and the numbers at risk in each bin are 
indicated. 
The overall survival rates were 73% (95% CI 67 – 78%), 50% (95% CI 43 – 56%) and 38% (95% 
CI 32 – 45%) at 1-, 2- and 3-years respectively, with a median overall survival of 24 months. 
No significant difference in survival was found between patients with and without toxicity, 
with 2-year survival rates of 44% (95% CI 28 – 59%) and 51% (95% CI 44 – 58%), respectively 
(p = 0.428). Local control rates were 84% (95% CI 77 – 90%) and 75% (95% CI 65 – 83%) at 
2- and 3-years, respectively.
6.5 Discussion 
In this study of centrally located lung tumors treated with stereotactic radiotherapy, high 
grade (≥ grade 3) acute or late esophageal toxicities were not observed. Acute grade 1 or 2 
esophageal toxicity occurred in 17% of patients and correlated significantly with the 
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esophageal dosimetric parameters Dmax,EQD2, D1cc,EQD2, D2cc,EQD2 and D5cc,EQD2. For D5cc,EQD2, 
each additional gray was associated with a 13.5% increased risk of toxicity. For Dmax,EQD2, 
D1cc,EQD2 and D2cc,EQD2 each additional gray was associated with a 5.8%, 10.7% and 11.9% 
increased risk of acute grade 1 – 2 toxicity, respectively. Multivariable analysis including 
both dosimetric and clinical predictors showed that acute grade 1 – 2 esophageal toxicity 
was significantly associated with esophageal D5cc,EQD2 and female gender. 
 
At both institutes, a maximum point dose limit was mandatory for the esophagus, ranging 
from 50 to 56 Gy EQD210, depending on the fractionation schedule. Our point dose limits 
were generally consistent with those used in the HILUS trial, which recommended an 
esophageal Dmax of 52.7 Gy EQD210 (17). However, in the phase I/II RTOG 0813 dose-
escalation trial, a substantially higher maximum point dose was allowed; a Dmax of > 105% 
of the prescription dose was considered as a protocol violation. This equals to 89.7 Gy 
EQD210 for a schedule with 5 fractions of 10 Gy (21). In our cohort, the highest Dmax was 82.2 
Gy EQD210, and 32% of the patients with a Dmax ≥ 56 Gy EQD210 (8 out of 25) developed grade 
1 – 2 esophageal toxicity. The corresponding rate of esophageal toxicity in patients with a 
Dmax < 56 Gy EQD210 was considerably lower at 15% (31 out of 207). Although the range of 
fractionation schedules makes it hard to directly compare studies, our failure to observe 
high grade toxicity suggests that higher point dose limits may be acceptable. 
 
Both institutes in our series did not use a volumetric dose limit, however an esophageal D5cc 
of ≤ 27.5 Gy in 5 fractions (35.5 Gy EQD210) was recommended in RTOG 0813. A D5cc ≥ 35.5 
Gy EQD210 was delivered to only 8 patients in our study, in whom a rate of 88% was reported 
for grade 1 – 2 toxicity, compared to only 14% for those with a D5cc <35.5 Gy EQD210. This 
observation suggests that it could be worthwhile to use volumetric parameters as well 
during stereotactic treatment planning, as D1cc,EQD2, D2cc,EQD2,and D5cc,EQD2 were all significant 
in the univariate analysis.  
 
Our NTCP model predicts toxicity rates that are in line with previously published 
retrospective data, when factoring in that our model predicted grade 1 – 2 toxicity whereas 
most previous analyses have predicted higher grades of toxicity. In a study of 125 patients 
reported by Wu et al., 12% experienced grade ≥ 2 toxicity within 120 days post-treatment. 
Fitted logistic regression response curves showed predicted probabilities of complication 
less than 20% for Dmax ≤ 44.2 Gy EQD210 and D5cc ≤ 21.9 Gy EQD210 (95). In our model, a Dmax 
of 44.2 Gy EQD210 corresponded to a 22% probability of toxicity, and a D5cc of 21.9 Gy EQD210 
to a 26% probability. Our slightly higher probability rates might be explained by the fact that 
our model predicted grade 1 and 2 toxicity, whereas Wu et al. reported grade 2 and 3 
toxicity. Another study described late grade 3 esophageal toxicity in 2 patients at a D0.01cc of 






51.5 Gy (65.0 Gy EQD210) and 52 Gy (65.9 Gy EQD210) and a D5cc of 37.3 Gy (42.7 Gy EQD210) 
and 21.5Gy (21.8 Gy EQD210), respectively (96). However, patients were treated 
concurrently with VEGF modulating agents, which perhaps increased the sensitivity of the 
organs at risk to radiotherapy and consequently the risk on toxicity. In our cohort, 10 
patients received a Dmax of ≥ 65.0 Gy EQD210 without experiencing toxicity. Only two patients 
received a D5cc higher than 42.7 Gy EQD210 with a toxicity rate of 50% and 42 patients 
received a D5cc ≥ 21.8 Gy EQD210 with a toxicity rate of 42%. Nuyttens et al. (97) also reported 
esophageal SBRT dose limits. The doses corresponding to a 50% probability of grade 2 
complications were 67.6 Gy EQD210 for Dmax, 45.5 Gy EQD210 for D1cc and 35.4 Gy EQD210 for 
D5cc, which are higher than in the current study. This difference could be explained by the 
inclusion of both grade 1 and 2 in our study compared to only grade 2 in the study by 
Nuyttens, the higher complication rates in the current study (16.5% vs 8.6%) and the 
different methods used to model the NTCP. A comparison of dose-response models based 
on the previously mentioned studies (95, 96) between the 50% probability of grade 2 
toxicity versus the 50% probability of grade 3 toxicity showed ± 20 Gy (absolute dose in 5 
fractions) difference for the Dmax and D1cc (97). 
 
High grade esophageal toxicity after SBRT is uncommon, but was described in a few other 
reports on both pulmonary and non-pulmonary tumors treated with SBRT (94, 98, 99). 
Following single-fraction paraspinal stereotactic radiosurgery of 16 to 24 Gy, grade ≥3 
esophageal toxicity occurred in 6.8% of patients and a D2.5cc higher than 14.0 Gy (28.0 Gy 
EQD210) was a significant predictor of grade ≥ 3 toxicity (98). High grade toxicity was also 
described in 2 patients treated with prior chemo- and/or radiotherapy before SBRT. One 
patient with early stage lung cancer, who received adjuvant chemotherapy (carboplatin, 
paclitaxel and gemcitabine) following 1 fraction of 25 Gy, developed a tracheoesophageal 
fistula 6 months after radiotherapy. A second patient with metastatic osteosarcoma in the 
7th thoracic vertebra, received conventionally fractionated radiation of 40 Gy in 20 fractions 
with concurrent chemotherapy (ifosfamide and etoposide) followed by 2 fractions of 12 Gy 
with SBRT and further adjuvant chemotherapy. Four months after SBRT, this patient 
developed an esophageal perforation and fatal mediastinitis. In both cases, the esophagus 
was within the high-dose radiation volume. High grade adverse events occurred at (single-
fraction biologically effective dose using α/β ratio of 3, SFBED) a Dmax of 21.0 Gy3 and D5cc of 
16.5 Gy3 for the first patient and Dmax of 18.5 Gy3 and D5cc of 11.4 Gy3 for the second patient 
(94). Severe esophageal toxicity has also been documented in a patient receiving adjuvant 
chemotherapy following a single fraction of 25 Gy; 6 months post-SBRT, tracheoesophageal 
and tracheavascular fistulas developed resulting in fatal hemoptysis (99). These studies 
highlight the potential role of prior radiotherapy or chemotherapy in severe esophageal 
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toxicity, especially following very high doses of SBRT. Antiangiogenic agents in combination 
with SBRT have previously been associated with gastro-intestinal toxicity (100).  
 
Female gender was the only significant clinical predictor for low grade esophageal toxicity 
in our multivariable analysis including both clinical and dosimetric factors. This association 
was also observed in previous studies on chemoradiotherapy, however a clear explanation 
is nevertheless lacking (101-103).  
 
Limitations of our study include the differences in treatment techniques between centers, 
as well as possible discrepancies between planned versus delivered doses, which may 
confound the observed dose-response relationships. Other limitations are those inherent 
to retrospective toxicity scoring, especially for lower toxicity grades. Given the difficulty in 
distinguishing between radiotherapy-related esophagitis and symptoms due to factors such 
as an acute airway infection, we did not collect rates of late grade 1 and 2 esophageal 
toxicity. Of note, we did not observe acute or late grade 3 – 5 toxicity, which could generally 
more easily be identified in retrospective data than lower grades of toxicity due to the 
severity of symptoms and the need for hospitalization. As low grade toxicity may be 
underestimated by retrospective scoring, the thresholds identified in our study have to be 
interpreted with caution. 
 
In conclusion, there was a low incidence of acute esophageal toxicity and high grade acute 
or late esophageal toxicity was not observed in this study of centrally located lung tumors 
treated with stereotactic or hypofractionated radiotherapy (≤ 12 fractions). Doses to small 
volumes of the esophagus are associated with low grade esophageal toxicity. An esophageal 
Dmax of 56.0 Gy EQD210 and a D5cc of 35.5 Gy EQD210 could be delivered without high risks of 
severe toxicity. The NTCP-models described in this study might be used as guidelines for the 
stereotactic treatment of central lung tumors. Further studies are necessary to validate 
these parameters for acute esophagus toxicity.
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The treatment of central lung tumors with stereotactic body radiation therapy (SBRT) is 
challenged by the risk of excessive esophageal toxicity. To improve clinical decision making, 
we aimed to derive normal tissue complication probability (NTCP) models in a patient 
cohort with central lung tumors treated with SBRT and to evaluate the currently used 
esophagus dose constraints. 
 
Methods and Materials 
Patients with a central lung tumor who received SBRT (8 fractions of 7.5 Gy or 12 fractions 
of 5 Gy) were included. Doses were recalculated to an equivalent dose of 2 Gy with an α/β-
ratio of 10 Gy for acute and 3 Gy for late toxicity (the cut-off was 3 months). The esophagus 
was manually delineated. NTCP modelling based on logistic regression was used to relate 
dose-volume histogram parameters (Dmax, D1cc, D2cc, D5cc) to acute and late toxicity. 
Parameters with a p-value < 0.05 were included in the model. Based on the NTCP models, 
we determined the probability of toxicity for the currently used dose constraints: D1cc ≤ 40 
Gy for 8 fractions and D1cc ≤ 48 Gy for 12 fractions. 
 
Results 
For this study, 188 patients with 203 tumors were eligible. Esophagus toxicity occurred in 
33 patients (18%). Late high-grade toxicity consisted of 2 possible treatment-related deaths 
(grade 5) and 2 patients with grade 3 toxicity. Acute toxicity only consisted of only grade 1 
(n = 19) and grade 2 toxicity (n = 10). All investigated dose-volume histogram parameters 
were significantly correlated to acute and late toxicity. The probability of late high-grade 




High-grade esophageal toxicity occurred in 2.1% of the patients including 2 possible 
treatment-related deaths. The currently used dose constraints correspond to a low risk of 
high-grade toxicity. 
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7.1 Introduction 
Patients with early stage non-small cell lung cancer (NSCLC) or small lung metastases not 
suitable for surgery are often candidates for stereotactic body radiation therapy (SBRT) (5). 
The treatment of central lung tumors, however, may result in excessive toxicity (13). To 
reduce this risk, risk-adapted fractionated schedules have been used (10, 17). The 
prospective Radiation Therapy Oncology Group (RTOG) 0813 trial showed that these 
schedules resulted in outcomes comparable with those of peripheral located tumors, but 
cases of high-grade toxicity were observed. Plan details to link delivered dose to toxicity 
were not reported (16). 
Tolerance data and predictive dosimetric parameters for the esophagus and central 
airways could help to select patients who can be safely treated with SBRT and to guide 
treatment planning (104). Previous studies reported on predictive parameters for 
esophageal toxicity after SBRT (97, 105, 106). None of them, however, described predictive 
parameters for high-grade esophageal toxicity.  
Based on predictive parameters, a normal tissue complication probability (NTCP) model can 
be generated, which shows the relationship between predictive factors and toxicity 
probability. Hence, an NTCP model will help physicians in the trade-off between risk of 
toxicity and dose needed for adequate tumor control.  
In this study, we analyzed dosimetric and toxicity data in a patient cohort with central 
lung tumors treated with SBRT to determine parameters that are related to high-grade 
esophageal toxicity. In addition, we derived NTCP models for late high-grade and acute low-
grade esophageal toxicity and used them to estimate the risk of toxicity for the dose 
constraints within our institute and for the dose constraints of the RTOG 0813 trial (16). 
7.2 Methods and materials 
We analyzed treatment outcome in patients from Haaglanden Medical Center with central 
lung tumors treated with fractionated stereotactic radiotherapy between 2012 and 2016. 
This study was granted approval from the institutional medical ethics committee (METC 
Zuidwest Holland). Central lung tumors were defined as tumors located ≤ 2 cm from the 
esophagus, trachea, and mainstem, intermediate, upper, middle, or lower lobe bronchus 
(Appendix 7A). Patients were excluded if they received prior radiotherapy to any part of the 
current radiation field, were treated with chemotherapy during SBRT, or received a 
diagnosis of small cell lung cancer. 
SBRT was initially delivered using a dedicated stereotactic linear accelerator (Novalis, 
Brainlab AG, Munich, Germany); from 2013, a linear accelerator with cone beam computed 
tomography (CT) guidance (Elekta AB, Stockholm, Sweden) was used. From the end of 2015 
all patients were treated with the cone beam CT-equipped linear accelerator. Patients were 
treated with 60 Gy in 8 fractions 3 times a week or 60 Gy in 12 fractions 4 times a week. If 
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the planning target volume (PTV) overlapped or was too close to organs at risk (treating 
physician's discretion), 12 fractions were prescribed.  
The gross tumor volume was contoured on a lung CT scan using lung and mediastinal 
setting. The esophagus was delineated on the average phase of the planning CT scan using 
mediastinal setting. Until 2014, the gross tumor volume was expanded to an internal target 
volume (ITV) based on 6 scans taken randomly during the breathing cycle. In 2014 this 
technique was replaced by a 4-dimensional CT scan, in which an ITV was obtained by 
contouring the tumor in 10 phases of the respiratory cycle. The ITV was expanded with 5 
mm (6 mm in craniocaudal direction) to a PTV for the Novalis linear accelerator and 6 mm 
in all directions for the Elekta linear accelerator. Treatment planning was done using Monte 
Carlo and collapsed cone algorithm for patients treated on the Novalis linear accelerator 
and the Elekta linear accelerator, respectively. Dose prescription for patients treated with 
12 fractions was based on ICRU-62 criteria such that the maximum dose of the PTV was ≤ 
107%. In the case of 8 fractions, the dose was prescribed to the 100% isodose line, and the 
Dmax was 110% to 140% of the prescribed dose. Regardless of the fractionation schedule, at 
least 95% of the PTV had to receive 100% of the prescribed dose and 99% of the PTV had to 
receive 90% of the prescribed dose.  
Various parameters of the esophagus were derived: maximum point dose (Dmax) and 
dose to specific volumes (D1cc, D2cc, D5cc). For the current analysis, doses were recalculated 
to an equivalent dose of 2 Gy per fraction (EQD2Gy) using the following formula: 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵2𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 = 
𝐵𝐵𝐵𝐵 ∗ (𝑑𝑑𝑑𝑑 + α/β)/(2.0 + α/β), in which D = total dose, d = dose per fraction, and the α/β ratio 
was 10 Gy (EQD2Gy,10Gy) for acute and 3 Gy (EQD2Gy,3Gy) for late toxicity.  
Toxicity rates and follow-up were retrospectively reviewed from medical hospital 
records. Follow-up for each patient was generally performed 3, 6, 9, 12, 18, and 24 months 
after radiation and annually thereafter. Esophageal toxicity was defined according to the 
Common Terminology Criteria for Adverse Events (version 4.03). Acute toxicity was defined 
as an event < 3 months after radiation and late toxicity as toxicity that occurred thereafter. 
In the case of multiple reports of toxicity in a single patient, the highest score was used for 
analysis.  
Toxicity was dichotomized into the presence or absence of late high-grade (≥ 3) and 
acute low-grade (≤ 2) toxicity. Differences between dose in patients with and without 
toxicity were described with the Mann-Whitney U test. Logistic regression was used to 
define clinical or dosimetric predictors for toxicity. The following clinical factors were 
entered in univariate analyses: age, sex, tumor origin, World Health Organization 
performance status, classification of Chronic Obstructive Pulmonary Disease (COPD GOLD), 
Charlson Comorbidity Index, number of fractions and distance between tumor and 
esophagus (in case of multiple tumors in a single patient, the shortest distance was used). 
Potential relations between factors were tested with the Mann-Whitney U test or χ2 test. 
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An NTCP model describes the relation between input variables and the observed toxicity 
probability. For this study we used the logistic regression model, which yields the sigmoidal 
relationship between the input variables and probability of toxicity. Each dosimetric 
parameter that was statistically significant (p-value ≤ 0.05) in the univariate logistic 
regression analysis was individually modelled with: NTCP =  100%
1+ e−(β0 + β1∗Dx) 
, in which Dx is 
the dose of the esophagus in the maximum point, 1 cc, 2 cc or 5 cc, and β0 and β1 are the 
constant term and the regression coefficient of Dx, respectively.  
Probabilities of toxicity for the institutional and RTOG 0813 dose constraints were 
estimated using the derived NTCP model. Dose constraints at the institution are D1cc ≤ 40 
Gy in 8 fractions (64 Gy EQD2Gy,3Gy and 50 Gy EQD2Gy,10Gy) and D1cc ≤ 48 Gy in 12 fractions (67 
Gy EQD2Gy,3Gy and 56 Gy EQD2Gy,10Gy). Dose constraints of the RTOG trial are Dmax ≤ 105% of 
the PTV prescription, which is 63 Gy in case of the maximum allowed dose of 12 Gy per 
fraction (197 Gy EQD2Gy,3Gy and 119 Gy EQD2Gy,10Gy) and D5cc < 27.5 Gy (47 Gy EQD2Gy,3Gy and 
36 Gy EQD2Gy,10Gy), where the volume maximum is a suggested limit. Based on mortality 
rates of surgical lung cancer treatment (lobectomy or pneumonectomy), doses coherent to 
the 5% probability rate were derived from NTCP curves (107).  
Overall survival (OS) was defined as first day of treatment until date of death or last day 
of contact for patients who were still alive. Local control (LC) was defined as first day of 
treatment until date of local recurrence. When no event occurred, the patient was censored 
on the last day of follow-up. Survival and time to local recurrence were estimated using the 
Kaplan-Meier method, and the log-rank test was used to evaluate differences in OS and LC 
between patients who had NSCLC and patients who had a metastatic tumor. In all analyses, 
p-value of ≤ 0.05 was considered to be statistically significant. All analyses were performed
using IBM SPSS statistics version 24.0.0.1 (SPSS Inc, Chicago, IL) and R version 3.4.1 (2017,
R Foundation for Statistical Computing Platform).
7.3 Results 
For this study, 191 patients with 206 central tumors were eligible. Three patients were 
excluded owing to absent follow-up data. Baseline patient and tumor characteristics of the 
remaining 188 patients are described in Table 1. Primary NSCLC was diagnosed in 82% (n = 
154) of the patients and metastatic tumor in the lung in the remaining 18%. Most patients
(n = 174, 93%) were treated for a single central tumor consisting of primary NSCLC or
metastatic lesion, 10 patients were treated for a central primary together with a central
lymph node, 2 patients for 2 central primary tumors, 1 patient for 2 central metastatic
tumors and 1 patient for 3 central metastatic tumors. Seventy-five patients (40%) were
treated with 12 fractions and 113 patients (60%) with 8 fractions. The median tumor
diameter was 36 mm (interquartile range 27 – 47 mm).
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Table 1 – Patient and tumor characteristics 
Patient characteristics (n = 188) n (%) or median (IQR, range) 
Age (y) 72  (66 – 79, 42 – 94) 
Gender 
Female 79  (42%) 
Male 109  (58%) 
Tumor origin 
Non-small cell lung cancer 154  (82%) 
Metastatic tumor in the lung 34  (18%) 
Charlson Comorbidity Index 
0 – 2 117 (62%) 
3 – 5 61  (33%) 
6 – 9 10  (5%) 
WHO performance Scale 
0 85  (45%) 
1 93  (50%) 
2 6  (3%) 
3 – 4 4  (2%) 
Radiation therapy indication 
Technically inoperable 31  (17%) 
Comorbidities 153  (81%) 
Refusing surgery 4  (2%) 
Fractionation schedule 
8 fractions of 7.5 Gy 113 60% 
12 fractions of 12 Gy 75 40% 
Tumor characteristics (n = 203) n (%) or median (IQR, range) 
Localization of the tumor 
Upper lobe 111 55% 
Middle or lower lobe 57 28% 
Mediastinum 35 17% 
Tumor diameter (mm) 36 (27 – 47, 7 – 88) 
Distance tumor to esophagus (mm) 21 (12 – 34, 0 – 75) 
Abbreviations: IQR = interquartile range; WHO = world health organization. 
Esophageal toxicity was seen in 33 patients (18%), of whom 6 reported late toxicity (3%). 
Late toxicity consisted of grade 5 (n = 2), grade 3 (n = 2), grade 2 (n = 1), and grade 1 (n = 1). 
Of the patients who died, 1 had a tracheoesophageal fistula 10 months after irradiation, for 
which a stent was placed. Two weeks after this procedure, the patient had hemoptoe and 
died within 2 days. Autopsy reported rupture of the vasa vasorum at a necrotic and fibrotic 
area close to the fistula, most likely caused by radiation. The other patient died 14 months 
after SBRT due to septic mediastinitis caused by a large esophagus perforation. This patient 
had increasing dysphagia 1 month after radiation therapy, resulting in grade 3 dysphagia 13 
months after treatment. The CT scan showed progression of mediastinal lymph nodes for 
which 1 cycle of FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) was given. During this 
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treatment the patient developed sepsis and died. The perforation was most likely caused 
by radiation, but tumor growth of the lymph nodes through the esophagus could not be 
excluded. Both grade 5 events were treated with 12 fractions for a subcarinal lymph node 
metastasis from colorectal origin. Late grade 3 esophagus toxicity consisted of dysphagia in 
1 patient resulting from circular ulceration of the esophagus 9.5 months after treatment, 
for which stent placement was scheduled. However, the patient died before this 
procedure from progressive metastatic disease complicated by severe pneumonia. The 
other grade 3 patient was hospitalized for dysphagia resulting from radiation esophagitis 
4.5 months after treatment. In all high-grade toxicity cases, the tumor was adjacent to the 
esophagus. The tumor was located directly next to the esophagus in both grade 5 cases, 
resulting in a complete esophagus-PTV overlap in multiple axial slices of the planning CT 
scan. In the grade 3 cases, the tumor was located next to the esophagus resulting in almost 
complete overlap between esophagus and PTV in 1 patient and in 50% overlap of the 
esophagus and PTV in the other patient. Dosimetric and fractionation details are displayed 
in Table 2, showing that all 4 cases exceeded the dose constraints currently used in the 
institution. Compared with the RTOG 0813 constraints, none of the patients exceeded 
the Dmax constraint, but all violated the suggested volume (D5cc) limit. 
Table 2 – Dosimetric details of patients with late high-grade (≥ 3) toxicity 
number of fractions Dmax (EQD2Gy,3Gy) D1cc (EQD2Gy,3Gy) D2cc (EQD2Gy,3Gy) D5cc (EQD2Gy,3Gy) 
Patients within our cohort 
Grade 5 12 101 Gy 97 Gy 95 Gy 77 Gy 
Grade 5 12 119 Gy 112 Gy 109 Gy 104 Gy 
Grade 3 12 98 Gy 96 Gy 96 Gy 94 Gy 
Grade 3 8 157 Gy 146 Gy 142 Gy 130 Gy 
Patients within literature  
Onimaru et al. 
Grade 5 8 94 Gy 71 Gy - 40 Gy 
Modh et al. 
Grade 3 5 112 Gy - - - 
Stephans et al. 
Grade ≥ 3 10 84 Gy * 75 Gy - 50 Gy 
Grade ≥ 3 10 85 Gy * 80 Gy - 22 Gy 
* Dose to 0.01 cm3 
Logistic regression showed significant relationship between all dosimetric parameters and 
late high-grade esophageal toxicity (all p-values < 0.01, Table 3). Based on the NTCP models 
(Figure 1), a 5% probability of late high-grade toxicity corresponds to Dmax, D1cc, D2cc or D5cc 
of 113.2, 89.2, 80.4, or 68.9 Gy EQD2Gy,3Gy, respectively (equal to Dmax 46.2 Gy, D1cc 40.3 Gy, 
D2cc 38.0 Gy, D5cc 34.7 Gy in a 5-fraction regimen). When the institution dose constraints are 
respected, the probability of late high-grade toxicity based on the NTCP model is 1.1% for 
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treatment with 8 fractions and 1.4% for 12 fractions. When applying the RTOG 0813 
constraints, the probability is 45.5% based on the Dmax constraint and 0.3% based on the 
D5cc suggested volume limit. 
Table 3 – Results of logistic regression used to determine the normal tissue complication 
probability model 
Odds ratio of late high-grade toxicity for each DVH parameter 
Dmax (EQD2Gy,3Gy) D1cc (EQD2Gy,3Gy) D2cc (EQD2Gy,3Gy) D5cc (EQD2Gy,3Gy) 
Odds ratio 1.03 1.06 1.08 1.14 
95% CI 1.01 – 1.06 1.02 – 1.10 1.03 – 1.14  1.02 – 1.28 
p-value 0.011 0.002 0.003 0.023 
Odds ratio of acute low-grade toxicity for each DVH parameter 
Dmax (EQD2Gy,3Gy) D1cc (EQD2Gy,3Gy) D2cc (EQD2Gy,3Gy) D5cc (EQD2Gy,3Gy) 
Odds ratio 1.04 1.05 1.06 1.07 
95% CI 1.02 – 1.05 1.03 – 1.07 1.04 – 1.08 1.04 – 1.09 
p-value < 0.001 < 0.001 < 0.001 < 0.001 
Abbreviation: 95% CI = 95% confidence interval 
Figure 1 – Normal tissue complication probability models for late high-grade toxicity 
The crosses represent the dose of the 4 dose-volume histogram parameters in patients without late high-grade 
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In 40 patients (21%) the tumor was located within 10 mm of the esophagus; 18 of these 
patients reported any kind of esophageal toxicity. Of the 9 patients with abutting tumors 
(distance from tumor to the esophagus is 0 mm or tumor and esophagus overlap), 7 
reported esophageal toxicity: 4 cases of late high-grade toxicity, 1 case of acute grade 2 
toxicity, and 2 cases of acute grade 1 toxicity. Regarding clinical factors related to acute 
toxicity, each extra millimeter distance between tumor and esophagus decreased the odds 
of acute toxicity with 9% (odds ratio 0.91; 95% confidence interval (CI) 0.88 – 0.95; p-value 
< 0.001) (Table 4). Additionally, receiving 12 fractions was correlated with increased acute 
toxicity (odds ratio 1.34 95% CI 1.09 – 1.64; p-value = 0.006). The distance between tumor 
and esophagus was significantly correlated with the number of fractions used (p-value = 
0.004), and therefore no multivariate analysis was done. 
Table 4 – Univariate logistic regression results for factors predicting acute grade 1 to 2 esophageal 
toxicity 
Univariate analysis 
Characteristic Toxicity No toxicity Odds Ratio (95% CI) p-value 
Age (y) 
median (IQR) 71  (65 – 79) 73 (66 – 80) 0.99 (0.95 – 1.03) 0.520 
Distance tumor to esophagus* 
median (IQR) 7 (1 – 19) 24 (15 – 36) 0.91 (0.88 – 0.95) < 0.001 
Sex 
Male n = 19  (17%) n = 90  (83%) 1 
Female n = 10  (13%) n = 69  (87%) 0.69 (0.30 – 1.57) 0.373 
Tumor origin 
Non-small cell lung cancer n = 23  (15%) n = 131  (85%) 1 
Metastatic tumor in lung n = 6  (18%) n = 28  (82%) 1.11 (0.68 – 1.81) 0.692 
Charlson Comorbidity Index 
0-2 n = 18  (15%) n = 99  (85%) 1 
≥ 3 n = 11  (15%) n = 60  (85%) 1.01 (0.45 – 2.28) 0.984 
WHO performance scale 
0 n = 13  (15%) n = 72  (85%) 1 
≥ 1 n = 16  (16%) n = 87  (84%) 1.01 (0.68 – 1.50) 0.964 
COPD GOLD** 
0-1 n = 5  (12%) n = 37  (88%) 1 
2-4 n = 19  (16%) n = 97  (84%) 1.45 (0.50 – 4.17) 0.491 
Amount of fractions 
8 n = 11  (9%) n = 105  (91%) 1 
12 n = 18  (25%) n = 54  (75%) 1.34 (1.09 – 1.64) 0.006 
*Distance tumor-esophagus: in case of multiple tumors irradiated in a single patient, the smallest distance between
tumor and esophagus is used; ** COPD status is missing in 30 patients 
Abbreviations: COPD GOLD = classification of chronic obstructive pulmonary disease; IQR = interquartile range, WHO 
= world health organization; 95% CI = 95% confidence interval 
Twenty-nine patients reported acute esophageal toxicity (15%) consisting only of grade 1 (n 
= 19) and grade 2 toxicity (n = 10). The median Dmax was 35 Gy EQD2Gy,10Gy higher in patients 
with acute toxicity compared with patients without acute toxicity (68.7 Gy EQD2Gy,10Gy vs 
31.4 Gy EQD2Gy,10Gy). All dose-volume histogram parameters were significantly higher (p-
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value < 0.001) in patients with acute toxicity (Appendix 7B). Furthermore, logistic regression 
showed increased odds of 4% to 7% on acute low-grade esophageal toxicity per extra gray 
given (Table 3). The 4 individual NTCP curves were plotted and when applying the currently 
used dose constraints, the probability of acute low-grade toxicity is 24% for 8 fractions and 
30% for 12 fractions (Figure 2). When applying the RTOG 0813 constraints this is 70% for 
the Dmax and 26% for the D5cc. 
Figure 2 – Normal tissue complication probability models for acute grade 1-2 toxicity 
The black solid line shows the logistic regression. The dashed lines reflect the 95% confidence interval. The x-axis 
shows the dose range, and is divided into 5 equal parts (bins). For each bin, the square represents the mean 
incidence of toxicity (%).  
Abbreviations: EQD2Gy = equivalent dose in 2 Gy fractions (α/β-ratio 10) 
Median OS for the whole group was 24.3 months (95% CI 17.3 – 31.2). The OS rates for 1, 2 
and 3 years were 73%, 51%, and 42%, respectively. There was no difference in the OS rates 
between patients with NSCLC and patients with lung metastases: a median OS of 23.3 
months (95% CI 14.9 – 31.7) versus 30.2 months (95% CI 6.6 – 53.7), respectively (p-value = 
0.947). Local control for the whole group was 95% at 1 year and 88% at 2 years. The LC rate 
at 2 years was 88% within the NSCLC group (165 tumors) and 87% within the metastatic 






















































































































































Dose delivered to 5cc of the esophagus (EQD2, α/β of 10)
3020 6040 503020 40 6010 50 70 
Dose delivered to 2cc of the esophagus (EQD2, α/β of 10)
20 30 40 50 60 70
Dose delivered to 1cc of the esophagus (EQD2, α/β of 10)
3020 40 6010 50 70 
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Severe esophageal toxicity occurred in 2.1% of patients including 2 treatment-related 
deaths, and 15% of patients reported acute low-grade toxicity. In all high-grade late toxicity 
cases, the tumor abutted the esophagus, resulting in overlap of the PTV with the esophagus. 
Late high-grade esophageal toxicity in patients treated solely with SBRT (without any 
confounding therapies) is rarely reported. Because of the high variance between studies, 
we will discuss different clusters of literature.  
Concerning late high-grade toxicity without any confounding therapies, Onimaru et al. 
reported, within a cohort of 46 patients, 1 case of grade 5 toxicity (2.2%). This patient died 
of a radiation-induced esophageal ulcer 5 months after receiving 48 Gy in 8 fractions to the 
PTV adjacent to the esophagus (46). In an analysis of 125 patients, Modh et al. reported 
grade 3 esophagitis 4 months after SBRT in 1 patient (0.8%) who had a tumor abutting the 
esophagus (53). Raman et al. reported 1 case of grade 3 esophagitis (cohort of 206 patients, 
0.5%) 4.7 months after SBRT (48 Gy, 12 Gy/fr), but no dosimetric parameters were reported 
(59). If we apply our NTCP model to the data of Onimaru et al. (46), the probability of late 
high-grade toxicity would be 2.7%, 1.7% or 0.1% based on the Dmax, D1cc or D5cc, respectively. 
The Dmax of the patient described by Modh et al. (53) corresponds to a 4.8% probability of 
late high-grade toxicity. Dosimetric characteristics of the studies are shown in Table 2. 
Four studies described late high-grade esophageal toxicity after SBRT in combination 
with possible confounding therapies, making it hard to directly compare these results with 
our analyses. The first study described a cohort of 32 patients with 1 fatal 
tracheoesophageal fistula (3.1%) after single-fraction radiotherapy (25 Gy) and 
chemotherapy (99). A second study described 2 patients (of a total 52 patients, 3.8%) with 
an esophageal fistula, both receiving adjuvant antiangiogenic agents within 2 months after 
SBRT (50 Gy, 5 Gy/fr) (96). In the study by Abelson et al., 2 of the 31 patients (6.5%) died 
within 6 months after radiation therapy and chemotherapy. One died of esophageal 
perforation causing mediastinitis, and the other patient had a tracheoesophageal fistula 
(94). The last study reported 8% (14 of 182 patients) high-grade esophageal toxicity after 
treatment with single-fraction SBRT (16 – 24 Gy) to metastases abutting the esophagus. In 
this study a D2.5cc < 14 Gy (47.6 Gy EQD2Gy,3Gy) was suggested to keep the high-grade toxicity 
at < 5%. However in 57% of these high-grade toxicity cases, patients received either 
doxorubicin or gemcitabine (98). 
Several studies have published dosimetric predictors for late or combined (acute and 
late) grade 1 to 3 esophageal toxicity. First, based on data of 58 patients with 9% grade 2 
toxicity, a Dmax of 43.4 Gy (101.4 Gy EQD2Gy,3Gy) and D1cc of 32.9 Gy (63.0 Gy EQD2Gy,3Gy) 
corresponded to 50% probability of late grade 2 esophageal toxicity after SBRT in 5 fractions 
(97). Chang et al. analyzed 100 patients with central NSCLC treated with 4 fractions of SBRT. 
Based on 3 patients with grade 2 esophagitis (moment of toxicity unknown), a Dmax ≤ 35 Gy 






(82.2 Gy EQD2Gy,3Gy) and V30 ≤ 1 cc (V63Gy EQD2Gy,3Gy) were recommended (38). Yau et al. made 
an NTCP model for (acute and late) grade 1 to 3 esophagus toxicity. A 15% risk of toxicity 
corresponded to Dmax of 142 Gy EQD2Gy,3Gy, D1cc of 124 Gy EQD2Gy,3Gy and D2cc of 118 Gy EQD-
2Gy,3Gy. The models of this study had low statistical power because of the small number of 
index events (106).  
According to studies reporting acute esophagus toxicity, Wu et al. showed < 20% 
(sub)acute esophageal toxicity when Dmax ≤ 44 Gy EQD2Gy,10Gy and D5cc ≤ 22 Gy EQD2Gy,10Gy 
(95). The same doses predict a 12.3% to 12.5% risk of toxicity based on our NTCP models. A 
second study predicted an 11% risk of (sub)acute grade ≥ 2 esophageal toxicity when D1.5cc 
≥ 17.6 Gy EQD2Gy,10Gy compared to 1% when D1.5cc < 17.6 Gy EQD2Gy,10Gy (108). In the absence 
of a D1.5cc model, a D2cc of 27.4 Gy EQD2Gy,10Gy corresponds to an 11% risk on acute toxicity 
in our NTCP model. Duijm et al. reported recently a 17% rate of acute low-grade esophageal 
toxicity within a cohort of 231 patients, which is comparable with our study. Note, that they 
did not report any grade 3 or higher toxicity, in contrast to our 4 cases of late high-grade 
toxicity. They showed that low-grade toxicity was correlated to the same dosimetric 
parameters found in our study (105). However, because the dose to the esophagus in our 
cohort was higher, the NTCP model derived by Duijm et al. calculates a lower probability of 
esophageal toxicity for a certain value of a dosimetric parameter than the model derived in 
this study. As also shown by other studies, there is a variety in probability rates and doses 
predictive of esophageal toxicity. Several explanations can be given for these differences. 
First, higher rates of toxicity are suggested in patients treated on consecutive days 
compared with patients treated on nonconsecutive days (109). Additionally, esophageal 
motion could result in a different delivered dose compared with the planned dose. This can 
lead to higher esophageal doses, which in turn may result in unexpected occurrence of 
toxicity (110). Moreover, there could be an additional influence of other dosimetric 
parameters aside from the Dmax and dose to small volumes of the esophagus (D1cc, D2cc and 
D5cc). Finally, retrospective scoring of low-grade toxicity can be challenging and could 
contribute to the differences in probability rates and predictive doses among various 
studies. 
Recently, the RTOG 0813 trial published their outcomes. In 13 patients, the esophagus was 
the main organ at risk. One patient had a late grade 5 esophageal event may have been an 
esophageal ulcer, but no autopsy was performed. Additionally, 6 cases of grade 3 and 2 
cases of grade 4 esophageal toxicity were reported (9% of high-grade toxicity) (16). Aside 
from the known dose constraints, no dosimetric information about these toxicity cases is 
available in the report, which limits comparison with our results. Therefore, we could only 
estimate the probability rates of toxicity for the Dmax RTOG 0813 constraints using the 
derived NTCP models. The estimated rates were as high as 46% for the late high-grade 
toxicity and 70% for the acute low-grade toxicity. When there is no clarity on the dose 
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received by the esophagus in the trial, we recommend that physicians take care with such 
high Dmax doses and use the suggested volume limit as a treatment planning goal as 
prescribed in the RTOG 0813 protocol. Some other prospective studies report either 
dosimetric or esophageal toxicity data, but not both, hindering direct comparisons with our 
results (71, 77). 
The prevention of high-grade toxicity is crucial in defining safe dose constraints for the 
esophagus. Although the amount of high-grade toxicity events within our study is not 
enough to formally recommend new dose constraints, it is of interest to compare the NTCP 
calculated probability of toxicity after SBRT for central lung tumors with an alternative 
treatment: lobectomy or pneumonectomy. After these alternative treatments, rates of 1 to 
5% are accepted (107, 111, 112). The reported esophageal doses coherent to the 5% 
probability of late high-grade toxicity could be seen as the limit within the stereotactic 
treatment of central lung tumors. Although we have reported 2 cases of grade 5 toxicity, 
the radiation-induced mortality rate within this study (1.06%, 2/188 patients) is at the lower 
bound of the lobectomy and pneumonectomy mortality range. Moreover, all patients with 
high-grade toxicity within our cohort were treated with a D1cc higher than the currently used 
dose constraints.  
Univariate analysis in our cohort showed 2 clinical predictors for acute esophagus 
toxicity: using 12 fractions as treatment and having a shorter distance between tumor and 
esophagus. A multivariate analysis including these 2 factors was not performed because a 
tumor close to the esophagus drives the physician’s decision to use a schedule of 12 
fractions. Hence, collinearity problems would arise when performing a multivariate analysis 
including these 2 factors. Likewise, the risk of acute esophagus toxicity decreases when the 
distance between tumor and esophagus increases. Harder et al. also mentioned the 
importance of the tumor-esophageal distance, showing significantly shorter distance for 
(sub)acute grade 2 to 3 esophageal toxicity compared with grade 0 to 1 (108). 
Some limitations of our study have to be mentioned. In addition to the limitations 
inherent to a retrospective design, we based the NTCP models for late high-grade toxicity 
on a limited number of events. Therefore, we could not test the assumptions of logistic 
regression, and no subset analyses were possible. However, the 95% CIs were relatively 
narrow for the amount of events. The models shown are reflecting the limits within the 
treatment of central lung tumors. 
 
  







Esophageal toxicity was reported in 18% of the patients treated with SBRT. Four patients 
had late high-grade toxicity including two treatment-related deaths (1.1%). No acute severe 
esophageal toxicity was reported. Late high-grade esophageal toxicity and acute low-grade 
esophageal toxicity were both significantly correlated with all dose-volume histogram 
parameters (Dmax, D1cc, D2cc, D5cc). The risk of late high-grade toxicity is low (< 1.5%) and the 
risk of acute toxicity is acceptable (< 30%) if the esophageal D1cc is ≤ 40 Gy in 8 fractions and 
≤ 48 Gy in 12 fractions. 
























8.1 Introduction  
Since 2006, patients with centrally located lung tumors have been treated with risk-adapted 
fractionation schedules. However, these fractionation schedules have changed over time 
and there is still no clear consensus. National or even global guidelines could lead to more 
uniform treatment schedules. Prediction models showing results in terms of overall survival 
(OS), disease control and toxicity, can be used as a basis for these guidelines and also 
support decision making for individual patients. This thesis describes different models 
focusing on survival outcomes, tumor outcomes and organs at risk (OAR) outcomes after 
stereotactic body radiation therapy (SBRT) of centrally located lung tumors. The following 
sections discuss the interpretation and possible limitations of these models. 
 
8.2 Outcome modelling; overall survival and local control 
In the past years, 2 prospective studies exclusively focusing on centrally located lung tumors 
have published their survival and disease control outcomes. The RTOG 0813 trial (113) 
included 120 patients with a tumor ≤ 5 cm. Of the 77 patients treated with 5 fractions of 
11.5 / 12 Gy, the 2 year OS was 68% to 73%. The 2 year LC (LC; defined as absence of infield, 
marginal or involved lobe failure) was 88% to 89% and the 2 year progression free survival 
(defined as local, regional or distant failure and development of a second primary or death 
as results of any cause) was 52% to 55%. The second prospective study enrolled 74 patients 
having non-small cell lung cancer (NSCLC) ≤ 7 cm in a phase I/II trial (39). The 2 year OS was 
43% in the phase II group consisting of 51 patients. Four patients failed locally resulting in a 
2 year LC rate of 85%. The 2 year disease free survival (DFS) was 28%. Other prospective 
studies like the HILUS and SUNSET have not published their (survival) outcomes yet (17). 
The outcomes of these 2 prospective studies are conflicting, as they show different 
survival rates and did not use the same LC definition. Other available disease control rates 
are all based on retrospective studies. Some of them will be discussed and compared with 
our data in the following paragraphs.  
 
Overall survival 
Chapter 2 discussed the OS of patients diagnosed with centrally located stage I – IIIA NSCLC. 
The 2 year OS rate in our cohort was 55%, which corresponds to the survival rates published 
by Roach et al (39). Nevertheless, the 2 year OS rates reported in literature vary widely. The 
rates range from 46% to 81% (19, 27, 28, 38, 71, 114) for centrally located NSCLC and from 
60% to 88% in studies reporting peripherally and centrally located NSCLC together (33, 36, 
43, 57, 61, 115-118). This variation in outcome rates could be explained by the differences 
in patient selection. Some studies are only including potentially operable patients or are 
including tumors smaller than 5 cm, while other studies also include patients not suitable 
for surgery and/or all T-stages. Additionally, over the past 15 to 20 years there have been 






significant developments in diagnostics, staging and treatment. For example, the PET-CT 
scan is nowadays a standard procedure within the diagnostic work-up, but in some 
literature the staging PET-CT scan was only used in 74% of the patients (28). All these factors 
together complicate the comparison of survival rates. The diversity within literature 
emphasizes the need of individualized survival predictions.  
Therefore, in Chapter 2, we have focused on developing a nomogram to guide physicians 
in patient risk-stratification and treatment decision making. The nomogram creation 
allowed us to identify the characteristics that are predominantly responsible for the 
differences in survival rates. Our nomogram consisted of age, planning target volume (PTV), 
performance status, tumor lobe location and dose to the PTV. Previously, each of these 
variables have been linked to OS, but this was the first time they have been combined into 
one predictive model. 
This first survival nomogram for centrally located NSCLC has been externally validated 
and showed acceptable predictive power. This nomogram is an important step towards 
personalized decision making, however there is certainly room for improvement. This can 
be realized by including the cause of death of each patient in the analysis. After all, OS not 
only reflects patient- or tumor-related factors, but also potential toxicity of the treatment. 
If, in future research, our nomogram is also able to predict for these non-treatment-related 
deaths, this could contribute to its predictive power.
Local control 
Chapter 3 investigated the clinical consequence of prioritizing the dose constraints of the 
OAR over the PTV coverage within the treatment of centrally located lung tumors. Although 
there was no relation between any PTV related treatment factors and local failure, both 
tumor size and forced expiratory volume in 1 second (FEV1) were found predictive for the 
development of a local recurrence. 
The 2 year LC rate within our cohort was 88%, whereas in literature it ranged from 64% 
to 98% in centrally located NSCLC (27, 28, 38, 71), and 81% to 97% in the combined patient 
cohorts (19, 36, 37, 43, 56, 61, 115, 116). In addition to the previously mentioned 
differences in patient selection and treatment between institutes, the variation in the 
definition of a local recurrence creates additional uncertainty when comparing the LC rates 
of different studies. While some studies use the response evaluation criteria in solid tumors 
(RECIST) to define local progression, others define local progression as a recurrence within 
the same lobe or even the same lobe and ipsilateral hilum or mediastinum. This results in 
higher recurrence rates in studies using a broader definition. 
Since LC rates after SBRT are promising, not many central lung studies were able to 
analyze possible predictors of local failure due to the low numbers of events. Predictive 
factors are mainly analyzed in combined groups in terms of centrally and peripherally 






located early stage NSCLC. Next to tumor size, a frequently found predictive factor was the 
central location of the tumor (55, 56). An explanation for this can be that adapted 
fractionation schedules result in a lower biologically effective dose to the tumor. Moreover, 
central tumors tend to be bigger (27) which was a predictive factor for local recurrences in 
this thesis and multiple other studies (Chapter 3). The benefit of a prescribed dose > 100 Gy 
BED10 (biologically equivalent dose, using an α/β ratio of 10 Gy) was also observed in 
Chapter 3 and confirmed in literature (19, 47).  
 
We were not able to demonstrate a potential link between local recurrence and 
underdosage of the PTV (Chapter 3). This suggests that underdosage has less impact on the 
development of a local recurrence than previously expected. However, we cannot fully 
exclude that underdosage harms the outcome in SBRT of central lung tumors. To exclude 
the role of the absolute or relative volume receiving a dose lower than 100 Gy BED10, a study 
with more statistical power is needed. Moreover, we have only investigated a threshold 
dose of 100 Gy BED10, and therefore we cannot draw conclusions on threshold doses lower 
than 100 Gy BED10.  
Instead of accepting a local underdosage, conventional radiotherapy could be an 
alternative option. However, the superior effect of SBRT compared to protracted 
radiotherapy in peripherally located early stage NSCLC is known (12). Future research could 
focus on the extent to which underdosing is still acceptable and when conventionally 
fractionated treatment schedules become a better option for treating the patient.  
 
The ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with 
small photon beams, recommends to report the median dose to the PTV and if the lesion is 
surrounded by lung parenchyma to also report the median dose to the clinical target volume 
(CTV) or gross tumor volume (GTV) (119). In addition, it recommends to report the near 
minimum dose and near maximum which is defined as D98% and D2% for target volumes 
larger than 2 cm3. In Chapter 3 we tested PTV median dose (D50%) and the D98% and D2%. The 
CTV/GTV median dose was not tested, because the CTV/GTV was not separately contoured. 
However, centrally located tumor are less surrounded by lung parenchyma than 
peripherally located tumors. We found that these parameters did not predict LC and DFS. 
Nevertheless, we suggest that the dosimetric parameters recommended by ICRU will be 
included in future studies. 
 
While defining cut-off values for dosimetric parameters would already be a major step 
forward, ideally treatment decision making is supported by an individualized tumor control 
probability (TCP) model. This sigmoid-shaped model could consist of patient, tumor and PTV 
parameters and predicts individual LC outcomes. To create a statistically sound model, a 






patient group with multiple events is needed. Especially when the goal is to include 3 or 
more parameters. A rule of thumb within multivariate analysis states that one predictive 
variable can be studied for every 10 events. However, to create a model with better 
predictive accuracy 20 events per parameters have been suggested (120). Whereas only 27 
local recurrences were found in our group of 220 patients, a group of at least 500 patients 
(approximately 60 events) having centrally located NSCLC treated with SBRT would be 
needed to create such a reliable model.
 
Disease free survival 
In Chapter 3, disease progression has been defined as a tumor recurrence in any part of the 
body, resulting in a 2 year DFS rate of 66%. Literature reported rates of 63% to 81% for 
centrally and/or peripherally located tumors (37, 38, 56, 71). In addition to the predictive 
factors found for local recurrence, a patient having a tumor located in the lower lobe had a 
significantly higher risk of disease recurrence in this thesis. This finding was explained by 
the more often unsuspected nodal involvement when a patient was diagnosed with a tumor 
in the lower lobe (34). During surgery, this unsuspected nodal involvement would result in 
adjuvant systemic treatment. However, as SBRT patients do not undergo pathologic staging, 
a small nodal involvement can easily be missed. Since the field of PET-CT scans evolves 
rapidly, and the scans become increasingly sensitive to small metastasis (121, 122), the 
chance of treating patients with unexpected nodal involvement with SBRT will become 
lower in the future.  
 
8.3 Toxicity modelling 
Toxicity is one of the major concerns when treating central lung tumors with SBRT. To 
prevent high-grade toxicity, nowadays each institute has strict dose constraints for the OAR 
which are prioritized over the PTV coverage. Hence, in case of PTV-OAR overlap, the PTV 
dose in the overlapping part is related to the constraint dose of the OAR. So, OAR dose 
constraints should not be taken too low on the one hand, but not too high on the other to 
keep toxicity rates at an acceptable level. Toxicity prediction models could be helpful to 
redefine the dose constraints. To this end, in this thesis, we analyzed the bronchial and 




Stereotactic body radiation therapy to the lungs can result in radiological changes in the 
lung. Stenosis and occlusion with or without atelectasis are patterns of toxicity that can be 
found in the bronchial branches (Chapter 4). Most of these radiological changes occurred in 
the smaller branches such as the upper, middle and lower lobe and the segmental bronchi. 






Only stenosis has been found in the trachea and main bronchi. The diameter of the trachea 
and main bronchi is larger compared to the smaller branches. Therefore, fibrosis of these 
bronchi will result in stenosis, but in the smaller branches fibrosis also results in occlusion 
with or without atelectasis (Chapter 4).  
The radiological changes in the smaller branches were correlated to Dmax, and the 
volume receiving a dose of 65, 80, 90, 100 and 130 Gy EQD2 (V65, V80, V90, V100 and V130, 
respectively). Despite being significantly different, the dose differences in the segmental 
bronchi with and without side effects were small and no difference in OS was found 
between these groups. Therefore, we decided to only focus on the radiographic toxicity in 
the main and lobar bronchi in Chapter 5.  
Stereotactic body radiation therapy can cause several types of radiological changes. In 
this thesis, we focused mainly on radiological changes of the bronchial branches and related 
that to dose. Additionally, changes in the lung parenchyma can be found in almost all 
patients after SBRT (123). This fibrotic process can be dynamic for many years, which 
creates additional difficulties in the diagnosis of a local recurrence (124). Clinicians should 
be aware of these radiological changes, which sometimes indicates a local recurrence. 
 
In Chapter 5, the correlation found in Chapter 4 between the bronchial dosimetric 
parameters and the radiographic bronchial toxicity was confirmed in a larger cohort. 
However, these radiological changes were not correlated with high-grade clinical bronchial 
toxicity. As mentioned before, the radiological changes mainly occurred in the smaller 
branches, which most likely causes only subclinical symptoms.  
Grade 3 or higher bronchial toxicity has been observed in 12% of our cohort. This rate 
was within the 6% to 15% range reported in literature (16, 53, 78, 90). Lung hemorrhage 
was one of the most frequently mentioned bronchial toxicities. In these cases, an 
endobronchial tumor location was more common, resulting in a PTV overlapping the main 
bronchi or trachea (Chapter 5). In this chapter, in 11 of the 13 patients the lung hemorrhage 
was fatal. However, fatal hemorrhage is not always the result of radiation induced toxicity. 
In case of a recurrence, the tumor can invade the vessels due to growth which can cause a 
fatal hemorrhage as well. Recent radiological images can confirm a possible recurrence. If 
this is not available, an autopsy could be taken to exclude radiation-induced toxicity.  
 
Clinical toxicity is not only caused by dose, certainly not in a patient group in which the 
comorbidity rates are relatively high. Next to the total bronchial volume receiving 130 Gy 
EQD2, chronic obstructive pulmonary disease and overlap of the PTV with the trachea / main 
stem bronchus were independently associated with high-grade toxicity.  
In this thesis, only dosimetric parameters were modeled in 4 NTCP curves. To create 
more individualized predictions, dosimetric and clinical factors can be combined into one 






NTCP model. Before combining these factors, a study is recommended that confirms the 
significance of parameters. Within such a study, the same parameters, including the 
dosimetric parameters, should be available for each of the patients. Moreover, the contours 
of the bronchial structures should be created following the same guidelines, as bronchial 
toxicity is related to volume dependent parameters. 
 
Esophageal toxicity 
Severe late esophageal toxicity can manifest as dysphagia, stricture, or the development of 
a fistula. The esophagus is a “serial organ”, which means that its function is lost when a 
short segment or a part of this organ is destroyed. In this type of organ, a high dose to a 
small volume, such as the dose to 1 cc or 2 cc of the esophagus, can have serious life-
threatening consequences (108, 125). 
From the beginning of the SBRT era, the esophagus has been an organ of great concern. 
In multiple institutes the dose constraints of the esophagus have always had priority over 
PTV coverage, resulting mainly in low-grade esophageal toxicity. Acute low-grade 
esophageal toxicity, meaning swallowing problems where sometimes pain medication is 
needed, was reported in 17% of our population (Chapter 6). Although not causing 
hospitalization or worse, the toxicity was correlated with the dosimetric parameters Dmax 
and the dose in 1 cc, 2 cc and 5 cc (D1cc, D2cc, D5cc) of the esophagus. Additionally, the hazard 
ratios confirmed that the dose to small volumes were of more importance than the Dmax. 
This could reflect the increased uncertainty in determining Dmax or could reflect a small 
volume effect that plays a role in the occurrence of the toxicity. 
The NTCP models that were created describe the relation between acute low-grade 
esophageal toxicity and dose. Unfortunately, the dose that would result in high-grade 
toxicity was missing in this analysis. Therefore, dose constraints derived from these models, 
will not automatically protect future patients from high-grade toxicity. 
 
In Chapter 7, we used data from a patient cohort in which 4 cases of high-grade esophageal 
toxicity were identified. This gave us the opportunity to explore dose limits for high-grade 
toxicity. In all cases with high-grade toxicity, the PTV overlapped the esophagus and PTV 
coverage was likely prioritized over the dose constraints. We found that high-grade toxicity 
could be predicted with the same dosimetric parameters as were found for low-grade 
toxicity. Similarly as in Chapter 6, we modelled the NTCP of high-grade toxicity for each of 
the 4 dosimetric parameters, separately. The hazard ratios also emphasized the greater 
influence of D1cc on esophageal toxicity compared to Dmax. Based on our data we suggest to 
use the D1cc parameter as a dose constraint instead of Dmax.  
Late high-grade esophageal toxicity has been rarely reported in literature. Three studies 
reported a single case of toxicity without confounding therapies, but not all of them 






reported the corresponding dosimetric details (46, 53, 59). To validate our NTCP models, 
more cases of esophageal toxicity are needed. However, this will be a challenge due to the 
small number of cases available in literature. The RTOG 0813 reported 4 cases of high-grade 
esophageal toxicity. Hopefully, dosimetric data of these cases will become available to 
confirm our conclusions.  
 
The rate of acute low-grade toxicity in Chapter 7 (15%) was comparable to the other cohort 
in Chapter 6. However, the dose corresponding to the same toxicity rate was much higher. 
This could be explained by differences in scoring low-grade toxicity. Some patients do not 
report these complaints to their radiation-oncologist or they receive medication from their 
general practitioner or pulmonologist without informing the radiation-oncologist. This 
uncertainty in toxicity scoring could also be the reason for the different predictive patient 




The bronchial structures and the esophagus have been considered the most important 
OARs in centrally located lung tumors in recent years. Recently, however, there has been 
increasing attention for the heart dose. Researchers are exploring the relation between 
(cardiac) death and heart dose received by SBRT. Because SBRT causes high doses in small 
volumes of the heart, the dose in these cardiac (sub)structures may cause non-cancer-
related death. The results, however, derived from analyzing different dosimetric 
parameters for different cardiac (sub)structures are conflicting (117, 126, 127). In one study, 
a significant correlation was found between non-cancer-related death and the maximum 
dose to the left atrium and the dose to 90% of the superior vena cava (117). Another study 
found more cardiac events in patients with a history of heart problems, but could not find 
a relation with the radiation dose to cardiac substructures (127). In another study, cardiac 
dose was not found as a predictor for OS and a high dose to small volumes of the whole 
heart (substructures were not included in the analysis) appeared to be safe (126).  
Analyzing non-cancer-related death is challenging because of the high rates of cardiac 
and pulmonary comorbidities within the SBRT patient group. This makes it hard to 
distinguish between death due to comorbidities and treatment-related death. By all means, 
the baseline heart condition should be taken into account when analyzing this group. More 











8.4 Future perspectives 
Each central lung patient is exposed to different risks of toxicity based on the location of the 
tumor and the patient’s pre-treatment condition. Therefore, individualized outcome 
modeling has a strong rational. The NTCP models and predictors of disease control created 
and found in this thesis could be used for decision making in central lung patients 
considered for SBRT.  
Based on expected survival probabilities, the radiation-oncologist can decide whether a 
patient qualifies for SBRT. The NCTP models make it possible to determine the expected 
toxicity on an individual basis. Thereafter, the radiation-oncologist and the patient can 
weigh the expected toxicity with the calculated disease control probability. In other words, 
the models can be used to aid shared decision making. Patients have indicated that 
maintaining independence and quality of life are more valued than survival or cancer 
recurrence (128). When the tumor is too close to the OAR, resulting in a high toxicity risk 
and/or a lower chance on LC, alternative treatment options should be discussed.  
 
Stereotactic body radiation therapy is a safe treatment option for patients with centrally 
located NSCLC (This thesis). Some subgroups, however, such as patients with interstitial lung 
disease (ILD), have been identified to have a higher risk of treatment-related toxicity and 
mortality. Chen et al. found a relationship between these higher risks and the dose received 
by the lung parenchyma (129). This highlights the need to even more lower the dose 
received by the tumor surrounding OAR. 
Recently introduced techniques, such as the MRI-linac and proton therapy, could 
provide more accurate radiotherapy and lead to lower high-grade toxicity risks. The MRI-
linac includes real-time magnetic resonance (MR) image-guidance during treatment. This 
can be used for motion management, for example gated delivery, or online plan adaption 
based to the daily anatomy. The first results of treating high-risk patients with MR-guided 
SBRT are encouraging. While no compromise had to be made with regard to tumor control 
by using a breath hold technique, only 8% of patients reported grade 3 toxicities (130). 
Proton therapy uses fine proton beams that deposit their dose locally. This may lead to a 
significant dose reduction to OARs compared to using X-rays that deposit their dose along 
the entire path of the beam. In the Netherlands, a model-based approach is used to select 
the patients who may benefit from proton therapy. In order to validate these models, the 
toxicity data of prospective stereotactic body proton therapy trials is needed (131).  
In the past years, the term “ultracentral tumor” has been introduced because of the 
expected higher toxicity rates due to its location (61). Some institutes have even decided to 
refuse these patients for SBRT and propose treating them with hypofractionated schemes 






using 2.5 Gy to 3 Gy per fraction (77, 132). In this thesis, we have found higher toxicity risks 
for PTVs overlapping the trachea and main bronchus and for tumors close to  
the esophagus (Chapter 5 and 7). On the other hand, the NTCP curves can calculate the 
toxicity probabilities based on the dosimetric parameters. Therefore, we believe there is no 
need to decline this subgroup in advance from SBRT treatment. In patients with an 
ultracentral tumor, the toxicity risks can be weighed against the expected disease outcomes 
and a personalized decision can be made in each individual case. 
 
The standard treatment for operable early stage NSCLC is still surgery. Within the field of 
peripherally located tumors, SBRT showed very good results with low toxicity rates, the 
perfect alternative for surgery. Therefore, it is suggested that there is clinical equipoise 
between the 2 treatment modalities, which would result in the use of SBRT in operable 
patients (133). Although equipoise has not yet been demonstrated in randomized control 
trials for peripheral tumors, the question arises whether this is also an option in the 
treatment of centrally located lung tumors. 
Although the outcomes of SBRT in central tumors are promising, the toxicity rates are 
much higher compared to peripheral tumors. However, this increased risk is also seen in 
the surgical treatment of central lung tumors. Due to its anatomical position, more invasive 
procedures are generally needed, resulting in less pulmonary capacity and higher morbidity 
and mortality rates (107). Whether surgery or SBRT can be used depends on the individual 
situation of the patient. If the identification of occult nodal disease is needed, surgery would 
be the preferred option. However, if lung preservation is more important, SBRT would be 
the preferred option. 
 
8.5 Conclusion 
Stereotactic body radiation therapy is a safe treatment option in medically inoperable 
patients diagnosed with a centrally located lung tumor. When the dose constraints are 
respected and prioritized over PTV coverage, survival and disease control rates will be 
satisfactory without high rates of high-grade toxicity. Toxicity in the surrounding OARs can 
be predicted for each individual patient using the NTCP models developed in this thesis. This 
will help to minimize the development of toxicity. 
The models provided in this thesis are based on data of multiple institutes, which limits 
institutional bias and supports the clinical applicability. In addition to developments in 
treatment techniques, improved NTCP models with a multivariate design along with models 
that predict tumor control probability, have the potential to improve the individualized 
treatment approach.  
  




























1A – T, N, and M descriptors for eighth edition of TNM classification for lung cancer 
 
T: primary tumor 
 Tx  Primary tumor cannot be assessed or tumor proven by presence of malignant cells in sputum 
or bronchial washings but not visualized by imaging or bronchoscopy 
 T0  No evidence of primary tumor 
 Tis  Carcinoma in situ 
 T1  Tumor ≤ 3 cm in greatest dimension surrounded by lung or visceral pleura without 
bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main 
bronchus) a) 
  T1a(mi) Minimally invasive adenocarcinoma b) 
  T1a Tumor ≤ 1 cm in greatest dimension a) 
  T1b Tumor > 1 cm but ≤ 2 cm in greatest dimension a) 
  T1c Tumor > 2 cm but ≤ 3 cm in greatest dimension a) 
 T2  Tumor > 3 cm but ≤ 5 cm or tumor with any of the following features c): 
- Involves main bronchus regardless of distance from the carina but without involvement of the 
carina 
- Invades visceral pleura 
- Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, 
involving part or all of the lung 
  T2a Tumor > 3 cm but ≤ 4 cm in greatest dimension 
  T2b Tumor > 4 cm but ≤ 5 cm in greatest dimension 
 T3  Tumor > 5 cm but ≤ 7 cm in greatest dimension or associated with separate tumor nodule(s) in 
the same lobe as the primary tumor or directly invades any of the following structures: chest 
wall (including the parietal pleura and superior sulcus tumors), phrenic nerve, parietal 
pericardium 
 T4  Tumor > 7 cm in greatest dimension or associated with separate tumor nodule(s) in a different 
ipsilateral lobe than that of the primary tumor or invades any of the following structures: 
diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, 
vertebral body, and carina 
N: Regional lymph node involvement 
 Nx  Regional lymph nodes cannot be assessed 
 N0  No regional lymph node metastasis 
 N1  Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary 
nodes, including involvement by direct extension 
 N2  Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) 
 N3  Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, 
or supraclavicular lymph node(s) 
M: Distant metastasis 
 M0  No distant metastasis 
 M1  Distant metastasis present 
  M1a Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodule(s) or 
malignant pleural or pericardial effusion d) 
  M1b Single extrathoracic metastasis e) 
  M1c Multiple extrathoracic metastases in one or more organs 
a) The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial 
wall, which may extend proximal to the main bronchus, is also classified as T1a; b) Solitary adenocarcinoma, ≤ 3 
cm with a predominately lepidic pattern and ≤ 5 mm invasion in any one focus; c) T2 tumors with these features 
are classified as T2a if ≤ 4 cm in greatest dimension or if size cannot be determined, and T2b if > 4 cm but ≤ 5 cm 
in greatest dimension; d) Most pleural (pericardial) effusions with lung cancer are due to tumor. In a few patients, 
however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor and the fluid is 
non-bloody and not an exudate. When these elements and clinical judgment dictate that the effusion is not 
related to the tumor, the effusion should be excluded as a staging descriptor; e) This includes involvement of a 
single distant (nonregional) lymph node. 
145960 Duijm BNW-def.indd   118 13-11-2020   16:08
Appendices 
119 
1B – Stage groupings of the eight TNM classification for lung cancer 
Occult carcinoma Tx N0 M0 
Stage 0 Tis N0 M0 
Stage IAI T1a (mi) N0 M0 
T1a N0 M0 
Stage IA2 T1b N0 M0 
Stage IA3 T1c N0 M0 
Stage IB T2a N0 M0 
Stage IIA T2b N0 M0 
Stage IIB T1a-c N1 M0 
T2a N1 M0 
T2b N1 M0 
T3 N0 M0 
Stage IIIA T1a-c N2 M0 
T2a-b N2 M0 
T3 N1 M0 
T4 N0-1 M0 
Stage IIIB  T1a-c N3 M0 
T2a-b N3 M0 
T3 N2 M0 
T4 N1 M0 
Stage IIIC T3 N3 M0 
T4 N3 M0 
Stage IVA Any T Any N M1a 
Any T Any N M1b 
Stage IVB Any T Any N M1c 
Abbreviations: TNM = tumor, node, metastasis; Tis = carcinoma in situ; T1a(mi) = minimally invasive  
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2A – Results of the univariate cox regression analyses focusing on patient- and 




median (IQR) / n (%) 
Death 




Age 77 (67 – 80) 75 (68 – 82) 1.12 (1.02 – 1.24)1 0.021 
FEV1 * 67 (52 – 83) 60 (48 – 76) 0.99 (0.99 – 1.00) 0.230 
Gender Male 40 (31%) 91 (69%) 1 
Female 35 (39%) 54 (61%) 0.81 (0.58 – 1.14) 0.233 
Tumor lobe location UMM 61 (39%) 95 (61%) 1 
Lower 14 (22%) 50 (78%) 1.66 (1.17 – 2.34) 0.004 
WHO performance status # 0 38 (51%) 36 (49%) 1 
1 – 4  37 (27%) 100 (73%) 1.74 (1.19 – 2.56) 0.004 
Pathology available No 39 (43%) 52 (57%) 1 
Yes 36 (28%) 93 (72%) 1.37 (0.98 – 1.93) 0.069 
CCI 0 – 3 62 (36%) 110 (64%) 1 
≥ 4 13 (27%) 35 (73%) 1.21 (0.83 – 1.77) 0.330 
Previous malignancies  No 42 (32%) 91 (68%) 1 
Yes 33 (38%) 54 (62%) 1.07 (0.76 – 1.50) 0.691 
Previous lung cancer  No 65 (33%) 132 (67%) 1 
Yes 10 (43%) 13 (57%) 0.74 (0.42 – 1.32) 0.309 
Disease stage I 40 (48%) 43 (52%) 1 
II 32 (28%) 83 (72%) 1.74 (1.20 – 2.52) 0.003 
III 3 (14%) 19 (86%) 3.75 (2.15 – 6.51) < 0.001 
PTV  64 (34 – 118) 93 (49 – 155) 1.24 (1.10 – 1.38)2 < 0.001 
PTV Dmax BED10  145 (134 – 173) 141 (121 – 175) 0.97 (0.92 – 1.02)3 0.261 
PTV D2% BED10 140 (128 – 164) 137 (114 – 163) 0.96 (0.90 – 1.02)3 0.173 
PTV Dmean BED10 123 (107 – 137) 120 (97 – 135) 0.95 (0.88 – 1.03)3 0.208 
PTV D50% BED10 124 (108 – 140) 120 (99 – 136) 0.95 (0.87 – 1.03)3 0.198 
PTV D98% BED10 102 (87 – 105) 96 (82 – 105) 0.96 (0.87 – 1.06)3 0.379 
PTV Dmin BED10 83 (68 – 91) 73 (62 – 88) 0.96 (0.88 – 1.05)3 0.361 
PTV Dmean BED10 < 100 8 (17%) 40 (83%) 1.52 (1.05 – 2.20) 0.026 
≥ 100 67 (39%) 105 (61%) 1 
* 24 cases missing # 9 cases missing 
1) HR per 5 year, 2) HR per 100 cc, 3) HR per 10 Gy 
Abbreviations: BED10 = biologically effective dose using α/β-ratio of 10 Gy; CCS = charlson comorbidity index; COPD = chronic 
obstructive pulmonary disease; Dmax = maximum point dose; Dmean = mean dose; Dmin = minimum point dose; D..% = dose to .. 
percent of the PTV; FEV1 = forced expiratory volume in 1 second; HR = hazard ratio; NSCLC = non-small cell lung cancer; PTV = 
planning target volume; SBRT = stereotactic body radiation therapy; UMM = upper/middle lobe or mediastinum
2B – Results of internal validation of the model building procedure through 1000 
bootstrap samples 
Original Sample Training Test Optimism Optimism – 
corrected 
C-index 0.661 0.689 0.642 0.047 0.614 
Slope 1.000 1.000 0.622 0.378 0.622 






3A – Currently used dose contraints of the organs at risk per institution 
 
Haaglanden MC  8 fractions 12 fractions 
Esophagus (D1cc) 40 Gy 48 Gy 
Trachea and main stem bronchus  (D1cc) 44 Gy 54 Gy 
 
Erasmus MC Cancer Institute  5 fractions 7 fractions 
Esophagus  (Dmax) 40 Gy 45.5 Gy 
Trachea (Dmax) 45 Gy 51.8 Gy 










5A – Institutional fractionation schedules for centrally located lung tumors 
 
 Fractionation schedule BED10 (Gy) 
VU University Medical Center   
Central tumor adjacent to and/or minimal 
overlap with pericardium, hilus, plexus, stomach 
8 fractions of 7.5 Gy 105.0 
Central tumor with a substantial overlap with 
mediastinal structures and/or 
pathological ipsilateral mediastinal nodes 
12 fractions of 5 Gy 90.0 
Erasmus Medical Center*   
Central tumor close to the esophagus: 
Ray Tracing 6 or 7 fractions of 8 Gy 86.4 or 100.8 
Monte Carlo 7 fractions of 7 Gy 83.3  
Other central lung tumors:   
Ray Tracing 5 fractions of 9, 10 or 12 Gy 85.5, 100.0 or 132.0 
Monte Carlo 5 fractions of 11 Gy 115.5  
*Initially, tumors were planned and treated using a ray tracing algorithm. Over time the schedules used were 
changed as no severe toxicity was observed. After introduction of the Monte Carlo calculation algorithm, the 
prescriptions were again revised. 
 
5B – Institutional point dose limits (Dmax) for the organs at risk 
 
VU University Medical Center 
 Fractionation schedule 
Organ(s) 8 x 7.5 Gy (total EQD2) 12 x 5 Gy (total EQD2) 
Esophagus (α/β = 3) 40 Gy  (64) 48 Gy  (67) 
Heart (α/β = 3)* 44 Gy  (75) 54 Gy  (81) 
Trachea (α/β = 3)* 44 Gy  (75) 54 Gy  (81) 
Main stem bronchus (α/β = 3)* 44 Gy  (75) 54 Gy  (81) 
Great vessels (α/β = 3)* - - 
Spinal canal (α/β = 2) 28 Gy  (39) 32 Gy  (37) 
Brachial plexus (α/β = 3) 36 Gy  (54) 42  (55) 
Erasmus Medical Center 
 Fractionation schedule 
Organ(s) 5 x 11 Gy (total EQD2) 7 x 7 Gy (total EQD2) 
Esophagus (α/β = 3) 35 Gy  (70) 42 Gy (76) 
Trachea (α/β = 3) 45 Gy (108) 49 Gy (98) 
Main stem bronchus (α/β = 3) 55 Gy (154) 49 Gy (98) 
Spinal cord (α/β = 2) 27.5 Gy (52) 32.9 Gy (55) 
Brachial plexus (α/β = 3) 30 Gy (54) 35 Gy (56) 
* = no specific dose limit was applied when the planning target volume is adjacent or overlapping the organ in 
question, but in practice the point Dmax was frequently constrained during planning.  
  






5C – Univariate logistic regression analyses of dosimetric parameters for clinical 
pulmonary or radiographic bronchial toxicity 
 
  
*Total volume of all bronchial structures receiving a specific dose (65 Gy EQD2, 80 Gy EQD2, 90 Gy EQD2, 100 Gy 
EQD2, 130 Gy EQD2) was calculated for each patient.  
Abbreviations: OR = odds ratio; 95% CI = 95% confidence interval; NTCP = normal tissue complication probability. 
Clinical high grade pulmonary toxicity (total number of patients = 193)* 















95% CI  
1.02  
1.01 – 1.03 
1.21 
1.11 – 1.31 
1.25  
1.14 – 1.40 
1.28  
1.16 – 1.42 
1.35  
1.20 – 1.53 
1.68  
1.26 – 2.24 
p-value 0.002 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 
       

















1.00 – 1.02 
1.18  
1.08 – 1.30 
1.21  
1.10 – 1.34 
1.23  
1.11 – 1.37 
1.27  
1.12 – 1.43 
1.26  
0.98 – 1.62 
p-value 0.029 < 0.001 < 0.001 < 0.001 < 0.001 0.066 
       

















1.00 – 1.02 
1.20 
1.08 – 1.34 
1.23 
1.10 – 1.38 
1.25 
1.10 – 1.42 
1.28 
1.11 – 1.47 
1.22 
0.90 – 1.65 
p-value 0.184 0.001 < 0.001 < 0.001 0.001 0.195 
       















95% CI  
1.01 
1.00 – 1.02 
1.11 
0.98 – 1.26 
1.13 
0.98 – 1.30 
1.14 
0.98 – 1.32 
1.16 
0.98 – 1.37 
1.25 
0.90 – 1.75 
p-value 0.053 0.114 0.091 0.09 0.084 0.183 
Radiographic toxicity of the main stem and intermediate bronchi (number of structures = 189) 
Any grade of toxicity (number of structures with toxicity = 17)  




1.00 – 1.03  
1.16 
0.96 – 1.40  
1.16  
0.94 – 1.43 
1.19  
0.95 – 1.49  
1.20  
0.93 – 1.56  
1.75  
0.81 – 3.77 
p-value  0.010  0.122  0.163  0.136  0.166  0.157 
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5D – Univariate and multivariate logistic regression analyses for factors predicting high 
grade clinical (n = 193) 
Grade ≥ 3 clinical pulmonary toxicity 
Univariate analysis Multivariate analysis 
Characteristic ≥ G3 toxicity No toxicity OR (95% CI) p-value OR (95% CI) p-value 
Age 0.98 (0.95 – 1.02) 0.306 - - 
Gender 
Female n = 8 n = 64 0.82 (0.33 – 2.03) 0.668 - - 
Male n = 16 n = 105 1 
COPD 
Yes n = 21 n = 96 5.03 (1.44 – 17.54) 0.011 4.09 (1.11 – 15.05) 0.034 
No n = 3 n = 69 1 1 
Unknown* n = 0 n = 4 
Previous treatment  
Yes n = 4 n = 26 1.10 (0.35 – 3.48) 0.871 - - 
No n = 20 n = 143 1 
Histology  
Primary n = 22 n = 130 1 0.117 0.38 (0.07 – 2.06) 0.263 
Metastastic n = 2 n = 39 0.30 (0.07 – 1.35) 1 
PTV overlap with main stem bronchi/trachea 
Yes n = 16 n = 48 5.04 (2.03 – 12.55) 0.001 4.16 (1.54 – 11.23) 0.005 
No n = 8 n = 121 1 1 
5C (continued) - Univariate logistic regression analyses of dosimetric parameters for 
clinical pulmonary or radiographic bronchial toxicity 
Radiographic toxicity of the lobar bronchi (number of structures = 311) 
Any grade of toxicity (number of structures with toxicity = 64)  




1.01 – 1.02  
1.56  
1.25 – 1.93  
1.61  
1.28 – 2.01 
1.62  
1.28 – 2.04 
1.75  
1.35 – 2.28 
2.47  
1.52 – 4.00 
p-value < 0.001  < 0.001  < 0.001  < 0.001  < 0.001  < 0.001  
High grade toxicity (number of structures with toxicity = 38)  




1.01 – 1.03 
1.60  
1.26 – 2.02 
1.69  
1.32 – 2.16 
1.76  
1.37 – 2.28 
1.96 
1.47 – 2.61 
2.29 
1.44 – 3.65 
p-value 0.021  < 0.001  < 0.001  < 0.001  < 0.001  0.001  
Abbreviations: OR = odds ratio; 95% CI = 95% confidence interval; NTCP = normal tissue complication 
probability. 






5D (continued) – Univariate and multivariate logistic regression analyses for factors predicting 
high grade clinical (n = 193) 
 
 Univariate analysis Multivariate analysis 
Characteristic ≥ G3 toxicity No toxicity OR (95% CI) p-value OR (95% CI) p-value 
Any grade of radiographic bronchial toxicity     
 Yes n = 8 n = 49 1.22 (0.49 – 3.05) 0.663 - - 
 No n = 16 n = 120 1    
High grade radiographic bronchial toxicity     
 Yes n = 4 n = 23 1.27 (0.40 – 4.05) 0.687 - - 
 No n = 20 n = 146 1    
Total V130Gy,EQD (all bronchial structures) 1.68 (1.26 – 2.24) < 0.001 1.52 (1.10 – 2.12) 0.012 
     
High grade radiographic toxicity in any bronchial structure 
   Univariate analysis Multivariate analysis 
Characteristic Toxicity No toxicity OR (95% CI) p-value OR (95% CI) p-value 
Age   1.05 (1.00 – 1.10) 0.036 1.04 (0.99 – 1.10) 0.100 
Gender       
 Female n = 4 n = 67 0.262 (0.09 – 0.79) 0.018 0.373 (0.12 – 1.19) 0.097 
 Male n = 23 n = 101 1  1  
COPD        
 Yes n = 18 n = 100  1.28 (0.54 – 3.02) 0.573 - - 
 No n = 9 n = 64 1    
 Unknown* n = 0 n = 4     
Previous treatment      
 Yes n = 6 n = 24 1.71 (0.63 – 4.68) 0.293 - - 
 No n = 21 n = 144 1    
Histology     
 Primary n = 23 n = 131 1 0.397 - - 
 Metastatic n = 4 n = 37 0.62 (0.20 – 1.89)    
PTV overlap with main stem bronchi/trachea     
  Yes n = 16 n = 50 3.43 (1.49 – 7.92) 0.004 2.87 (1.16 – 7.06) 0.022 
  No n = 11 n = 118 1  1  
Total V130Gy,EQD (all bronchial structures) 1.35 (1.07 – 1.71) 0.012 1.237 (0.95 – 1.62) 0.120 
Bold values resemble a p-value of ≤ 0.20 on univariate analysis or < 0.05 on multivariate analysis. Variables with a 
p-value of ≤ 0.20 were included in a multivariate logistic regression analysis.  
*This subgroup was not used in the analysis.  
Abbreviations: CI = confidence interval; COPD = chronic obstructive pulmonary disease; OR = odds ratio; PTV = 
planning target volume.  
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5E – Example of a patient with an ultracentral tumor who was treated with 12 
fractions of 5 Gy. 
The left panel shows two axial slices of the planning CT-scan, and the right panel shows corresponding slices of the 
follow-up CT scan 12.7 months later. Patient developed a stenosis of the left upper lobe bronchus (images A and 
B), and also an occlusion with atelectasis of the left lower lobe bronchus (images C and D).  
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5F – I 
In all figures: The x-axis shows the dose range and is divided into 5 equal parts (“bins”). Solid black squares represent 
the observed incidence of toxicity for each bin (%). Both the number of patients with toxicity and the numbers at 
risk in each bin are indicated. Bins not containing any patients had no square shown in the graph. For clinical normal 
tissue complication probability models, the maximum point dose in all analyzed structures, and a total volume of 
all structures receiving the specified doses, were calculated for each patient.  
5F – NTCP models for grade 3 or higher clinical pulmonary toxicity 
5G – NTCP models for possible or likely treatment-related death (G5 toxicity) 
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5H – NTCP models for any grade of radiographic toxicity (stenosis, occlusion 
without atelectasis, or occlusion with atelectasis) in the lobar bronchi  
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Figure 5I – NTCP models of an occlusion without or with atelectasis in the lobar bronchi 






6A – Institutional fractionation schedules for central located lung tumors 
 
 Fractionation schedule BED10 (Gy) 
VU University Medical Center (VUmc)   
Central tumor adjacent to and/or minimal 
overlap with pericardium, hilus, plexus, stomach 
8 fractions of 7.5 Gy 105.0 
Central tumor with a substantial overlap with 
mediastinal structures and/or 
pathological ipsilateral mediastinal nodes 
12 fractions of 5 Gy 90.0 
Erasmus Medical Center (EMC)*   
Central tumor close to the esophagus: 
Ray Tracing algorithm 6 or 7 fractions of 8 Gy 86.4 or 100.8 
Monte Carlo algorithm 7 fractions of 7 Gy 83.3  
Other central lung tumors:   
Ray Tracing algorithm 5 fractions of 9, 10 or 12 Gy 85.5, 100.0 or 132.0 
Monte Carlo algorithm 5 fractions of 11 Gy 115.5  
*In the early period, tumors were planned using with Ray Tracing algorithm. Subsequently, treatment 
schedules were changed as no severe toxicity was observed. After introduction of the Monte Carlo calculation 
algorithm, the prescription changed.  
Abbreviations: BED = biologically effective dose 
 
6B – Institutional point dose limits (Dmax) for the organs at risk 
 
VU University Medical Center (VUmc) 
Organ(s) Fractionation schedule 
8x 7.5 Gy  
Fractionation schedule 
12x 5 Gy  
Esophagus (α/β = 3) 40 Gy (64Gy EQD23) 48 Gy (67Gy EQD23) 
Heart (α/β = 3)* 44 Gy (74.8Gy EQD23) 54 Gy (81Gy EQD23) 
Trachea (α/β = 3)* 44 Gy (74.8Gy EQD23) 54 Gy (81Gy EQD23) 
Main bronchus (α/β = 3)* 44 Gy (74.8Gy EQD23) 54 Gy (81Gy EQD23) 
Great vessels (α/β = 3)* - - 
Spinal Cord (α/β = 2) 28 Gy (39Gy EQD22) 32 Gy (37Gy EQD22) 
Brachial plexus (α/β = 3) 36 Gy (54Gy EQD23) 42 (55Gy EQD23) 
Erasmus Medical Center (EMC) 
Organ(s) Fractionation schedule 
5x 11 Gy  
Fractionation schedule 
7x 7 Gy 
Spinal Cord (α/β = 2) 27.5 Gy (52Gy EQD22) 32.9 Gy (55Gy EQD22) 
Esophagus (α/β = 3) 35 Gy (70Gy EQD23) 42 Gy (75.6Gy EQD23) 
Trachea (α/β = 3) 45 Gy (108Gy EQD23) 49 Gy (98Gy EQD23) 
Main Bronchus (α/β = 3) 55 Gy (154Gy EQD23) 49 Gy (98Gy EQD23) 
Brachial plexus (α/β = 3) 30 Gy (54Gy EQD23) 35 Gy (56Gy EQD23) 
* = no specific dose limit when the planning target volume is adjacent or overlapping, but in practice the 
point Dmax is frequently constrained during planning. 
Abbreviations: EQD2x = equivalent dose of 2 Gy per fraction with an α/β ratio of x 
 
  






6C – Univariate and multivariate logistic regression analyses for factors predicting acute 
grade 1 – 2 esophageal toxicity 
    Univariate analysis Multivariate analysis  
Characteristic Toxicity No toxicity OR (95% CI) p-value OR (95% CI) p-value 
Age   0.982 
(0.952 – 1.014) 
0.270   
PTV (cc)   1.004 
(1.000 – 1.007) 
0.051 0.998 
(0.993 – 1.003) 
0.371 
Gender       
 Male n = 20 n = 129 1  1  
 Female n = 18 n = 64 1.814 
(0.897 – 3.667) 
0.097 3.020 
(1.304 – 6.994) 
 
Charlson       
 0 – 2 n = 23 n = 96 1    
 ≥ 3 n = 15 n = 97 0.645 
(0.318 – 1.312) 
0.226   
Amount of fractions       
 3 – 6 n = 18 n = 84 1    
 7 – 12 n = 20 n = 109 0.856 
(0.426 – 1.720) 
0.663   
Dose per fraction       
 5 – 7 Gy n = 11 n = 44 1    
 > 7 Gy n = 27 n = 149 0.725 
(0.333 – 1.577) 
0.417   
D5cc (EQD210)   1.135 
(1.086 – 1.187) 
< 0.001 1.158 
(1.100 – 1.219) 
< 0.001 
Abbreviations: EQD210 = equivalent dose of 2 Gy per fraction with α/β ratio of 10; 95% CI = 95% confidence interval; 
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7A – Bronchial structures 
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7B – Dosimetric parameters of all DVH-parameters, divided in group with and without 
acute toxicity 
The band inside the box shows the median and the borders of the box the first and third quartile. The whiskers 
show 1.5 times the interquartile range and the circles the outliers.
No toxicity No toxicity
No toxicity No toxicity Acute toxicityAcute toxicity
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The aim of this thesis was to improve decision making in stereotactic body radiation therapy 
(SBRT) of centrally located lung tumors by modelling the outcome in terms of overall 
survival, local disease control and toxicity probabilities. 
Chapter 1 contains a general introduction into the field of SBRT for centrally located lung 
tumors and ends with an outline of this thesis. The subgroup of central lung patients has 
been treated with risk adapted fractionation schedules and accompanying dose constraints 
for more than 10 years, however evidence-based guidelines are still missing. The models 
provided within this thesis could be used to support nationwide or even worldwide 
consensus. 
Chapter 2 offers a nomogram to predict overall survival in patients having centrally located 
early stage NSCLC treated with SBRT. This nomogram includes the variables planning target 
volume (PTV), age, WHO performance status, tumor lobe location and mean dose to the 
PTV. The discriminatory ability was moderate and the calibration plots showed favorable 
predictive accuracy. The external validation in a cohort of 94 central lung patients showed 
acceptable validity. The 5 factors together predict overall survival at 6 months, 1, 2 and 3 
years.  
The impact of underdosage of the PTV on local control is discussed in Chapter 3. Twelve 
percent of the 220 patients developed a local recurrence resulting in local control rate of 
88% at 2 years. There was no correlation between a local recurrence and the relative or 
absolute PTV receiving less than 100 Gy BED10. Additionally, no correlation was found with 
any of the other analyzed PTV parameters. Bigger tumor size and lower forced expiratory 
volume in 1 second (FEV1) were independently predictive for the development of a local 
recurrence. Disease progression was reported in 75 patients with a 2-year disease free 
survival rate of 66%. Disease recurrence was associated with larger tumor diameter, a 
tumor located in the lower lobe and decreased FEV1.  
Chapter 4 describes radiological changes of the bronchi after SBRT and its relation to the 
prescribed dose. The radiological changes were divided in stenosis and occlusion with or 
without atelectasis. No changes were found in the trachea and only stenosis was reported 
in the main bronchi and intermediate bronchus. Occlusion with and without atelectasis was 
seen in the smaller branches; the upper, middle, and lower lobe bronchi and the segmental 
bronchi. The dose was significantly higher in these branches with radiological changes. 
Normal tissue complication probability (NTCP) models were derived for the maximum point 
dose (Dmax) and the bronchial volume receiving 65, 80 and 100 Gy EQD2 (V65-100Gy) in the 
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main bronchi and bronchus intermedius, in the upper, middle, and lower lobe bronchi and 
in the segmental bronchi. 
In Chapter 5 both clinical pulmonary (grade 3 or higher) and radiological bronchial toxicity 
were evaluated in a group of 195 patients. Several dosimetric parameters, Dmax and V65Gy, 
V80Gy, V90Gy, V100Gy, V130Gy (in EQD2), were analyzed and all of them were correlated with 
clinical and lobar bronchial radiological toxicity. After identifying the predictors, NTCP 
models were derived showing volume dependency for the development of both toxicities.  
High-grade clinical toxicity was independently correlated with a PTV overlapping the 
trachea or main stem bronchus, chronic obstructive pulmonary disease (COPD) and the total 
V130Gy. Radiological toxicity did not correlate with clinical toxicity, which was explained by 
the subclinical symptoms caused by occlusion of the lobar bronchi. 
Chapter 6 reports the incidence of low-grade radiation esophagitis after SBRT and its 
relation to the prescribed dose. Acute low-grade toxicity was reported in 17% of the 221 
patients without the occurrence of high-grade toxicity. All analyzed DVH-parameters, the 
Dmax and the dose in 1 cc, 2 cc and 5 cc of the esophagus (D1cc – 5cc, in EQD2), were correlated 
with low-grade toxicity. NTCP-curves of each dosimetric parameter were modelled. A 
multivariable analysis showed significant correlation with the development of low-grade 
esophageal toxicity for D5cc and female gender. 
Chapter 7 discusses 4 cases of high-grade esophageal toxicity and their relation with SBRT 
in a cohort of 188 central lung patients. Two patients reported grade 3 toxicity and 2 
patients died due to esophageal toxicity. Acute low-grade toxicity occurred in 15% of the 
patients. All investigated DVH-parameters (Dmax, D1cc, D2cc, D5cc, in EQD2) were significantly 
correlated with acute and late toxicity. NTCP-curves for acute and late toxicity were derived 
for all DVH-parameters. Both a smaller distance between tumor and esophagus and the use 
of 12 fractions (versus 8 fractions) were correlated with increased acute low-grade toxicity 
in the univariate analysis. No multivariate analysis was possible due to the correlation 
between both parameters. 
In Chapter 8 the main findings and limitations of the studies in this thesis are 
described. Finally, the results of this thesis are put into perspective of current 
developments and future research.




Het doel van dit proefschrift was het verbeteren van besluitvorming door het modelleren 
van algehele overleving, lokale ziekte controle en toxiciteitskansen bij patiënten met een 
centraal gelokaliseerde longtumor die behandeld worden met stereotactische 
radiotherapie.  
Hoofdstuk 1 bevat een algemene inleiding over de stereotactische behandeling van centraal 
gelokaliseerde longtumoren en eindigt met een kort overzicht van dit proefschrift. De groep 
centrale longtumor patiënten wordt al meer dan 10 jaar behandeld met risico aangepaste 
fractioneringsschema’s en de bijhorende dosis-constraints, maar desondanks ontbreken op 
wetenschap gebaseerde richtlijnen nog steeds. De modellen in dit proefschrift kunnen 
gebruikt worden om landelijke of zelfs wereldwijde consensus te ondersteunen. 
Hoofdstuk 2 introduceert een nomogram om de algehele overleving te voorspellen bij 
patiënten met een centraal gelokaliseerd vroeg stadium niet-kleincellig longcarcinoom 
behandeld met stereotactische radiotherapie. Dit nomogram bevat de variabelen ‘planning 
target volume’ (PTV), leeftijd, WHO status, tumor kwab locatie en de gemiddelde dosis in 
het PTV. Het onderscheidend vermogen was acceptabel en de kalibratie grafieken toonden 
een gunstige voorspellende nauwkeurigheid. De externe validatie in een cohort van 94 
centrale longtumor patiënten liet acceptabele validiteit zien. De 5 genoemde factoren 
voorspellen samen de algehele overleving op 6 maanden, 1 jaar, 2 jaar en 3 jaar. 
De invloed van onderdosering van het PTV op de lokale controle wordt besproken 
in Hoofdstuk 3. Twaalf procent van de 220 patiënten ontwikkelde een lokaal 
recidief resulterend in een lokale controle van 88% op 2 jaar. Er was geen correlatie 
tussen de ontwikkeling van een lokaal recidief en de relatieve of absolute PTV die minder 
dan 100 Gy BED10 ontving. Bovendien werd er ook geen relatie gevonden met één van de 
andere PTV parameters. Een grotere tumorafmeting en een lager geforceerd expiratoir 
volume in 1 seconde (FEV1) waren onafhankelijk voorspellend voor de ontwikkeling 
van een lokaal recidief. Ziekte progressie werd vermeld in 75 patiënten met een ziektevrije 
overlevingskans van 66% op 2 jaar. Recidief van ziekte werd geassocieerd met grotere 
tumorafmeting, een tumor in de onderste kwab en afgenomen FEV1. 
Hoofdstuk 4 beschrijft de radiologische veranderingen in de bronchiale structuren na 
stereotactische radiotherapie in relatie met de voorgeschreven dosis. De radiologische 
veranderingen werden opgedeeld in stenose en occlusie met of zonder atelectase. Er 
werden geen veranderingen gevonden in de trachea, en in de hoofdstambronchus en de 
bronchus intermedius was alleen stenose aanwezig. Occlusie met en zonder atelectase 
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werd gevonden in de kleinere aftakkingen; de bovenste, middelste en onderste kwab 
bronchus en de segmentale bronchiën. In deze aftakkingen met radiologische 
veranderingen was de dosis significant hoger. ‘Normal tissue complication probability’ 
(NTCP) modellen werden afgeleid van de maximale punt dosis (Dmax) en het bronchiaal 
volume dat 65, 80 en 100 Gy EQD2 (V65-100Gy) ontving in de hoofdstam bronchus en de 
bronchus intermedius, in de bovenste, middelste en onderste kwab bronchus en in de 
segmentale bronchiën.  
In Hoofdstuk 5 werd binnen een groep van 195 patiënten zowel de klinische long (graad 
3 of hoger) als de radiologische bronchiale toxiciteit geëvalueerd. 
Verschillende dosimetrische parameters, Dmax en V65Gy, V80Gy, V90Gy, V100Gy, V130Gy (in 
EQD2), werden geanalyseerd en allemaal waren deze gecorreleerd met klinische 
toxiciteit en lobulaire bronchiale radiologische toxiciteit. Na het identificeren van de 
voorspellers, werden er NTCP-modellen afgeleid. Deze toonden volume afhankelijkheid 
voor de ontwikkeling van beide soorten toxiciteit.  
Hooggradige klinische toxiciteit was onafhankelijk gecorreleerd met een PTV die de 
trachea of hoofdstambronchus overlapt, chronische obstructieve longziekten en de totale 
V130Gy. Radiologische toxiciteit correleerde niet met de klinische toxiciteit. Dit werd 
verklaard door de subklinische symptomen die veroorzaakt worden bij de occlusie van 
lobulaire bronchi.  
Hoofdstuk 6 behandelt de incidentie van laaggradige radiatie oesofagitis na stereotactische 
radiotherapie en de relatie van deze bijwerking met de voorgeschreven dosis. Acute 
laaggradige toxiciteit werd gemeld bij 17% van de 221 patiënten zonder het optreden van 
hooggradige toxiciteit. Alle geanalyseerde DVH-parameters, de Dmax en de dosis in 1 cc, 2 cc 
en 5 cc van de slokdarm (D1cc-5cc, in EQD2), waren gecorreleerd met laaggradige toxiciteit. 
NTCP grafieken werden gemodelleerd voor elk van deze parameters. Een multivariate 
analyse toonde een significante correlatie met de ontwikkeling van laaggradige slokdarm 
toxiciteit voor de D5cc en het vrouwelijk geslacht. 
Hoofdstuk 7 bespreekt 4 casussen van hooggradige slokdarm toxiciteit en de relatie hiervan 
met stereotactische radiotherapie in een cohort van 188 centrale longtumor patiënten. 
Twee patiënten hadden klachten van graad 3 toxiciteit en 2 patiënten zijn overleden aan de 
slokdarm toxiciteit. Acute laaggradige toxiciteit trad op in 15% van de patiënten. Alle 
onderzochte DVH-parameters (Dmax, D1cc, D2cc, D5cc, in EQD2) waren significant gecorreleerd 
met acute en late toxiciteit. Voor alle DVH-parameters werden NTCP grafieken voor acute 
en late toxiciteit afgeleid. In de univariate analyse werd toename van acute slokdarm 
toxiciteit gezien bij een kleinere afstand tussen de tumor en de slokdarm en bij het 
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voorschrijven van 12 fracties (versus 8 fracties). Door de correlatie tussen beide parameters 
was geen multivariate analyse mogelijk.  
In Hoofdstuk 8 worden de belangrijkste bevindingen en eventuele beperkingen van 
de studies in dit proefschrift beschreven. Tenslotte, worden de resultaten van dit 
proefschrift in perspectief tot huidig en toekomstig onderzoek besproken. 
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